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The endocannabinoid (eCB) system is a key modulator of central brain 
processes that control feeding, however recent evidence points to peripheral 
mechanisms by which eCB signaling may modulate feeding in various disease 
states. This body of work provides novel mass spectrometric analyses for 
components of the eCB system, while describing the pitfalls of currently used 
techniques. Using the described methods, a role for increased small intestinal 
eCB ligands signaling via peripheral cannabinoid type 1 receptor (CB1R) in the 
control of hyperphagia is discussed in the context of obesity. These findings were 
enhanced by further scrutiny of the intestinal eCB system, which revealed that 
corn-oil induced secretion of an intestine-derived satiation peptide, 
cholecystokinin (CCK), is blunted by CB1R activation; activation occurred via 
pharmacological agonists or enhanced eCB levels following diet induced obesity. 
Further, administration of a CCKA receptor antagonist, devazepide, blocked the 
anorexigenic effects of peripheral CB1R restriction, suggesting that peripheral 
 x 
CB1R act via intestine derived CCK to block satiation by impaired gut-brain 
signaling. Additionally, helminth infection was used to evaluate intestinal and lung 
eCB levels in a model of hookworm infection. For the first time, it was observed 
that the helminth Nippostrongylus brasiliensis produces endocannabinoids. 
Together, this body of work provides novel insight to the varied roles that 
intestinal and peripheral eCBs have during obesity in the modulation of feeding 
behaviors and immune responses. 
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Introduction 
 
 The Endocannabinoid System 
 The endocannabinoid (eCB) system plays a large role in regulating 
feeding behaviors by centrally- and peripherally-mediated biochemical processes 
in humans and rodents (1-4). Named for the bioactive constituents of the plants 
Cannabis indica and Cannabis sativa, the eCB system comprises the 
cannabinoid receptor types 1 (CB1R) and 2 (CB2R), their endogenous ligands 2-
arachidonoyl-sn-glycerol (2-AG) and N-arachidonoyl ethanolamide (AEA; 
Anandamide)(5-10) and corresponding synthetic and degradative enzymes. 
CB1R is a Gi/o protein-coupled receptor that modulates neurotransmitter release 
in glutamatergic synapses by cAMP-dependent inhibition of voltage-gated 
calcium channels, thereby reducing the probability of glutamate release (11-13). 
Peripheral CB1R demonstrates control over energy homeostasis and feeding 
through yet-unknown mechanisms, but positron emission tomography (PET) 
imaging has identified large amounts of human CB1R expression in the small 
intestine (1, 14-19). CB2R has been found primarily in immune cells and 
regulates immune response (20). Recent evidence suggests that CB2R is 
involved in feeding and a large expression profile in the small intestine (2, 21). 
Mixed agonism of CB1/2R with the psychoactive -Δ9-tetrahydrocannabinol (THC) 
displays a hyperphagic, or “munchies”, phenotype in rodents and 
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pharmacologically increasing 2-AG and AEA contents has a similar effect (22, 
23). 
De novo synthesis of the monoacylglycerol 2-AG occurs via hydrolysis of 
1-stearoyl-2-arachidonoyl-sn-glycerol by diacylglycerol lipase alpha (DGL-α) in 
neuronal tissue (11). 2-AG is subsequently broken down by its main and minor 
degradative enzymes – monoacylglycerol lipase (MGL) and alpha beta 
hydrolyzing domain type 6 (ABHD6), respectively (24). Diacylglycerol lipase 
exists in a beta isoform (DGL-ß), which is dispensable for 2-AG signaling in 
neuronal cells, that may regulate 2-AG production in peripheral tissue (25). 
Despite sharing an arachidonic acid acyl component with 2-AG, anandamide has 
a distinct synthetic and degradative pathway; anandamide is synthesized by N-
acyl phosphatidyl ethanolamine specific phospholipase D (NAPE-PLD) and 
degraded by fatty acid amide hydrolase (FAAH)(26-30). The DGL-α/ß, MGL, 
NAPE-PLD, and FAAH pathways are not specific to 2-AG and AEA; other 
monoacylglycerols (MAGs) and fatty acid ethanolamines (FAEs) share these 
pathways (27, 29). MAG and FAE species containing the omega-3 
docohosahexaenoyl acid are suggested CBR agonists, but physiological effects 
of large amounts of omega-3 derivatives are still under investigation. 
Current tools for evaluating amounts of the endocannabinoids in biological 
tissues typically rely on mass spectrometry as their detection method. Mass 
spectrometry is then coupled to either gas chromatography or liquid 
chromatography, each having strengths that are chosen by application (31). 
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Ultra-performance liquid chromatography tandem mass spectrometry (UPLC-
MS/MS) offers a high-throughput, highly sensitive, highly resolved, and highly 
specific readout, while also maintaining a relatively low cost of sample 
preparation (32). Notwithstanding, the potential for contamination and 
subsequent type I (false positive) errors exist, and adequate sample preparation 
and method development are necessary for robust detection and quantification of 
biological analytes (see Chapter 1). 
Obesity and Feeding Behaviors 
Obesity is the most common preventable disease in the United States; 
currently, more than sixty percent of adults are overweight and approximately 
forty percent are obese (33). Diet greatly contributes to the obesity epidemic, 
especially with the ease of access to calorically-dense foods (i.e. high amounts of 
fats and sugar)(34, 35). Obesity drives the dysregulation of biochemical signals 
involved with satiation and regulating meal patterns (36, 37), where efforts to 
uncover novel therapeutics have been largely ineffective (38, 39). Due to the 
hyperphagia associated with obesity, modulation of feeding behavior has 
become a target for therapy. 
Humans and rodents detect dietary fats (40-44) and sugars (45) with 
receptors inside the oral cavity and along the alimentary tract, and these 
receptors are critical in mediating fat and sugar preference (43, 46, 47). Many 
biological pathways play an important role in controlling food intake, energy 
homeostasis, and hedonic reward (46, 48), including the endocannabinoid (eCB) 
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system, signaling through central and peripheral CB1Rs (1, 19, 22, 23, 49-67). 
Targeting central endocannabinoids has proven deleterious in the clinic, 
especially in the cases of patients with existing psychiatric disorders (68); 
however, peripheral endocannabinoid control of feeding is a suggested safe 
alternative (19, 59). Additionally, intestinal endocannabinoid mobilization has 
been observed in response to taste of dietary fats, obesity, and fasting (61-63, 
69). Taken together, the body of research is suggestive of a peripheral 
mechanism for hyperphagia that may be modulated by intestine-derived 
endocannabinoids (see Chapter 2). 
The Gut-Brain Axis 
The gut-brain axis is a dynamic circuit that comprises biochemical 
messages to the gastrointestinal tract via vagal efferent neurons and back to the 
brain via vagal afferent neurons and intestine-derived hormones. Due to its role 
in energy balance, the gut-brain axis is a target for diseases and conditions that 
impact feeding and energy balance. Gut-brain signaling controls food intake and 
energy homeostasis via direct neurotransmission and control of neuropeptide 
secretion and signaling (70). Impaired signaling of efferent vagal fibers has been 
associated with over-secretion of neuropeptides, such as the stomach-derived 
peptide ghrelin, which is observed in the case of bulimia nervosa (71). Efferent 
vagal signaling controls 2-AG biosynthesis in response to fat taste and fasting, 
which is mediated by subtype 3 muscarinic acetylcholine receptors (62, 72). 
Vagal signaling to the brainstem and hypothalamus reduce food intake via 
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neurotransmission initiated by the gut neuropeptides cholecystokinin (CCK), 
peptide YY (PYY), glucagon-like peptide 1 (GLP-1), and the adipocyte-derived 
leptin (37, 73-82). CCK, PYY, and GLP-1 are produced in enteroendocrine cells 
found along the gastrointestinal tract and release in response to sensing dietary 
nutrients (83-89). Conversely, ghrelin stimulates appetite by vagal afferent 
signaling (90, 91). These compounds and their homeostatic regulation have been 
extensively reviewed by Steinert et al (92). Vagal signaling has been widely 
investigated for its potential to treat feeding disorders, and the endocannabinoid 
system has been identified as a potential target due to its vast interactions with 
the various components of gut-brain communication. For example, THC 
administration in human adults attenuated the nutrient-induced release of GLP-1 
and enhanced preference scores for palatable foods (93). Endocannabinoid 
control of gut-derived GIP and GLP-1 has been demonstrated (88), but the role 
for cholecystokinin in intestinal endocannabinoid signaling has not been 
investigated. Recent evidence has indicated a presence of mRNA encoding 
CB1R on CCK-producing enteroendocrine I-cells (94), and new evidence 
suggests a functional link between CB1R activation and decreased CCK 
secretion in DIO (see Chapter 3). 
Hookworm Infection 
Another field of research that is heavily involved in impaired feeding is the 
investigation of hookworm infections. Helminth parasite infections affect 
approximately two billion individuals worldwide (95). Although not typically fatal, 
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helminth infection presents with an array of comorbidities, including malnutrition 
and growth retardation. Most soil-transmitted helminths occupy the 
gastrointestinal tract of their host, where they can hinder the host’s nutritional 
status by stealing nutrients or preventing nutrient absorption via intestinal tissue 
damage and/or inflammation (96). Additionally, new mechanisms by which 
helminths impact host feeding and metabolism have been identified in the 
gastrointestinal tract (97). Gastrointestinal helminth infection has been shown to 
decrease food intake (98), and proved to be beneficial in mice fed a high-fat diet; 
infection improved glucose metabolism and reduced adiposity (99, 100). The 
beneficial effect is partly mediated through T helper type 2 (Th2) cytokine-
activated M2 macrophages in the adipose tissue, which exert beneficial effects in 
metabolic homeostasis (101). Helminth infection in the intestine induces a Th2 
cytokine-dependent expansion of cholecystokinin (CCK)-positive 
enteroendocrine cells, which secrete satiation hormones that regulate meal size 
(102). Identification of novel helminth or host-derived mechanisms that regulate 
feeding may provide greater insight to the pathologic or beneficial outcomes of 
helminth infection, which may be leveraged therapeutically. 
Among the many host-derived molecules that affect feeding and 
metabolism pre- and post-infection, endocannabinoids are important research 
targets that control these physiologic processes (46, 103); endocannabinoids 
promote neural-mediated behaviors such as food intake and reward (46). 
Endocannabinoids, however, are generated ubiquitously in the mammalian body, 
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and cannabinoid receptors are expressed in extraneuronal cells, which include 
intestinal epithelial and immune cells (6, 7, 62). Signaling by the 
endocannabinoids, 2-AG or AEA, via cannabinoid receptors on intestinal cells 
modulates feeding behavior (36, 61), while their immune cell signaling promotes 
anti-inflammatory pathways (104). Despite functional outcomes on intestinal 
physiology and immune response, no studies in the current literature have 
evaluated the role of endocannabinoids in intestinal parasite infection. The host-
pathogen interaction of helminths and mammals with emphasis on the 
endocannabinoid system may provide a useful route for investigating potential 
modulation or treatment of infections (see Chapter 4). 
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Abstract 
Fatty-acid ethanolamides (FAEs) are a family of lipid mediators that 
participate in a host of biological functions. Procedures for the quantitative 
analysis of FAEs include organic-solvent extraction from biological matrices (e.g., 
blood), followed by purification and subsequent quantitation by LC/MS or GC/MS. 
During the validation process of a new method for LC/MS analysis of FAEs in 
biological samples, we observed unusually high levels of the FAE, 
palmitoylethanolamide (PEA), in blank samples that did not contain any biological 
material. We investigated a possible source of this artifact and found that high 
levels of a contaminant indistinguishable from PEA is present in new 5¾” glass 
Pasteur pipets, which are routinely used by laboratories to carry out lipid 
extractions. This artifact might account for discrepancies found in the literature 
regarding PEA levels in human blood serum and other tissues. It is 
recommended to take into account this pitfall by analyzing potential 
contamination of the disposable glassware during the validation process of any 
method used for analysis of FAEs. 
 
Introduction 
Fatty-acid ethanolamides (FAEs) are a family of endogenous lipid 
mediators whose chemical structures consist of a fatty acid moiety bound to 
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ethanolamine by an amide linkage. These compounds are synthesized by cells 
throughout the body and control inflammation, appetite and food intake, learning 
and memory, and pain among other functions (1). PEA and oleoylethanolamide 
(OEA) suppress inflammation by activating the ligand-operated transcription 
factor, peroxisome proliferator-activated receptor-α (PPAR-α) (2). Anandamide, 
i.e. arachidonoylethanolamide (AEA), acts as a partial agonist at cannabinoid 
receptor (CBR) type 1 and 2, and therefore belongs to the diverse family of lipid 
signaling molecules called endocannabinoids (ECBs) (3, 4). Due to their similar 
physicochemical properties, FAEs and other ECBs such as 2-arachidonoyl-sn-
glycerol (2AG) are usually co-extracted from biological samples (5). The 
procedure for their analysis includes extraction with organic solvents (e.g., 
methanol and chloroform) followed by purification through solid-phase extraction 
(e.g., open-bed silica gel) and subsequent quantitation by LC/MS or GC/MS. 
FAEs are present in blood serum or plasma in the pmol per mL scale and in 
biological tissues in concentration ranging from the pmol to nmol per gram scale. 
A review of the literature, however, reveals that data from different laboratories 
reporting concentration of FAEs in human serum from healthy subjects often do 
not corroborate one another. In particular, reported levels of PEA and OEA in 
serum or plasma of healthy human subjects differ by up to two orders of 
magnitude, from 5-30 pmol per mL (6-17) up to 200 pmol per mL of serum or 
plasma (18, 19).  
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During the validation process of a new method for LC/MS analysis of 
FAEs and ECBs in human serum extracts, we observed unexpectedly high levels 
of PEA, as compared to data previously obtained in our laboratory (6). We 
suspected that these abnormal levels could be due to a recurrent contamination. 
We found that 5”¾ Pasteur pipets of most, if not all, commercial brands, contain 
multiple contaminants detectable by LC/MS, including readily detectable 
quantities of a compound indistinguishable from PEA.  
Materials and Methods 
Materials 
All solvents including chloroform, methanol and acetone, were of the 
highest purity commercially available, suggested for pesticide residue analysis, 
residue 1mg/L max, from Burdick & Jackson (Honeywell International Inc., Morris 
Plains, NJ). Water was HPLC grade from Fisher Scientific (Thermo Fisher 
Scientific Inc., Waltham, MA). Synthetic standards of FAEs including deuterium-
containing internal standards (ISTDs) for isotope dilution ([2H4]PEA, [2H4]OEA, 
[2H4]AEA and [2H5]2AG) were purchased from Cayman Chemical (Ann Arbor, 
MI). Ammonium acetate and acetic acid were Optima grade from Fisher 
Chemical (Thermo Fisher Scientific Inc., Waltham, MA). Disposable glass 
Pasteur pipets (5¾” and 9” corresponding to 150 and 230 mm, respectively) were 
from the following vendors: Fisher Scientific (Thermo Fisher Scientific Inc., 
Waltham, MA), VWR (VWR International LLC, Radnor, PA), Corning (Corning, 
NY), and Wheaton (Wheaton Industries Inc., Millville, NJ). Eight-mL vials were 
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from Thermo Scientific (Thermo Fisher Scientific Inc., Waltham, MA). LC amber 
vials with inserts were from Agilent Technologies (Santa Clara, CA). Beakers and 
cylinders were Fisher Scientific (Thermo Fisher Scientific Inc., Waltham, MA). 
Glass syringes were from Hamilton (Reno, NV). Silica Gel was 60Å 230-400 
Mesh ASTM from Whatman Inc. (Sigma-Aldrich Corp., St. Louis, MO). Untreated 
glass wool was from Grace (Columbia, MD). 
Extraction of FAEs from blood serum 
Samples of human serum from healthy subjects were kindly provided by 
Dr. Hamid Moradi. The study protocol was approved by the institutional review 
board of the University of California-Irvine and was completed with the 
assistance of the University of California-Irvine General Clinical Research 
Center. Written informed consent was obtained from all subjects. Blood samples 
were collected in red top blood collection tubes (vacutainers, silicon-coated, no 
additives) which were left sitting upright at room temperature for a minimum of 30 
to a maximum of 60 minutes to allow clotting. The blood sample was centrifuged 
immediately at the end of the clotting time in a horizontal rotor (swing-out head) 
for 20 minutes at 1100-1300 g at room temperature. The serum was transferred 
into labeled cryogenic vials, which were immediately stored upright in a rack at -
80°C. Aliquot volume was 1mL. This process was completed within 1 hour of 
centrifugation. Aliquots were transported in dry ice, then slowly defrosted at 4°C 
and stirred for 30 sec prior use. A volume of serum of 0.6 mL was transferred in 
an 8 mL glass vial. Protein precipitation was performed by adding 1mL of cold 
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acetone containing deuterium labeled ISTDs as follows: 1.2 pmol of [2H4]PEA, 
1.2 pmol of [2H4]OEA, 0.6 pmol of [2H4]AEA and 30 pmol of [2H5]2AG. Samples 
were stirred for 60 sec then left in a cold room (4°C) for 20 min, then centrifuged 
at 2000 rpm at 4°C for 20 min. The supernatants were transferred with a Pasteur 
pipet in another 8 mL glass vial before undergoing lipid extraction procedure. 
Lipid extraction was performed using a modified Folch procedure (20), as follows. 
The excess of acetone was evaporated under N2. Water was added up to 1 mL 
of total volume and the sample was vortexed for 60 sec. Then 1 mL of methanol 
was added and the sample vortexed for 60 sec. Finally, 2 mL of chloroform were 
added and the sample vortexed for 60 sec before centrifugation for 15 min at 
3500 rpm at 4°C. The lower chloroform phase was collected with a Pasteur pipet 
and transferred in another glass vial, evaporated under N2 stream and 
reconstituted in 2 mL of chloroform. Afterwards, fractionation of the lipid extract 
through open bed chromatography was performed as previously described (5). 
Briefly, the standardized extraction procedure employed in our lab is an open-
bed silica-gel column chromatography (Silica gel 60 230–400 mesh) that 
precedes LC/MS analyses (i.e. a custom-made solid phase extraction 
procedure). Silica gel columns were prepared as follows: a 5” ¾ glass Pasteur 
pipette was plugged with glass wool at the beginning of the thin tip; 1 mL of a 
slurry of silica gel (60Å 230-400 Mesh ASTM) in chloroform (1:1, v/v) was poured 
into the pipet held in a rack with a metal tray underneath; the column was 
washed with 2 mL of chloroform. The reconstituted 2 mL of lipid extract were 
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loaded onto the column. FAEs were eluted with 2 mL of chloroform/methanol 
(9:1, v/v). The eluate was collected in another 8 mL glass vial, evaporated under 
N2, reconstituted in 60 µL of methanol and transferred in a 250-µL insert of a 2 
mL LC vial before LC/MS analysis.  The final concentrations of ISTD were 
therefore the following: 20 nM [2H4]PEA and [2H4]OEA, 10 nM [2H4]AEA and 500 
nM [2H5]2AG. The same concentrations were used for the calibration curves 
described in the LC/MS section below. 
 
Pipet extraction 
Disposable glass Pasteur pipets were washed with 8 mL of chloroform. 
The chloroform was collected in an 8 mL vial, spiked with 20 moles of ISTD 
[2H4]PEA, evaporated under a stream of N2, reconstituted in 100 µL of methanol 
and transferred with a glass syringe in a 250-µL insert of a 2 mL LC vial before 
LC/MS analysis. The final concentration of [2H4]PEA ISTD was therefore 200 nM. 
Foam extraction 
Polyurethane foam is used by vendors to wrap the glass Pasteur pipets to 
protect them from breakage. Small pieces of this plastic material were cut and 
weighed. Pieces of 1, 2.5, 5 and 10 mg were deposited in 8 mL glass vials that 
were previously washed with chloroform twice. Each vial was filled with 5 mL of 
chloroform containing 20 pmol of ISTD [2H4]PEA. Vials were stirred thoroughly. 
The chloroform was evaporated under N2 and the extracts were suspended in 
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100 µL of methanol and transferred with a glass syringe in a 250-µL insert of a 2-
mL LC vial. 
Transferring PEA from the foam to the glass 
A PEA-free 9” glass Pasteur pipet was further washed with chloroform. 
The pipet was warmed up at 60°C and wrapped in polyurethane foam used by 
vendors for packaging. Subsequently, a pipet extraction was performed as 
described above to check whether PEA could be transferred from the foam to the 
glass.  
 
 
LC/MS 
LC/MS analyses of samples were performed using an Agilent 1200 LC 
system coupled to an Agilent G6410A triple quadrupole (QQQ) MS detector 
(Agilent Technologies, Inc., Santa Clara, CA) equipped with an electrospray 
ionization (ESI) interface. FAEs were separated using a XDB Eclipse C18 
column (2.1 x 50 mm i.d., 1.8 µm,), eluted with an isocratic method of methanol 
in water (A: 20% Water + 0.25% Acetic acid + 5 mM ammonium acetate and B: 
80% methanol + 0.25% acetic acid + 5 mM ammonium acetate in 8 min) at a flow 
rate of 0.4 mL/min. Column temperature was kept at 40˚C. MS detection was in 
the positive mode, capillary voltage is set at 4 kV, fragmentor voltage is varied 
from 120 to 140 V and collision energy was 20 eV. Helium was used as collision 
gas while nitrogen was used as drying gas at a flow rate of 12 liters/min at 350˚C. 
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Nebulizer pressure is set at 50 PSI. In parallel, LC/MS and MS/MS data were 
also acquired on an Acquity I Class UPLC system coupled to a Xevo TQ-S Micro 
Mass Spectrometer (Waters, Milford, MA, USA) with accompanying electrospray 
ionization (ESI) interface (data presented in Figures 3B, S5, S7). On both set-ups 
we quantified FAEs with an isotope-dilution method, monitoring protonated 
adducts of the molecular ions [M+H]+ in multiple reaction-monitoring (MRM) 
mode. The MRM transitions monitored for FAEs detection and quantitation were 
the following: PEA (m/z = 300.3>62.1); OEA (m/z  = 326.3>62.1); AEA (m/z  = 
348.3>62.1); 2AG (m/z  = 379.3>287.2); [2H4]PEA (m/z  = 304.3>66.1); [2H4]OEA 
(m/z  = 330.3>66.1); [2H4]AEA (m/z  = 352.3>66.1); [2H5]2AG (m/z  = 
384.3>287.2). Additional analytes were investigated on the Waters UPLC/MS/MS 
as possible contaminants in foam: docosahexaenoylethanolamide (DHEA, Fig 
S5G, H) (m/z = 372.3>62.1), and docosahexaenoyl glycerol (DHG, Fig S5K, L) 
(m/z = 403.4>311.2). We used two different sets of calibration curves, one for the 
serum analysis with low ISTD and one for pipets and foam extracts with higher 
ISTD. In particular, we prepared standard calibration curves by adding a constant 
amount of deuterium-labeled standards to increasing amount of the 
corresponding unlabeled FAEs, followed by MS analysis as described above. 
The relative concentrations of unlabeled versus labeled ions were plotted against 
their relative response (i.e. peak area) and the calibration curves were 
constructed using linear regression. R2 was 0.998 for all analytes, indicating 
linear response. In the calibration curve for serum extracts analysis the ISTDs 
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were kept as follows: [2H4]PEA and [2H4]OEA at 20 nM, [2H4]AEA at 10 nM and 
[2H5]2AG at 500 nM. In the calibration curve for foam and pipets extracts 
analysis, the ISTD [2H4]PEA was kept at 200 nM. In both cases the non-
deuterated reference standard of PEA, OEA, AEA and 2AG were at 
concentrations ranging from 1 nM to 2 µM, for a total of 11 points of calibration.  
Highly accurate mass data were obtained on a Shimadzu IT-TOF (ion trap 
– time-of-flight) coupled to Shimadzu Nexera HPLC system following a similar 
LC/MS method. A reverse phased endcapped C18 column from Knauer was 
employed (Eurospher II 100 C18: 2 x 100 mm i.d., 3µm, 100 A). The solvent 
system and oven temperature were the same as described above for the Agilent 
instrument. The LC method was 13 minutes long and proceeded as follows: from 
85 to 98%B in 5 min, then kept at 98%B for 5 min followed by a re-equilibration 
step at 85%B for 3 min. Source temperature was kept at 250°C, drying gas 
pressure was 103 kPa (10 L/min), detector voltage was 1.55 kV and probe 
voltages were 4.5 and -3.5 kV. Data were acquired and analyzed with the 
Shimadzu software LCMS Solution (Acquisition and Analysis) and Formula 
Predictor. All LC/MS data showed in this manuscript were obtained in the positive 
ion mode. 
Results 
Quantitation of FAEs and 2-AG in human serum samples 
We quantified PEA, OEA, AEA and 2AG levels in serum samples from 
three healthy subjects. Table 1 contains a comparison of average FAEs and 2-
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AG levels, measured in this work and by independent laboratories, in human 
serum/plasma from healthy subjects, by LC/MS analysis. For most compounds, 
concentrations measured in the present study were in close agreement with 
those previously reported by our group (6) and others (7). PEA levels were 
similar to those reported by Bilgin et al. (18) and by Sipe et al. (19), but 10 to 20 
times higher than those reported by other groups (7-17)and previously by us (6). 
This suggested that a contamination might be present.  
Identification of PEA in glass Pasteur pipets and plastic foam 
First, all solvents were carefully checked as a possible source of 
contamination. Skonberg and coworkers (21) have found that chloroform from 
certain vendors contained small amounts of PEA. We could not confirm those 
findings: all solvents used during our procedure for extraction of FAEs and ECBs 
from serum were found to be FAEs-free. This prompted us to carefully check all 
the glassware, disposable and not, used to carry out the extraction procedure. 
This included: 2mL LC vials, vial inserts, 8mL disposable glass vials, glass 
beakers, glass solvents bottles, disposable glass Pasteur pipets, and the 
polyurethane foam used to wrap them. LC-MS and MS/MS traces of authentic 
PEA standard and chloroform-methanol washout of glass pipets and extracts of 
polyurethane foam were recorded in the positive ion mode. LC-MS data were 
acquired on two separate triple quadrupole (QQQ) instruments (Agilent G6410A 
and Waters Xevo TQ-S Mass Spectrometer) and on a high accuracy ion-trap 
time-of-flight (IT-TOF) mass spectrometer (Shimadzu IT-TOF) to confirm 
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identification by accurate mass measurement. Fig. 1 shows the comparative LC-
MS (panel A) and LC-MS/MS (panel B) analysis of PEA standard (traces a), pipet 
washout (traces b) and foam extract (traces c) carried out on the Agilent QQQ. 
The MS1 analysis in panel A shows the Extracted Ion Chromatograms (EIC) for 
the m/z 300.3 belonging to the PEA positive pseudomolecular ion [M+H]+. These 
three chromatograms show co-eluting peaks at RT 5.7 min for the m/z 300.3. 
The MS2 analysis in Fig 1B shows the fragmentation pattern obtained by 
Collision Induced Dissociation (Fragmentor 135V, CID 20eV) of the peaks at 
300.3 in each chromatogram. The obtained MS/MS spectra are superimposable 
and show peaks of: the positive pseudomolecular ion of PEA [M+H]+ at 300.3 Th, 
the fragment deriving from the water loss [M+H-H2O]+ at 282.3 Th and the 
diagnostic fragment of ethanolamine [Ethanolamine+H]+ at 62.1 Th. The signal 
belonging to the ammonia loss (-17) at 283.3 Th is also visible except in trace a 
and b, but not c. Collectively, results in Fig. 1 demonstrate that one of the 
contaminants, present in the pipet and in the foam extracts, gives rise to a signal 
detected by LC/MS analyses that is attributable to PEA, having the same RT and 
MS/MS fragmentation pattern of authentic standard. 
To confirm the presence of PEA as contaminant in the pipets and foam 
extracts we also analyzed the pure standard of PEA and the pipet extract on a 
different instrument capable of providing accurate mass measurement up to the 
fourth decimal and with a ppm deviation lower than 5 (Shimadzu IT-TOF). The 
EIC for the high accurate exact mass of the positive pseudomolecular ion of PEA 
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[M+H]+ at 300.2897 Th is shown in Fig. 2. The spectra show co-eluting peaks at 
RT 6.3 min for the m/z 300.2897 with ppm deviation < 5. The brute formula of this 
compound was predicted by the Formula Predictor software as C18H37NO2 both 
for the PEA standard and the contaminant in the pipet with a ppm deviation of 2.7 
and 3.7 respectively (Fig S1 and S2). This experiment unambiguously 
demonstrates the presence of PEA as a contaminant in the glass Pasteur pipet 
extract. 
Other possible contaminants 
To determine whether PEA was the only contaminant present in glass 
pipets we analyzed the TIC of an MS1 scan of the pipet washout. We performed 
this analysis in the positive ion mode on the QQQ and in both positive and 
negative ion mode on the IT-TOF machine (Fig S3 and S4, respectively). The 
analysis in the negative ion mode (Fig S4, blue trace) clearly identified two peaks 
attributable to palmitic acid and stearic acid by RT and accurate exact mass 
(data not shown). Analysis in the positive ion mode showed a number of peaks 
on both instruments among which PEA is a contaminant. It is outside the scope 
of this manuscript to provide a comprehensive identification of all contaminants, 
which would require extensive structure elucidation work by MS analysis. 
Importantly, however, analysis of other FAES and monoacylglycerols commonly 
studied in the ECB field resulted in no evidence of their presence in foam (5 mg). 
These analytes included: PEA for reference (Fig S5A, 100pmol; S5B, foam), 
OEA (Fig S5C, 100pmol; Fig S5D, foam), anandamide [AEA (Fig S5E, 100pmol; 
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Fig S5F, foam)], docosahexaenoylethanolamide [DHEA (Fig S5G, 100pmol; Fig 
S5H, foam)], 2-AG [2-AG (Fig S5I, 100pmol; Fig S5J, foam)], docosahexaenoyl 
glycerol [DHG (Fig S5K, 100pmol; Fig S5L, foam)]. 
Quantitation of PEA in glass Pasteur pipets and in plastic foam 
We quantified the amount of PEA that can be extracted from a single glass 
pipet when washed with 8 mL of chloroform. Figure 3A shows proportional 
increase in concentrated extracts of 1, 2 and 3 pipets. We also tested 9” pipets, 
where PEA was present in negligible trace amount or absent. In order to quantify 
the PEA content in each pipet we used an isotope dilution LC/MS method with 
acquisition in MRM mode as described in the experimental procedures. PEA was 
quantified in 100 µL of concentrated washout of each pipet and results are 
expressed as pmol of PEA in the reconstituted extract (Fig. 3A). We also 
quantified PEA content in pipets from different vendors (Fig. S5). Although the 
concentration of PEA increases with the number of pipets used in the extraction 
procedure, the multiple experiments show a range of standard deviations (SD) in 
triplicate experiments. This is observed also in pipets produced by the same 
manufacturer and having the same lot number but taken from different boxes 
(Fig. 1 as compared to groups 1-2 in Fig. S6, showing independent experiments 
in triplicate). The average amount of PEA present in one pipet, calculated 
considering all 9 experiments shown in Fig. 3 and Fig. S6, is 33.4 ± 4.02 pmol 
(mean ± SEM, n = 9). Altogether, these results show that one wash with 8 mL of 
chloroform can extract an average amount of PEA of 33.4 pmol per pipet. 
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Notably, the SD within all pipet extraction experiments ranges from 10 to 75% 
(average SD is around 30% in triplicate experiments). This considerable data 
scattering indicates that an extraction from a single pipet produced by the same 
manufacturer can give rise to PEA contaminations of very different extent. 
Finally, we employed our LC/MS method to quantify the amount of contaminant 
PEA present in the polyurethane foam used to wrap the glass pipets. Fig. 3B 
shows a strong linear relationship between mass of foam insert and calculated 
PEA values.  
Transfer of PEA from the foam to the glass 
A washed clean glass Pasteur pipet was incubated in contact with the 
foam as described in experimental procedures. Pipet extractions with subsequent 
LC/MS analysis were carried out before and after the washing step as well as 
after exposure to the foam. For reference, the intensity (ion counts) of 100 pmol 
PEA standard was 1.45e8 (Fig S7A). The PEA signal was present in the 
unwashed pipet at 2.19e7 (Fig S7B), absent in the washed pipet extract (Fig 
S7C) and present again in the pipet exposed to 5 mg foam at 1.56e6  (Fig S7D). 
 
Discussion 
A contaminant that is undistinguishable from PEA is present in glass 
Pasteur pipets in amounts that are sufficient to interfere with analysis of 
biological samples. The contaminant was identified based on its LC retention 
time, accurate mass, and tandem mass spectrometric (MS/MS) fragmentation 
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pattern, which were identical to those of authentic PEA. By contrast, only a 
negligible PEA contamination was found in 9” Pasteur pipets. Furthermore, we 
isolated the PEA contamination to the polyurethane foam used to package the 
pipets, which is transferred to glass pipets by contact. In line with this finding, 
Oddi et al. (22) recently reported that FAEs can be absorbed by plastic materials 
during laboratory assays. It is therefore conceivable that FAEs incidentally 
absorbed by plastics during industrial processes can be released later in organic 
solvents. Lastly, no other commonly analyzed FAEs or monoacylglycerols were 
found to be present in the pipets. 
We published GC/MS (23) and LC/MS (5) analytical methods for the 
quantitation of ECBs and other related FAEs and monoacylglycerols in biological 
samples, including human serum (6). Prompted by the need for a novel 
quantitative LC/MS method to analyze ECBs in blood, we reviewed the literature 
and noticed discrepancies in the reported concentrations of FAEs and ECBs in 
human blood serum and plasma (Table 1). The EC50 for anandamide and 2-AG 
vary depending upon assay and tissue; however, it is important to note that 
levels reported in Table 1 for both compounds in plasma/serum are below the 
apparent biologically active concentrations required to activate CB receptors [see 
for comprehensive review of specific assays used by a variety of research groups 
(24)]. Regarding relative levels of PEA and OEA, a number of studies reported 
very similar concentrations for both compounds (8-11, 15), whereas others 
reported PEA approximately twice higher than OEA (6, 7, 12, 13, 16, 17). 
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Regarding absolute values, two separate laboratories reported levels of PEA and 
OEA in plasma that were excessively high (18, 19), which reached or exceeded 
the concentrations needed by these ligands to engage PPAR-α as agonists. PEA 
and OEA are, in fact, considered high potency ligands of PPAR-α; in 
heterologous expression systems, these FAEs engage the receptor with median 
effective concentration (EC50) values of 0.12 µM for OEA and 3 µM for PEA (25, 
26). In the above-mentioned reports (18, 19), although PEA levels did not exceed 
the EC50, levels of PEA were high relative to other reports (6-17). The steady-
state concentrations of FAEs (and ECBs) in plasma/serum of healthy individuals 
possibly reflect an equilibrium of ECBs released by peripheral tissues and their 
enzymatic degradation in the blood stream. In animal tissues (e.g., brain, upper 
small intestine), levels of PEA and OEA are present in the same order of 
magnitude (27, 28); therefore, it was predictable to find a similar pattern in 
human serum or plasma, as also shown by the literature reports in Table 1. 
Surprisingly, in our preliminary experiments, the measured level of OEA was in 
agreement with most literature reports whereas PEA was one order of magnitude 
higher than expected (Tab. 1). This finding prompted us to carefully screen all 
possible sources of contamination including solvents, reagents, and glassware 
used for lipid extraction and quantitative analysis.  
In the present manuscript, we identify glass Pasteur pipets (5”¾) used to 
transfer solvents and lipid extracts as the source of PEA contamination. The 
contaminant was identified as PEA by its exact mass and RT in three similar but 
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different chromatographic systems, as well as by its MS2 fragmentation pattern, 
which were identical to those of standard PEA. Further, we show that PEA is 
present in the polyurethane foam that manufacturers use to wrap the pipets 
before packing, from which it leaks onto the glass pipets. Moreover, accurate 
exact mass measurements with ppm deviation lower than 5 unambiguously 
confirmed the identity of the contaminant as PEA. Quantitative assessment 
showed that the content of PEA is 33.4 ± 4.02 pmol per pipet. Unfortunately, 
none of the various manufacturers whose pipets were tested provides 5¾” glass 
Pasteur pipet that are contaminant-free (Fig. S6). Only 9” pipets from one vendor 
were free of PEA traces (Fig. 3A), allowing the use of these consumables in the 
overall procedure. 
The field of lipidomics is rapidly developing; however, reproducible 
standard procedures across laboratories are not established. Therefore, it is not 
uncommon for lipidomics data to differ among from independent laboratories 
(29). It is generally thought that these discrepancies are a result of the use of 
different instruments for lipid analysis, as well as differing extraction and 
separation protocols. In the present manuscript, however, all results were 
confirmed by two independent laboratories using different LC systems and QQQ 
mass spectrometers (Agilent 1200 LC system coupled to an Agilent G6410A 
QQQ Mass Spectrometer in the Piomelli laboratory, and Waters Acquity I Class 
UPLC system coupled to a Xevo TQ-S QQQ Mass Spectrometer in the DiPatrizio 
laboratory). Furthermore, accurate mass data were acquired on a third Shimadzu 
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IT-TOF High Resolution Mass Spectrometer for definitive confirmation that the 
contaminant was indeed PEA. Another well-known issue in lipidomics is that 
various sources of contamination can originate artifacts. Lipids, especially fatty 
acids, are common contaminants in detergents, mineral oils, greases and 
plasticizers; hence, they are often present in laboratory equipment including 
glassware and solvents. As shown in the present manuscript, assessment of 
FAEs, a group of lipids with diverse signaling properties, is not sheltered from 
this pitfall. We have shown that glass Pasteur pipets, commonly used in lipidomic 
laboratories to transfer lipid extracts and organic solvents, can contain PEA as 
contaminant. This contamination gives rise to artifacts in the measurement of 
PEA in biological samples, especially when the procedure for sample preparation 
includes fractionation of the lipid extract, which concentrates the contaminant. 
The scope of the present manuscript is an alert to the ECB and FAE scientific 
community about possible PEA analytical artifacts and thus, great care is needed 
to exclude the possibility of contaminants when analyzing endogenous PEA 
levels in biological tissues. 
Conclusion:  In the present manuscript, we identified PEA as a quantitatively 
relevant contaminant present in glass pipets as well as in the polyurethane foam 
used to wrap pipets in the packaging. We strongly recommend examining 
glassware used to carry out the procedure by including in analysis a “blank” 
extraction, whereby one additional extract is subjected to the exact protocol of 
lipid extraction and processing, but with no biological sample present. In 
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particular, we warn readers to be cautious with all plastic (foam) and glass 
materials that can release FAE-like compounds leading to an overestimation of 
concentrations in biological samples. To avoid these pitfalls it would be 
convenient to indicate vendors in the material section for all consumables 
including glassware. High quality certified disposable glassware for LC/MS 
analysis is already on the market but limited to vials and inserts. The present 
paper shows that there is an urgent need to expand the variety of high-quality 
disposable glassware, including glass pipets, optimized for lipid extraction. In the 
meantime, we additionally recommend including a washing step of the 
glassware, with either sulpho-cromic acid mixture or chloroform, in the laboratory 
workflow. 
Author Disclosure Statement:  All authors declare no conflict of interest in 
connection with the submitted manuscript; hence, no competing financial 
interests exist. 
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Tables 
Table 1. Comparison of serum/plasma average concentrations of FAEs and 2AG determined in this study with 
other reports.  
 
 
Values are expressed in pmol/mL of serum. The PEA value obtained in this work is marked with an asterisk, 
indicating that is an artifact due to the unveiled contamination. In the selected reports, when only plotted and not 
reported in the text, values were back calculated from digitized images. S = serum; P = plasma.
Lipid 
Specie 
This 
work 
Shreiber 
et al. 
2007 
Gachet 
et al. 
2015 
Balvers 
et al. 
2009 
Balvers 
et al. 
2013 
Lin et 
al. 
2012 
Ozalp 
et al. 
2009 
Bilgin 
et al. 
2015 
Sipe 
et al. 
2010 
Ottria 
et al. 
2014 
Lam 
et al. 
2010 
Lam 
et al. 
2010 
Jumpertz 
et al. 
2010 
Caraceni 
et al. 
2009 
Hill 
et al. 
2009 
Schaefer 
et al. 
2013 
S S P P P P P P P P P S P P S S 
AEA 0.6 0.9 1.7 0.7 1.1 2.6 0.7 14.5 12.8 0.8 0.72 1.01 1.8 5.1 2.6 2.0 
OEA 4.2 3.7 9.9 4.2 6.1 8.6 4.9 162.5 107.9 4.9 4.6 6.0 4.0 12.6 5.5 9.6 
PEA 419.4* 28.4 23 4.7 4.9 8.0 5.2 203.6 213.3 24.8 16.9 16.3 - 12.6 12.5 20.5 
2AG 12.1 - 16.5 18.8 - - 18.8 11.8 5.6 - - - 32.8 1.7 39.0 10.0 
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Figures 
 
Figure 1. Comparative LC/MS (panel A) and LC-MS/MS (panel B) analysis of 
PEA standard (traces a), pipet extract (traces b) and foam extract (traces c) by 
triple quad mass spectrometer. A) Positive EIC chromatogram for the m/z 300.3 
Th generated from a 5 µL injection of a 1 µM solution of PEA, 5 pmoles on 
column (trace a), of the pipette extract (trace b) and of the foam extract (trace c); 
B) MS/MS analysis in the positive ion mode of the peaks in panel A at RT=5.7 
min having m/z 300.3 Th. Panel A shows coeluting peaks at RT=5.7. In panel B 
the MS/MS spectra show peaks of the protonated PEA molecular ion [M+H]+ at 
m/z = 300.3 Th and of its two fragment: the molecular ion arising from the water 
loss [M+H-H2O]+ at 282.3 Th and the ethanolamine positive pseudomolecular ion 
[Ethanolamine+H]+ at 62.1 Th. 
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Figure 2. Comparative LC/MS analysis by high-resolution accurate mass 
spectrometer. Positive EIC chromatogram for the m/z 300.2897 Th (ppm dev < 5) 
generated from a 2 µL injection of a 1 µM solution of PEA, 2 pmoles on column 
(trace a) and of the pipet extract (trace b). The two chromatograms show 
coeluting peaks for the interrogated m/z. 
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Figure 3. Concentrations of PEA in extracts of pipettes. Each pipette was washed 
once with 8 mL of CHCl3. Number of pipettes washed in each experiment is 
indicated in brackets. Error bars represent SD, n=3. The Fisher Pasteur pipettes, 
5¾”, were from LOT n. 16168998 (Box 1). 
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Supplementary Figure 1. 
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Supplementary Figure 2. 
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Supplementary Figure 3. A) BPC chromatogram generated from a 5 µL injection 
of a 1 µM solution of PEA, 5 pmol on column; B) BPC chromatogram generated 
from the injection of the concentrated pipette extract; C) MS2 scan in positive ion 
mode at RT=5.7 min of the pipette extract showing peaks of the protonated PEA 
molecular ion at m/z = 300 Th, of the sodium adduct at 322 Th and of the 
molecular ion arising from the water loss at 282 Th. MS2 spectra of both PEA 
standard and pipette extract at 5.7 min are identical (only trace of standard is 
shown). 
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Supplementary Figure 4. MS1 LC profile of the pipet extract. Negative TIC is 
shown in blue; positive TIC is in violet and summed TIC is in black. In brown EIC 
of PEA accurate mass at 300.2897 Th, RT 6.3. 
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Supplementary Figure 5. 
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Supplementary Figure 6. 
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Supplementary Figure 7. 
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internal standards; LLOQ, lower limit of quantitation; MRM, multiple reaction-
monitoring; UPLC/MS/MS ultra-performance liquid chromatography coupled to 
tandem mass spectrometry. 
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Abstract 
The endocannabinoid system in the brain and periphery plays a major role 
in controlling food intake and energy balance. We reported that tasting dietary 
fats was met with increased levels of the endocannabinoids, 2- arachidonoyl-sn-
glycerol (2-AG) and anandamide, in the rat upper small intestine, and 
pharmacological inhibition of this local signaling event dose-dependently blocked 
sham feeding of fats. We now investigated the contribution of peripheral 
endocannabinoid signaling in hyperphagia associated with chronic consumption 
of a western-style diet in mice ([WD] i.e., high fat and sucrose). Feeding patterns 
were assessed in male C57BL/6Tac mice maintained for 60 days on WD or a 
standard rodent chow (SD), and the role for peripheral endocannabinoid 
signaling at CB1Rs in controlling food intake was investigated via 
pharmacological interventions. In addition, levels of the endocannabinoids, 2-AG 
and anandamide, in the upper small intestine and circulation of mice were 
analyzed via liquid chromatography coupled to tandem mass spectrometry to 
evaluate diet-related changes in endocannabinoid signaling and the potential 
impact on food intake. Mice fed WD for 60 days exhibited large increases in body 
weight, daily caloric intake, average meal size, and rate of feeding when 
compared to control mice fed SD. Inhibiting peripheral CB1Rs with the 
peripherally-restricted neutral cannabinoid CB1 receptor antagonist, AM6545 (10 
mg/kg), significantly reduced intake of WD during a 6 h test, but failed to modify 
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intake of SD in mice. AM6545 normalized intake of WD, average meal size, and 
rate of feeding to levels found in SD control mice. These results suggest that 
endogenous activity at peripheral CB1Rs in WDmice is critical for driving 
hyperphagia. In support of this hypothesis, levels of 2-AG and anandamide in 
both, jejunum mucosa and plasma, of ad-libitum fed WD mice increased when 
compared to SD mice. Furthermore, expression of genes for primary components 
of the endocannabinoid system (i.e., cannabinoid receptors, and 
endocannabinoid biosynthetic and degradative enzymes) was dysregulated in 
WD mice when compared to SD mice. Our results suggest that hyperphagia 
associated with WD-induced obesity is driven by enhanced endocannabinoid 
signaling at peripheral CB1Rs. 
 
Introduction 
Significant scientific and clinical evidence suggests one major driver of 
obesity is chronic consumption of foods that contain large quantities of fats and 
sugars (i.e., the western diet) (1, 2). Humans, rodents, and possibly other 
mammals detect dietary fats (3-7) and sugars (8) via receptors in the oral cavity 
and alimentary tract, which are critical in mediating preferences displayed for 
these high-energy foods (6, 9, 10). Numerous signaling pathways play important 
roles in the control of food intake, energy balance, and reward (9, 11), including 
endocannabinoid (eCB) signaling at cannabinoid CB1Rs in the brain (12-23) and 
periphery (12, 24-34).  
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Recent evidence suggests that the intake of palatable foods may be 
controlled by peripheral eCB signaling (9). For example, tasting emulsions 
containing mono- (i.e., oleic acid) or di-unsaturated fats (i.e., linoleic acid) – but 
not carbohydrate (i.e., sucrose) or protein – was met with large increases in eCB 
levels in the rat upper small intestine (27, 29). Pharmacological inhibition of eCB 
signaling at peripheral CB1Rs blocked (i) the intake of dietary fats in sham 
feeding rats (27) and (ii) robust preferences for di-unsaturated fats in a sham 
feeding two-bottle choice test (29) [see (6, 35) for description of the sham feeding 
paradigm in rat, which isolates the cephalic phase of feeding from post-ingestive 
influence].   
In addition to tasting dietary fats, we reported that fasting for up to 24 h is 
associated with increases in production of the eCB, 2-arachidonoyl-sn-glycerol 
(2-AG), in the upper small intestine of rats through a cholinergic-dependent 
mechanism that possibly involves the vagus nerve (28). For these experiments, 
fasting-induced 2-AG biosynthesis in the jejunum mucosa was blunted in rats 
that received either full subdiaphragmatic vagotomy or local intraduodenal 
infusion of the subtype 3 muscarinic acetylcholine receptor (m3 mAChR) 
antagonist, DAU5884 (28). Furthermore, pharmacological inhibition of small 
intestinal m3 mAChRs or CB1Rs blocked fasting-induced refeeding (28). Thus, 
gut-brain eCB signaling is a proposed orexigenic signal that may promote 
feeding under several distinct behavioral and metabolic conditions.  
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Several studies in humans and rodents suggest that peripheral eCB levels 
are increased under conditions of obesity (36-42); however, a role for peripheral 
eCB signaling in driving hyperphagia associated with a western-style diet (WD) is 
unknown.  In the current study, we investigated the impact of chronic 
consumption of WD on eCB levels in circulation and the upper small intestinal 
epithelium of mice, the contribution of WD-induced enhancements in eCB 
signaling at peripheral CB1Rs in promoting hyperphagia associated with a WD, 
and expression of genes encoding key eCB system components in the small 
intestine. 
 
Materials and Methods 
Animals 
Eight-week old male C57BL/6 mice (Taconic, Oxnard, CA, USA) were 
group-housed with free access to water and food, unless otherwise noted for 
food deprivation studies, and maintained on a 12 h light/dark cycle (lights off at 
1800 h). Test diets consisted of standard lab rodent chow[(SD) Lab Diet 5001, 
St. Louis,MO, USA; 13.4% kcal as fat, 56% kcal from carbohydrates, mostly 
starch], or western-style diet [(WD) Research Diets D12709B, New Brunswick, 
NJ, USA; 40% kcal as fat, 43% kcal fromcarbohydrates,mostly sucrose]. Five 
days prior to experimentation, animals were single-housed in cages with wire 
mesh inserts to prevent coprophagia during 24 h food deprivation experiments. 
For studies analyzing feeding behaviors, mice were single-housed in feeding 
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chambers (TSE, Chesterfield, MO, USA) with free access to water and SD or WD 
(described further below in Feeding behavior). All procedures met the U.S. 
National Institute of Health guidelines for care and use of laboratory animals, and 
were approved by the Institutional Animal Care and Use Committee of the 
University of California, Riverside. 
Feeding behavior 
Animals were acclimated to feeding chambers for five days prior to 
experimentation, and tested following 60 days on their respective test diet. 
Feeding behavior was monitored for the subsequent 24 h to assess daily intake 
patterns, or for 6 h following drug treatments. Feeding parameters included total 
caloric intake, average meal size, average rate of intake (kcals from food per 
minute), average number of meals, average meal duration, and average post-
meal interval. 
Chemicals and administration schedule 
 The peripherally restricted Cannabinoid Receptor Type 1 (CB1R) 
antagonist, AM6545 (Sigma, St. Louis, MO, USA), was administered by IP 
injection at 10 mg/kg in 2 mL/kg. Vehicle consisted of 7.5% dimethyl sulfoxide 
(DMSO, Sigma, St. Louis, MO, USA), 7.5% tween 80 (Chem Impex Intl Inc., 
Wood Dale, IL, USA), 85% sterile saline (warmed in a bath sonicator for 30 min) 
30 min prior (16:30 h) to the onset of behavioral analysis in feeding chambers. All 
control conditions were identical, except without drug present in the vehicle. The 
pharmacokinetics and half-life of AM6545 are not well-established, thus we 
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chose to evaluate intakes over a period of 6 h from time of administration after 
the onset of the dark phase. Mice maintained on SD or WD were split into two 
groups and analyzed across two sessions of behavioral testing such that each 
subgroup received either vehicle or drug with 72 h between administration. 
Tissue processing 
Lipid extraction 
 Isofluorane was used to anesthetize animals at time of tissue harvest 
(0900 to 1100 h), following 24 h food deprivation or ad-libitum feeding. Blood was 
collected by cardiac puncture and stored in EDTA-lined tubes on ice, then 
plasma was obtained by centrifugation (1500 g for 10 min, maintained at 4 °C). 
Jejunum was rapidly collected, washed with phosphate-buffered saline (PBS) on 
ice, sliced longitudinally on a stainless steel plate on ice, scraped with a glass 
slide to obtain mucosa, then snap-frozen in liquid N2 All samples were stored at 
−80 °C until processing. Frozen tissues were weighed and subsequently 
homogenized in 1.0 mL of methanol solution containing the internal standard, 
[2H5] 2-AG and [2H4]-AEA (Cayman Chemical, Ann Arbor, MI, USA). Lipids were 
extracted with chloroform (2 mL) and washed with water (1 mL). Lipids were 
similarly extracted from plasma samples, with the exception of a 0.9% saline 
wash replacing water (0.1 mL plasma at the expense of saline). Organic phases 
were collected and separated by open-bed silica gel column chromatography as 
previously described (28). Eluate was gently dried under N2 stream (99.998% 
pure) and resuspended in 0.1 mL of methanol:chloroform (9:1), with 1 μL 
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injection for analysis by ultra-performance liquid chromatography coupled to 
tandem mass spectrometry (UPLC/MS/MS). 
Measurement of 2-AG and anandamide 
Data was collected using an Acquity I Class UPLC system coupled to a 
Xevo TQ-S Mass Spectrometer (Waters, Milford, MA, USA) with accompanying 
electrospray ionization (ESI) interface. Lipids were separated on an Acquity 
UPLC BEH C18 column (2.1 × 50 mm i.d., 1.7 μm, Waters) with inline Acquity 
guard column (UPLC BEH C18 VanGuard Pre-column; 2.1 × 5 mm i.d., 1.7 μm, 
Waters), and eluted by a gradient of methanol in water (0.25% acetic acid, 5 mM 
ammonium acetate) according to the following gradient at a flow rate of 0.4 mL 
per min: 80% methanol 0.5 min, 80% to 100% methanol 0.5–2.5 min, 100% 
methanol 2.5–3 min, 100% - 80% methanol 3– 3.1 min). Column temperature 
was maintained at 40 °C, and samples were maintained in the sample manager 
at 10 °C. Argon (99.998%) was used as collision gas. MS detection was in 
positive ion mode and capillary voltage set at 0.1 kV. Cone voltage and collision 
energy as follows, respectively: 2-AG = 30v, 12v; [2H5] 2-AG = 25v, 44v; 
anandamide =30v, 14v; [2H4] anandamide =26v, 16v. Lipids were quantified 
using a stable isotope dilution method detecting protonated adducts of the 
molecular ions [M+H]+ in the multiple reaction monitoring (MRM) mode. Acyl 
migration from 2-AG to 1-AG is known to occur (43),  thus all reported values for 
2-AG represent the sum of 2-AG and 1-AG. Tissue processing and LCMS 
analysis from an individual experiment occurred independently of other 
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experiments. Extracted ion chromatograms were used to quantify 2-AG (m/z = 
379.3 > 287.3) and anandamide (m/z = 348.3 > 62.0), and [2H5] 2-AG (m/z = 
384.3 > 93.4) and [2H4] anandamide (m/z = 352.3 > 66.1), which were used as 
internal standards. Our established lower limit of quantitation (LLOQ; signal-to-
noise ratio of > 10) of analytes using our optimized UPLC/MS/MS methods are 
as follows: 2-AG, 0.5 pmol; AEA, 0.008 pmol. 
Gene expression analysis 
Total RNA was extracted from jejunal mucosa using a Trizol (Invitrogen, 
Carlsbad, CA) and RNeasy (Qiagen, Valencia, CA) combined method, and 
generated first-strand complementary DNA using M-MLV reverse transcriptase 
(Invitrogen, Carlsbad, CA). All surfaces for tissue collection and processing were 
sanitized using 70% ethanol and then treated with an RNAse inhibitor (RNAse 
out, G-Biosciences, St. Louis, MO, USA) to maintain integrity of isolated RNA. 
Reverse transcription of total RNA (9.5 μg) was performed with random 
hexamers (Invitrogen, Carlsbad, CA) for 50 min at 37 °C. qRT-PCR was carried 
out using PrimePCR Assays (Biorad, Irvine, CA, USA) with primers for 
cannabinoid receptor 1 (CNR1), cannabinoid receptor 2 (CNR2), diacylglycerol 
alpha and beta (DAGLA and DAGLB), monoacylglycerol lipase (MGLL), and fatty 
acid amide hydrolase (FAAH) using the preconfigured Sybr green assay (Biorad, 
Irvine, CA). Reactions were run in triplicate. Hprt was selected as a 
housekeeping gene for experimental conditions; no changes in its expression 
were found across conditions included in our analysis (Cq values for conditions, 
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n=4, two replicates: ad-libitum fed standard diet, 24.09 ± 0.10; 24 h fasted 
standard diet, 24.29 ± 0.13; ad-libitum fed western diet, 24.09 ± 0.44; 24 h fasted 
western diet, 24.21 ± 0.23; not significant). 
Statistical analyses 
Data was analyzed using Graphpad Prism6 software. Results are 
expressed as the mean ± S.E.M. Significant differences between groups were 
assessed using Student's two-tailed t-test, and regular or repeated measures 
two-way analysis of variance (ANOVA) with Student-Newman-Keuls or Sidak 
post hoc test, respectively, for comparison of means. Differences were 
considered significant if P < 0.05. 
Results 
Western diet-induced obese mice are hyperphagic 
Mice fed WD ad-libitum for 60 days, when compared to mice maintained 
on standard diet (SD), rapidly gained body weight [Fig. 1a, diet effect on 
cumulative change in body weight F(1,30) = 125.6 p < 0.001, and interaction 
between diet and time F(29,870) = 157.3 p < 0.001; Fig. 1b, diet effect on 
cumulative gross body weight F(1,30) = 91.74 p < 0.001, and interaction between 
diet and time F(29,870) = 157.3 p < 0.001], and consumed substantially higher 
calories over a 24 h period (Fig. 1c: t=3.89, p < 0.001). This effect was met with 
increased average meal size (Fig. 1d: t=4.75, p < 0.001) and rate of food 
consumption (Fig. 1e: t = 3.77, p < 0.001), and remained irrespective of body 
weight (SD versus WD: total calories, from 241.6 ± 32.8 to 405 ± 44.7 kcal per kg 
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bodyweight, t = 2.96, p = 0.01; average meal size, from 23.4 ± 1.5 to 33.0 ± 2.7 
kcal per kg body weight, t = 2.78, p = 0.01; average rate of intake, from 11.0 ± 
0.8 to 14.3 ± 1.2 kcal per kg per minute, t = 2.08, p = 0.04; data from 8 animals 
per condition). Other feeding parameters including meal duration (Fig. 1f: t = 
1.03, p = 0.31), frequency (Fig. 1g: t = 1.69, p = 0.11), and post-meal interval 
(Fig. 1h: t = 0.31, p = 0.76) remained unchanged in WD mice when compared to 
SD mice. These results indicate that mice fed WD for 60 days exhibit 
hyperphagia due to larger meal size and rate of consumption. 
Western diet intake is associated with increases in levels of endocannabinoids in 
jejunum epithelium and circulation 
We previously reported that tasting dietary fats was met with increased 
levels of 2-AG and anandamide in the jejunum of rats, but in no other peripheral 
organ tested (27, 29). Importantly, direct infusion of low doses of the CB1R 
antagonist, rimonabant (0.3mg/kg), into the jejunum, or peripheral administration 
of peripherally-restricted CB1R inhibitors that do not reach the brain (see for 
AM6545 (24, 30) and URB447 (26)) blocked fat sham feeding (27) and 
preferences for linoleic acid in a two-bottle choice sham feeding test (29). These 
results suggest that tasting dietary fats drives eCB signaling in the upper small 
intestine, which in turn, generates positive feedback that promotes dietary fat 
intake (27, 29).  
In order to elucidate the molecular underpinnings of WD-induced 
hyperphagia in the current study and evaluate the contribution of peripheral eCB 
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signaling in these processes, we quantified small intestinal and circulating levels 
of the eCBs, 2-AG and anandamide, in mice maintained on WD or SD under 
free-feeding and 24 h fasting conditions.  Free-feeding mice fed WD for 60 days 
(Fig 2a), when compared to free-feeding mice maintained on SD, displayed 
higher levels of 2-AG in jejunum mucosa that reached concentrations 
indistinguishable from fasted SD or fasted WD mice [Fig 2a, diet effect on 2-AG 
levels F(1,24)=4.52 p=0.04, and interaction between diet and feeding condition 
F(1,24)=4.98 p=0.03; multiple comparisons test of free-feeding SD versus fasted 
SD and both free-feeding and fasted WD p<0.05, multiple comparisons test of 
free-feeding WD versus both fasted SD and WD p=ns]. In addition, anandamide 
levels in jejunum of WD mice were elevated when compared to SD mice 
irrespective of feeding status [Fig 2b, diet effect on anandamide levels 
F(1,24)=25.88 p<0.001, and no interaction between diet and feeding condition 
F(1,24)=0.53 p=0.47; multiple comparisons test of FF SD versus FF WD, p<0.05; 
FD SD versus both FF and FD WD, p<0.001]. Furthermore, levels of 2-AG were 
greatly elevated in plasma of both free-feeding and 24 h fasted WD mice when 
compared to SD mice [Fig 2c; diet effect on 2-AG levels F(1,33)=141.3 p<0.001, 
and interaction between diet and feeding condition F(1,33)=6.62 p=0.02 ; multiple 
comparisons test of all SD feeding conditions versus WD, P<0.001], an effect 
also found for anandamide [Fig 2d, diet effect on anandamide levels 
F(1,33)=168.5 p<0.001, and no interaction between diet and feeding condition 
F(1,33)=0.01 p=0.94; multiple comparisons test of all SD feeding conditions 
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versus WD, p<0.001]. Collectively, these data suggest that chronic ad-libitum 
consumption of a WD is associated with elevated levels of eCBs in mouse jejunal 
epithelium and plasma, which may in turn, activate peripheral CB1Rs and 
promote hyperphagic responses to WD. 
Inhibiting peripheral CB1Rs blocks hyperphagia in mice maintained on a western 
diet 
We next evaluated the contribution of heightened eCB signaling at 
peripheral CB1Rs (see Fig 2) in hyperphagia associated with WD-induced 
obesity. Mice fed ad-libitum WD or SD for 60 days were treated with the 
peripherally-restricted neutral CB1R antagonist, AM6545 ((25, 30) 10 mg per kg 
IP) or vehicle prior to a 6 h feeding test. When compared to vehicle treatment, 
AM6545 inhibited intake of WD [Fig 3a, drug effect on WD intake F(1,12)=7.45 
p=0.018, and interaction between drug effect and time (F(5,60)=11.39 p<0.001; 
multiple comparisons test of AM6545 treatment versus vehicle, 4hr p<0.05, 5hr 
p<0.01, 6hr p<0.001)]. In contrast to WD, AM6545 failed to affect intake of SD at 
all time points [Fig 3b, no drug effect on WD intake F(1,14)=0.06 p=0.82, and no 
interaction between drug effect and time F(5,70=1.01 p=0.42]. Similar to results 
found for 24 h intakes of WD versus SD (Fig 1b-g), vehicle-treated WD mice, 
when compared to vehicle-treated SD mice, displayed increased 6 h caloric 
intake [Fig 3c, diet effect on intake F(1,26)=4.23 p=0.05; multiple comparisons 
test of SD versus WD p<0.01], average meal size [Fig 3d, diet effect on intake 
F(1,26)=5.41 p=0.02; multiple comparisons test of SD versus WD, p<0.01], and 
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rate of feeding [Fig 3e, diet effect on intake F(1,26)=5.52 p=0.02; multiple 
comparisons test of SD versus WD, p<0.05]. Treatment with AM6545, when 
compared to vehicle, significantly decreased WD intake [Fig 3c, drug effect on 
intake F(1,26)=9.83 p=0.01, and interaction between drug and feeding condition 
F(1,26)=13.96 p=0.001; multiple comparisons test of AM6545 WD versus vehicle 
WD, p<0.01], and normalized intake to levels found for SC (Fig3c; multiple 
comparisons test of AM6545 WD versus both AM6545 SD and vehicle SD, 
p=ns). Treatment with AM6545, when compared to vehicle, similarly decreased 
WD meal size [Fig 3d, drug effect on meal size F(1,26)=10.68 p=0.01, and 
interaction between drug and feeding condition F(1,26)=5.52 p=0.02; multiple 
comparisons test of AM6545 WD versus vehicle WD, p<0.01], and normalized 
intake to levels found for SC (Fig 3d; multiple comparisons test of AM6545 WD 
versus both AM6545 SD and vehicle SD, p=ns). Increased rate of intake found 
for vehicle WD versus vehicle SD was absent in AM6545-treated animals (Fig 
3e; multiple comparisons test of WD versus SD in AM6545-treated mice, p=ns); 
however, there was high variability and a lack of group effect of drug [Fig 3e, 
drug effect on rate of intake F(1,26)=0.598 p=0.44, and no interaction between 
drug and feeding condition F(1,26)=2.25 p=0.14]. Treatment with AM6545 had no 
effect on any meal parameters included in our analysis in SD mice (Fig 3c-e; 
multiple comparisons test of AM6545 SD versus vehicle SD, p=ns). Our results 
suggest that elevated levels of endogenous eCB signaling at peripheral CB1Rs 
drives hyperphagia in WD-induced obesity.  
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Western diet affects gene expression of eCB system components in jejunum 
Expression of gene transcripts were increased in fasted SD mice when 
compared to free-feeding controls for cannabinoid receptor 1 [(CNR1) Fig 4a, 
feeding condition effect on expression F(1,41)=4.63, p=0.04; multiple 
comparisons test of free-feeding SD versus fasted SD, p<0.01), cannabinoid 
receptor 2 [(CNR2) Fig 4b, feeding condition effect on expression F(1,41)=6.83, 
p=0.01; multiple comparisons test of free-feeding SD versus fasted SD, p<0.05], 
and diacylglycerol lipase α [(DAGLA, 2-AG biosynthetic enzyme) Fig 4c, feeding 
condition effect on expression F(1,44)=13.21, p<0.001, multiple comparisons test 
of free-feeding SD versus fasted SD, p<0.05]. In addition, gene expression was 
significantly modified in WD-fed mice, when compared to SD-fed mice, such that 
fasting effects were absent for CNR1 [Fig 4a, diet effect on expression 
F(1,41)=5.39 p=0.03, and interaction between diet and feeding condition 
F(1,41)=4.698 p=0.04; multiple comparisons test of free-feeding WD versus 
fasted WD, ns; multiple comparisons test of both free-feeding and fasted WD 
versus fasted SD, p<0.01] and DAGLA [Fig 4c, diet effect on expression 
F(1,44)=6.42 p=0.02, and no interaction between diet and feeding condition 
F(1,44)=0.2481) p=0.63; multiple comparisons test of free-feeding WD versus 
fasted WD, p=ns; multiple comparisons test of both free-feeding and fasted WD 
versus fasted SD p<0.05]; however, a group diet effect was not found for CNR2 
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[Fig 4b, diet effect on expression F(1,41)=1.863, p=0.19], despite a lack of effect 
of fasting in WD mice (Fig 4b, multiple comparisons test of free-feeding WD mice 
versus fasted WD mice, p=ns). 
Feeding status was not met with any significant changes in gene expression in 
SD and WD mice for diacylglycerol lipase β [DAGLB, 2-AG biosynthetic enzyme; 
Fig 4d, feeding condition effect on expression F(1,44)=2.1 p=0.154], 
monoacylglycerol lipase [(MGLL, 2-AG degradative enzyme) Fig 4e, feeding 
condition effect on expression F(1,44)=0.07 p=0.79], and fatty acid amide 
hydrolase [(FAAH, anandamide degradative enzyme) Fig 4f, feeding condition 
effect on expression F(1,41)=1.33 p=0.26]. There was, however, a significant 
group diet effect for expression of MGLL in WD-fed mice versus SD-fed mice for 
[Fig 4e, diet effect on expression F(1,44)=11.95 p=0.001, and interaction 
between diet and feeding condition F(1,44)=5.25 p=0.03; multiple comparisons 
test of both free-feeding and fasted WD mice versus free-feeding SD mice] and 
FAAH [Fig 4f, diet effect on expression F(1,41)=4.1 p=0.05, and interaction 
between diet and feeding status F(1,41)=4.81 p=0.03 ; multiple comparisons test 
of both free-feeding and fasted WD mice versus free-feeding SD mice]. 
Collectively, the results suggest a dysregulation in the expression of eCB 
components in WD mice; however, elevated levels of eCBS in jejunum and 
plasma are not entirely explained by these effects.   
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Discussion 
In 2013, the American Medical Association announced that obesity is a 
disease, which affects nearly one-third of American adults with significant 
negative impact on life expectancy (44). Mounting evidence suggests that a 
primary contributing factor of these obesity rates is overconsumption of high-
energy foods containing large quantities of fats and sugars, known as the 
“western diet” (WD (1, 2)). We utilized a mouse model of WD-induced obesity in 
the present study to investigate the role for peripheral eCB signaling in 
hyperphagia associated with consumption of western diet. Collectively, our 
results suggest that chronic consumption of a WD is associated with elevated 
levels of 2-AG and anandamide in jejunum mucosa and plasma of mice, which 
may in turn, activate peripheral CB1Rs and promote hyperphagic responses to 
WD. 
Mice fed ad-libitum WD for 60 days displayed robust increases in caloric 
intake as a result of increased meal size, and rate of feeding (i.e., consummatory 
behaviors) when compared to control mice maintained on SD that contained low 
levels of fats and sugar (Fig 1). These data suggest that hyperphagia associated 
with WD-induced obesity may be driven by hedonically-positive feedback from 
specific constituents of the diet. Indeed, merely tasting dietary fats (i.e., corn oil) 
or carbohydrates (i.e., sucrose) induced dopamine outflow in the ventral striatum 
in rats (45, 46), which suggests that palatable food taste may promote intake by 
a mechanism that includes activating regions of the brain associated with food 
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reward. Furthermore, we reported that tasting liquid diets containing dietary fats 
increased levels of the eCBs in the upper small intestine of rats, but no other 
organ tested, and pharmacological inhibition of this local signaling event with 
selective CB1R antagonists blocked intake and preferences for fat (27, 29). 
These studies suggest a gut-brain eCB signaling axis that promotes palatable 
food intake based on its unique gustatory properties (6). 
In the current study, hyperphagia observed in WD-induced obese mice 
was blocked by peripheral administration of the peripherally-restricted neutral 
CB1R antagonist, AM6545; however, AM6545 exerted no effect on the intake of 
SD during a 6 h test (Fig 2). The pharmacokinetics and half-life of AM6545 are 
not well-established, thus we evaluated intakes over a period of 6 h from the 
onset of the dark phase. Importantly, inhibiting peripheral eCB signaling at 
CB1Rs in WD mice normalized enhancements in meal size to levels found in SD 
mice and blocked increases in rate of feeding. These results suggest that 
heightened endogenous activity at peripheral CB1Rs is responsible for driving 
hyperphagia associated with chronic consumption of WD, an effect not present in 
mice fed SD, which might not display active eCB signaling during ad-libitum 
feeding conditions. Based on these results and our previous studies in rats that 
revealed increases in eCB signaling exclusively in the small intestine in response 
to tasting fats (27, 29) and fasting for 24 h (28), we asked whether eCB levels in 
the epithelium of the jejunum may also be elevated in WD mice and drive 
hyperphagia. Indeed, levels of 2-AG were significantly elevated in the epithelium 
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of the jejunum in free-feeding mice fed WD for 60 days when compared to ad-
libitum fed mice maintained on SD, and reached levels comparable to those in 
fasted mice maintained on SD (Fig 3a). This result is consistent with reports from 
other groups that show an enhancement of eCB levels in peripheral organs, 
namely in the upper small intestine (39, 47) and liver (40, 48), of mice maintained 
on high-fat diets for eight and 14 to 16 weeks, respectively. In contrast to fasting-
induced increases in levels of jejunal 2-AG displayed by SD mice – which is an 
effect similar to results we previously reported in rats (28) – WD mice failed to 
display any further increases in 2-AG after a 24 h fast when compared to free-
feeding conditions (Fig 3a). This result suggests a maximal level of 2-AG 
production in small intestinal epithelium, possibly due to a limited availability of 2-
AG precursors (e.g., 1,stearoyl,2-arachidonoyl-sn-glycerol (28, 49)). 
Furthermore, in contrast to reports in rats (31, 39), we found no significant 
changes in anandamide levels in jejunum mucosa in response to fasting in SD 
mice, which might indicate species and/or strain differences among rodents. 
Similar to 2-AG, levels of anandamide were not affected by fasting in WD mice. 
Collectively, the results suggest that enhanced eCB activity at CB1Rs in the 
jejunum of WD mice may promote hyperphagia by increasing meal size and rate 
of feeding. Further studies that investigate discrete components of WD in these 
responses, however, are warranted.  
Specific downstream pathways that communicate peripherally-derived 
eCB signals to the brain and promote feeding of WD remain to be determined; 
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however, neural and endocrine mechanisms may play a prominent role. One 
potential downstream candidate mechanism includes enhanced eCB-mediated 
inhibition of cholecystokinin release from the upper small intestine in WD-induced 
obesity, which may in turn, act to increase meal size and rate of feeding of WD 
by delaying the activation of cholecystokinin-mediated satiation signaling to the 
brain carried by the afferent vagus nerve (50). In support of this hypothesis, gene 
transcripts for CB1Rs have been identified in enteroendocrine I cells within the 
duodenum of rodents, which may act to inhibit cholecystokinin release (51). In 
addition to enhanced local signaling in the upper small intestine of WD mice, 
elevated levels of circulating eCBs in WD mice may also act as an endocrine 
signal that directly interacts with feeding- and reward-related pathways in the 
brain, and thereby contribute to hyperphagia and WD-induced obesity found in 
our studies. Indeed, studies in normal weight and obese humans suggest that 
consumption of highly palatable foods (i.e., hedonic eating) is associated with 
elevated levels of 2-AG in plasma (52, 53). Furthermore, when compared to 
normal weight human subjects, plasma levels of 2-AG were elevated in obese 
women (38), and both 2-AG and anandamide were elevated in saliva of obese 
male and female subjects (36). It remains to be determined, however, if 
circulating eCBs may also directly interact with feeding- and reward-related 
pathways in the brain.  
Analysis of gene expression of primary constituents of the eCB system 
suggests a dysregulation in the expression of key components of the eCB 
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system following chronic consumption of WD; however, heightened eCB tone in 
WD obesity is not entirely explained by these results. We found that fasting for 24 
h was met with increased expression of mRNA for CB1Rs, CB2Rs, and DAGLα in 
the jejunum mucosa of mice maintained on SD; however, WD mice failed to 
display a similar response (Fig 4a,b,c). Interestingly, there was group effect on 
the expression of DAGLAα such that WD mice had significantly lower expression 
when compared to SD. In light of elevated levels of 2-AG in the jejunum mucosa 
and plasma of mice fed a WD versus SD, this result is counter to what we 
expected for expression of this biosynthetic enzyme for 2-AG. Furthermore we 
found increases in the expression of mRNA for the 2-AG and anandamide 
degradative enzymes, MAGL and FAAH respectively, in mucosa of WD mice 
when compared to levels in SD mice (Fig 4e), which is counter to our expectation 
that eCB degradative enzyme expression would decrease given elevations in 2-
AG and anandamide. This result may reflect an adaptive response to elevated 
levels of 2-AG and anandamide in WD mice. No changes were found in DAGLβ 
expression under all conditions (Fig 4d), which suggests that similar to results 
found in brain (49), the DAGLα isoform rather than DAGLβ, may be primarily 
involved in the biosynthesis of 2-AG in jejunum mucosa. Collectively, our gene 
expression results do not provide clear evidence that explains elevations in eCB 
levels in WD mice when compared to SD mice. 
An analysis of levels of protein for all components of the eCB system is 
warranted, as well as analysis of the function of eCB biosynthetic and 
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degradative enzymes via functional enzyme assays, which will help to address 
the underpinnings of eCB elevations in WD mice. Furthermore, it is plausible that 
that cholinergic signaling is enhanced under conditions of ad-libitum feeding of 
WD rather than any specific changes in the expression of eCB machinery. A test 
of these hypotheses remain. The latter scenario is supported by previous 
evidence from our group that suggests a key role for cholinergic signaling at 
small intestinal muscarinic m3 receptors, and likely the efferent vagus nerve, in 
driving 2-AG production and re-feeding after a fast in rats (28). In further support 
of this hypothesis, we reported that tasting dietary fats drives production of the 
eCBs in the upper small intestine of rats, an effect that is absent in animals that 
received complete subdiaphragmatic vagotomy. This result suggests that critical 
signals from the oral cavity related to fat taste are transmitted to the small 
intestine via the vagus nerve (27, 29). Future studies will be important to evaluate 
the contribution of cholinergic signaling in driving eCB production in the periphery 
that promotes hyperphagia associated with consumption of WD. 
Conclusion: Our results suggest that mice fed a WD for 60 days are 
hyperphagic due to increases in meal size and rate of consumption, and that 
feeding responses are driven – at least in part – by increases in peripheral eCB 
tone in the upper small intestinal epithelium and circulation. Future studies will be 
critical to evaluate the specific downstream pathways that peripheral eCBs 
interact with to communicate with the brain in the control of feeding, including 
possible neural (e.g., vagal) and endocrine (i.e., circulation) mechanisms. In 
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addition, it will be important to evaluate the interaction between a variety of 
species of lipids (e.g., high in mono- or di-unsaturated fats versus saturated and 
polyunsaturated fats) and carbohydrates (e.g., fructose, sucrose) on eCB 
signaling in the gut and brain, and their impact on hedonic feeding behaviors that 
can lead to obesity.  
Together, our work suggests peripheral CB1Rs may be an effective 
therapeutic target for the treatment of western diet-induced obesity and eating 
disorders.  This therapeutic approach has substantial advantage over traditional 
CB1Rs antagonists/inverse agonists (e.g., rimonabant) that cross the blood-brain 
barrier and interact with central brain mechanisms. For example, rimonabant was 
found to be effective for the treatment of obesity and metabolic syndrome in 
humans; however, benefits were met with severe psychiatric side effects, 
including depression and in some instances, suicide (54). These outcomes 
precluded rimonabant from gaining FDA approval. On the other hand, the work in 
the present report as well as others (12, 24-34) suggests that targeting peripheral 
CB1Rs with antagonists (e.g., AM6545) that do not reach the brain may be an 
effective treatment strategy for metabolic syndrome and possibly eating 
disorders, without deleterious psychiatric side-effects inherent to brain-penetrant 
CB1R inhibitors.  
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Figures 
 
Figure 1. Chronic consumption of a western diet is associated with hyperphagia. 
Male mice maintained for 60 days on a western diet (Western) become obese (a, 
cumulative change in body weight; b, gross body weight) and display increases 
in 24 h caloric intake, meal size, and rate of intake (c-e) when compared to mice 
maintained on a standard chow diet (Stand). Meal duration, frequency, and post 
meal interval do not significantly differ between diets (f-h). Repeated measures 
two-way ANOVA, with Sidak's multiple comparison post hoc test, *** = p  0.001 
(a); unpaired Student's t-test (two-tailed), *** = p < 0.001 between Stand and 
Western. Results are expressed as means ± SEM; n=16/condition (a,b), 
n=8/condition (c-h). 
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Figure 2. Mice fed a western diet display increases in levels of 2-AG and 
anandamide in jejunum mucosa and plasma. Mice maintained on a standard diet 
(Stand) that were fasted for 24 h (FD) display increases in 2-AG levels in jejunum 
mucosa, when compared to free feeding controls [FF (a)], and FF male mice 
maintained on western diet (Western) display increases in levels of 2-AG in 
jejunum mucosa to levels found in fasted Stand mice (a). Western mice display 
elevated anandamide in jejunum mucosa when compared to Stand mice, 
irrespective of feeding condition (b). Western mice display increases in plasma 
levels of 2-AG (c) and anandamide (d) when compared to Stand mice. Two-way 
ANOVA with Student-Newman-Keuls multiple comparison post hoc test. * = p < 
0.05, *** = p < 0.001, ns = not significant. Results are expressed as means ± 
SEM; n = 7/condition for jejunum, n=9–10/condition for plasma. 
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Figure 3. Inhibiting peripheral CB1Rs reduces food intake in mice fed a western 
diet, but not a standard diet, and normalizes intake and meal patterns in western 
diet fed mice. Pharmacological blockade of peripheral CB1Rs with AM6545, 
when compared to vehicle treatment (Veh), inhibits the caloric intake of male 
mice maintained for 60 days on western diet [WD (a)] during a 6 h test, but has 
no effect on caloric intake in mice maintained on standard chow diet [b (SD)]. 
Vehicle-treated WD mice display an increase in caloric intake (c), average meal 
size (d), and rate of feeding [e (kcal per minute of feeding)], when compared to 
Veh-treated SD mice during a 6 h test. Pharmacological blockade of peripheral 
CB1Rs with AM6545 reduces total caloric intake (c), meal size (d), and rate of 
intake (e) in WD mice to levels indistinguishable from SD control mice, and has 
no effect on meal parameters in SD mice (c-e). Repeated measures (a,b) or 
regular (c-e) two-way ANOVA, with Sidak's or Student-Newman-Keuls, 
respectively, multiple comparison post hoc test, * = p < 0.05, ** = p < 0.01, *** = p 
< 0.001. Results are expressed as means ± SEM; n=7–8/condition. 
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Figure 4. Expression of genes for components of the endocannabinoid system is 
modified in mice fed a western diet. Expression of mRNA encoding CB1R [a 
(CNR1)], CB2R [b (CNR2)], DAGL-α [c (DAGLA)], and FAAH (f) are elevated in 
standard chow-fed (Stand) 24 h fasted (FD) male mice, an effect absent in mice 
fed a western diet (Western). No changes are found under all conditions for 
DAGL-β [d (DAGLB)]. Expression of MAGL and FAAH genes are elevated in 
Western mice when compared to Stand (e,f). Two-Way ANOVA with Student-
Newman-Keuls multiple comparison post hoc test. ** = p < 0.01, * = p < 0.05, ns 
= not significant. Results are expressed as means ± SEM; n = 3–4/condition in 
triplicate. 
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Abstract  
Gut-brain signaling controls feeding behavior and energy homeostasis; 
however, the underlying molecular mechanisms and impact of diet-induced 
obesity (DIO) on these pathways are poorly defined. We tested the hypothesis 
that elevated endocannabinoid activity at cannabinoid CB1 receptor (CB1Rs) in 
the gut of mice rendered DIO by chronic access to a high-fat and sucrose diet 
inhibits nutrient-induced release of satiation peptides and promotes overeating. 
Immunoreactivity for CB1Rs was present in enteroendocrine cells in the mouse 
upper small-intestinal epithelium that produce and secrete the satiation peptide, 
cholecystokinin (CCK), and expression of mRNA for CB1Rs was greater in these 
cells when compared to non-CCK producing cells. Oral gavage of corn oil 
increased levels of bioactive CCK (CCK-8) in plasma from mice fed a low-fat no-
sucrose diet. Pretreatment with the cannabinoid receptor agonist, WIN55,212-2, 
blocked this response, which was reversed by co-administration with the 
peripherally-restricted CB1R neutral antagonist, AM6545. Furthermore, 
monoacylglycerol metabolic enzyme function was dysregulated in the upper 
small-intestinal epithelium from mice fed a high-fat and sucrose diet, which was 
met with increased levels of a variety of monoacylglycerols including the 
endocannabinoid, 2-arachidonoyl-sn-glycerol.  Corn oil failed to affect levels of 
CCK in DIO mouse plasma; however, pretreatment with AM6545 restored the 
ability for corn oil to stimulate increases in levels of CCK, which suggests that 
elevated endocannabinoid signaling at small-intestinal CB1Rs in DIO mice 
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inhibits nutrient-induced CCK release. Moreover, the hypophagic effect of 
AM6545 in DIO mice was reversed by co-administration with the CCKA receptor 
antagonist, devazepide. Collectively, these results provide evidence that 
hyperphagia associated with DIO is driven by a mechanism that includes CB1R-
mediated inhibition of gut-brain satiation signaling. 
Introduction 
Food intake and energy homeostasis are controlled by a dynamic interplay 
of gut-brain signaling pathways that are not well-defined but are thought to 
become dysregulated in obesity (1).  Recent studies in humans and rodents 
suggest a critical role for the endocannabinoid (eCB) system in these processes 
(2-4). The eCB system is located in cells throughout the body and is comprised 
of the eCBs, 2-arachidonoyl-sn-glycerol (2-AG) and anandamide (AEA), their 
biosynthetic and degradative enzymes, and the cannabinoid receptor subtypes 1 
and 2 [CB1R and CB2R, respectively (5, 6)]. CB1Rs in the brain control food 
intake and energy homeostasis (3, 7); however, targeting central CB1Rs with 
antagonists for the treatment of human obesity led to psychiatric side-effects that 
preclude their use as safe and effective anti-obesity therapeutics (8). In contrast, 
CB1Rs antagonists that are restricted to the periphery and do not readily cross 
the blood-brain barrier are associated with improvements in a variety of 
metabolic parameters in rodents and may be an effective anti-obesity strategy 
that is devoid of psychiatric side-effects inherent to brain-permeable drugs (9-17). 
Nonetheless, peripheral mechanisms influence brain function [e.g., signals from 
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the gut microbiome (18)]; thus, the impact of  disrupting endocannabinoid 
signaling at peripheral CB1Rs on these functions is largely unknown and 
warrants future investigation. 
Studies from our lab and others suggest key roles for the peripheral eCB 
system in controlling feeding behavior and energy homeostasis (2, 7, 19). 
Indeed, eCB levels are increased in the small-intestinal epithelium of rodents (i) 
during a fast (11, 20-22), (ii) after oral exposure to dietary fats (9, 10), and (iii) in 
a mouse model of western diet-induced obesity (DIO) (22). Pharmacological 
inhibition of elevated eCB signaling at small-intestinal CB1Rs with peripherally-
restricted CB1R antagonists blocks (i) re-feeding after a fast (11), (ii) intake of 
dietary fats based on their orosensory properties (9, 10), and (iii) overeating (i.e., 
increased meal size and caloric intake) associated with DIO, (22). These studies 
suggest that the eCB system in the small-intestinal epithelium plays a key role in 
feeding behavior and energy balance, and becomes dysregulated in DIO. 
The mechanism(s) underlying eCB control of gut-brain signaling and its 
dysregulation in DIO is largely unknown. Nonetheless, CB1Rs are expressed on 
the afferent vagus nerve and suggested to control feeding behavior and energy 
balance by directly modifying gut-brain vagal signaling important for food intake 
(23-25). For example, expression of CB1Rs in the rat nodose ganglion is 
upregulated after fasting, and refeeding or administration of the gut-derived 
satiation peptide, cholecystokinin (CCK), reversed this effect (23, 25). Moreover, 
both, fasting-induced increases in CB1R expression in the nodose ganglion and 
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the ability for CCK to decrease this response were blunted in rats fed a high-fat 
diet  (26). Elmquist and colleagues, however, reported that select deletion of 
CB1Rs on the afferent and efferent vagus nerve had no effect on food intake or 
body weight in mice fed a standard rodent chow or high-fat diet (27). These 
findings suggest that CB1Rs expressed on the vagus nerve may be dispensable 
for feeding behavior and maintenance of body weight.  
Dietary fats and other macronutrients are sensed by enteroendocrine cells 
in the small-intestinal epithelium and stimulate release of satiation peptides 
including CCK (1, 28-30), which controls meal size and satiation by activating 
CCKA receptors on the afferent vagus nerve (31-37) and possibly in the brain  
(38, 39).  Furthermore, CCK-containing I-cells in the upper small-intestinal 
epithelium of mice express genes for CB1Rs (40). Thus, CB1Rs in the small-
intestinal epithelium may control feeding behavior by an indirect mechanism that 
includes controlling release of gut-derived satiation peptides. We investigated 
this possibility by testing the hypothesis that elevated endocannabinoid activity at 
CB1Rs in the gut of mice rendered DIO by chronic access to a high-fat and 
sucrose diet inhibits nutrient-induced release of satiation peptides, which in turn, 
leads to overeating by delaying satiation. 
Materials and Methods 
Animals  
Eight-week old C57BL/6 mice (Taconic, Oxnard, CA, USA) were group-
housed with ad libitum food and water access and maintained on a 12 h 
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dark/light cycle. C57BL/6-Tg(Cck-EGFP)2Mirn/J mice with enhanced green 
fluorescent protein on the promoter for cholecystokinin were used for 
immunohistochemistry and fluorescence-activated cell sorting (FACS) of small-
intestinal CCK-containing cells (Jackson Laboratories, Bar Harbor, ME, USA). 
Test diets included Teklad 2020x soy-purified Standard Rodent Chow (SD; 
Envigo, Huntingdon, UK) or Western-style diet (WD; Research Diets D12709B, 
New Brunswick, NJ, USA; 40% kcal as fat, 43% kcal as carbohydrates, mainly 
sucrose). Body weights were recorded every other day at noon. To assess 
feeding behaviors, mice were single-housed in behavior chambers (TSE 
Systems, Chesterfield, MO, USA). All procedures met the U.S. National Institute 
of Health guidelines for care and use of laboratory animals and were approved 
by the Institutional Animal Care and Use Committee of the University of 
California, Riverside. 
Feeding behaviors 
Animals were placed into feeding chambers five days prior to recording for 
acclimation, and testing began at 60 days after being placed on their respective 
experimental diets. Feeding behaviors were assessed starting 1 h prior to dark 
cycle (1700 h) over a 24 h period for acclimation and for 12 h following drug 
administrations. Behavioral parameters include total caloric intake, average meal 
size, average rate of intake, average number of meals, first meal size, average 
meal duration, and average post meal interval. Data were processed using TSE 
Phenomaster software. 
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Chemicals and administration schedule 
AM6545, a peripherally-restricted CB1R neutral antagonist, was given by IP 
injection at 10 mg per kg (Northeastern University Center for Drug Discovery, 
Boston, MA, USA). Devazepide (Tocris, Bristol, UK), a CCKA receptor 
antagonist, was given IP at 0.3 mg per kg. Both drugs were dissolved in vehicle 
consisting of 7.5% DMSO, 7.5% Tween80, and 85% sterile saline, and warmed 
in a water bath to ensure solubility. All control conditions were matched, using 
vehicle in place of drugs and injections occurred 1 h prior to behavior recording 
(1600 h). A 72-h washout period was allowed between drug treatments. JZL184 
(Tocris, Bristol, UK), a potent inhibitor of monoacylglycerol lipase (MGL), was 
used to prevent monoacylglycerol hydrolysis in the diacylglycerol lipase (DGL) 
assay and to validate our MGL assay (described below). Tetrahydrolipstatin 
(Tocris, Bristol, UK), a lipase inhibitor used routinely to study DGL activity (41, 
42), was used to validate our DGL assay.  
Measurement of intestinal lipids 
Tissue harvest and lipid extraction  
Animals were anesthetized with isofluorane at time of tissue harvest 
(1500-1700 h) following ad libitum food and water access. Blood was collected 
by cardiac puncture and deposited into vacutainers containing EDTA; plasma 
was collected as supernatant following 10 min centrifugation at 1500 G (kept at 
4oC). Jejunum was quickly removed and washed in phosphate-buffered saline 
(PBS), opened longitudinally on a stainless-steel tray on ice, and contents 
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removed. Jejunum mucosa was isolated using glass slides to scrape the 
epithelial layer and was snap-frozen in liquid N2. Samples were stored at -80oC 
pending analysis. Frozen tissues were weighed and then homogenized in 1 mL 
methanol solution containing 500 pmol [2H5]-2-AG (Cayman Chemicals, Ann 
Arbor, MI) as an internal standard. Lipids were extracted as previously described 
(22) and resuspended in 0.1 mL methanol:chloroform (9:1) and analyzed via 
ultra-performance liquid chromatography tandem mass spectrometry (UPLC-
MS/MS). 
LCMS detection of 2-arachidonoyl-sn-glycerol and other monoacylglycerols 
Data were acquired using an Acquity I Class UPLC with direct connection 
to a Xevo TQ-S Micro Mass Spectrometer (Waters Corporation, Milford, MA, 
USA) with electrospray ionization (ESI) sample delivery. Lipids were separated 
using an Acquity UPLC BEH C18 column (2.1 x 50 mm i.d., 1.7 µm, Waters 
Corporation) and inline Acquity guard column (UPLC BEH C18 VanGuard 
PreColumn; 2.1 x 5 mm i.d.; 1.7 µm, Waters Corporation), and eluted by a 
gradient of water and methanol (containing 0.25% acetic acid, 5 mM ammonium 
acetate) at a flow rate of 0.4 mL per min and gradient: 80% methanol 0.5 min, 
80% to 100% methanol 0.5 – 2.5 min, 100% methanol 2.5 – 4.5 min, 100% to 
80% methanol 4.5 – 4.6 min, and 80% methanol 4.6 – 5.5 min. The column was 
maintained at 40oC, and samples were kept at 10oC in accompanying sample 
manager. MS/MS detection was in positive ion mode with capillary voltage 
maintained at 1.10 kV, and argon (99.998%) was used as collision gas. Cone 
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voltages and collision energies for respective analytes: 2-AG (20:4) = 30v, 12v; 
2-DG (22:6) = 34v, 14v; 2-PG (16:0) = 18v, 10v; 2-OG (18:1) = 42v, 10v; 2-LG 
(18:2) = 30v, 10v; monononadecadienoin (19:2 monoacylglycerol; product of 
DGL assay, see below) = 18v, 10v; and [2H5]-2-AG = 25v, 44v. Lipids were 
quantified using a stable isotope dilution method detecting H+ or Na+ adducts of 
the molecular ions [M + H/Na]+ in multiple reaction monitoring (MRM) mode. Acyl 
migration occurs in monoacylglycerols; thus, the sum of 2-AG and 1-AG is 
presented. Tissue processing and LCMS analyses for experiments occurred 
independently of other experiments. Extracted ion chromatograms for MRM 
transitions were used to quantify analytes: 2-AG (m/z = 379.3 > 287.3), 2-DG 
(m/z = 403.3 > 311.1), 2-PG (m/z = 331.3 > 239.3), 2-OG (m/z = 357.4 > 265.2), 
2-LG (m/z = 355.3 > 263.3), 19:2 monoacylglycerol (m/z = 386.4 > 277.2), and 
[2H5]-2-AG (m/z = 384.3 > 93.4), which was used as an internal standard for 
quantitation of monoacylglycerols. 
ELISA analysis of CCK-8 octapeptide  
Mice were fasted for 12 h in order to ensure an empty stomach. Mice were 
pretreated with CB1R ligands, then administered corn oil (0.5 mL) by oral gavage 
30 min later. Levels of CCK-8 were assessed in blood plasma 30 min following 
gavage. Blood was placed in BD vacutainer lavender-top EDTA blood collection 
tubes on ice and plasma obtained by centrifugation of tubes at 1500 G for 10min 
at 4°C) by a sensitive and selective CCK-8 ELISA (Cloud Clone Corp; Katy, TX, 
USA). Mice were maintained for 60 days on standard diet (SD) and given IP 
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injection of vehicle or the general cannabinoid receptor agonist, WIN55,212-2 (3 
mg per kg), or WIN 55,212-2 in combination with the peripherally-restricted CB1R 
antagonist, AM6545 (10 mg per kg). In addition, mice maintained for 60 d on 
Western diet (WD) were given IP injection of vehicle or AM6545 (10 mg per kg). 
ELISA reaction was measured using iMark microplate reader (BioRad, Hercules, 
CA, USA). 
Immunohistochemistry 
Intact proximal small intestine was removed, and contents were flushed 
with ice-cold 4% paraformaldehyde (PFA)/PBS, then fixed in 4% PFA for 4 hours 
at 4°C. Samples were transferred to 20% sucrose/PBS and incubated 1 d at 4°C 
for cryopreservation. Cross sections of upper small intestine were cut and frozen 
in OCT (Fisher Healthcare, Chino, CA, USA) on dry ice. 16 µm sections were 
taken on a cryostat (Leica) and mounted onto charged glass slides. Sections 
were permeabilized with 0.5% Tween-20/PBS and then blocked with 0.1% 
Tween in casein solution (Thermo Fisher). Primary antibodies from rabbit for 
Cholecystokinin (CCK; ABcam, Cambridge, UK) and Cannabinoid Receptor 1 
(Generously provided by Dr. Ken Mackie, Indiana University) were diluted 1:500 
in blocking buffer and separately added to slides. Slides were washed three 
times with 0.1% Tween/PBS solution before being incubated with AlexaFluor 647 
(Donkey anti-rabbit, Thermo Fisher). Tissue was washed again and mounted 
with Prolong Gold Antifade reagent with DAPI (Thermo Fisher) for nuclear 
counterstaining. Images were obtained at room temperature using an Axio 
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Observer Z1 Inverted Microscope (Zeiss, Oberkochen, Germany) at 63x 
magnification with a CSU-X1 Confocal Scanner Unit (Yokogawa, Tokyo, Japan), 
and images were captured using a Prime 95B Scientific CMOS Camera 
(Photometrics, Huntington Beach, CA, USA). Micro-Manager open source 
software was used for image capture, and final images were optimized using 
ImageJ 1.51n (NIH, Bethesda, MD, USA).  
Fluorescence-activated cell sorting  
Isolation of intestinal epithelial cells 
Approximately 4 cm of proximal small intestine was inverted and 
mechanically disrupted with frosted glass slides into ice-cold buffer containing 
5% BSA, 0.6 mM dithiothreitol (DTT) and 1 mM EDTA in PBS to disrupt mucosal 
cell layer. Live cells were counted following trypan blue staining and 20 x 106 
cells were pelleted at 200 G for 5 mins and resuspended in 1 mL of 3% BSA 
containing 1 mM EDTA in PBS. Cell suspension was filtered through 30-micron 
mesh and subsequently processed by fluorescence-activated cell sorting 
(FACS).  
FACS sorting of eGFP (+) and eGFP (-) cells 
Isolated cells were sorted and analyzed on a MoFlo Astrios (Beckman 
Coulter, Brea, CA, USA). Debris was detected and excluded using forward and 
side scatter profiles generated with a 488 nm laser. eGFP positive (+) cells were 
detected by fluorescence intensity, using excitation and emission spectra of 488 
and 513/26, respectively. A wild-type mouse from C57Bl/6J background was 
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used to establish autofluorescence, and gating for eGFP was used for final 
sorting (See Figure 1D,E). Samples were sorted into fresh resuspension buffer 
prior to qPCR analysis of gene expression. Mice were fasted for 10 h prior to 
acquisition of cells. 
Enzyme activity assays 
Tissue preparation 
Intestinal epithelium was collected as described above and approximately 
100 mg of frozen tissue was homogenized in 2 mL of ice-cold 50 mM Tris-HCl, 
320mM sucrose (pH 7.5) buffer. Homogenates were centrifuged at 800 G for 10 
minutes at 4°C and supernatant was collected. Protein supernatants were 
sonicated twice for 10 s and then freeze-thawed in liquid nitrogen twice. Samples 
were spun again, and supernatant protein content was quantified using BCA 
assay and diluted to working concentration with Tris-HCl/sucrose buffer. 
DGL activity assay 
Small-intestinal epithelial tissue homogenates (25 µg, room temperature) 
were incubated with the MGL inhibitor, JZL184 (0.3 µM), for 10 minutes in order 
to block MGL activity during the assay. Homogenates were then incubated in 0.2 
mL solution of Tris-HCL with 0.2% Triton X-100 (pH 7.0) containing 20 nmol 
dinonadecadienoin (19:2 DAG) at 37°C for 30 min. Reactions were stopped by 
adding 1 mL of ice-cold MeOH containing 25 pmol [2H5]-2-AG as internal 
standard. Lipids were extracted and the product of the reaction, 
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monononadecadienoin (19:2 monoacylglycerol), was analyzed via UPLC/MS/MS 
as described above for 19:2 monoacylglycerol.  
 
MGL activity assay 
Small-intestinal epithelial tissue (10 µg) was incubated with 0.4 mL 
solution of Tris-HCL with 0.1% BSA (pH 8.0) containing 50 nmol 
nonadecadienoin (19:2 monoacylglycerol; Nu-Chek Prep, Waterville, MN, USA; 
final volume 0.5 mL per reaction) at 37°C for 10 min. Reactions were stopped by 
adding 1 mL of MeOH containing 10 nmol heptadecanoic acid (17:1 FFA; Nu-
Chek Prep) as internal standard. Lipids were extracted and the product of the 
reaction (19:2 free fatty acid) was analyzed via UPLC/MS/MS according to the 
following protocol. Data were acquired using equipment described above and 
eluted by a gradient of water and methanol (containing 0.25% acetic acid, 5 mM 
ammonium acetate) at a flow rate of 0.4 mL per min and gradient: 90% methanol 
0.1 min, 90% to 100% methanol 0.1 – 2.0 min, 100% methanol 2.0 – 2.1 min, 
100% to 90% methanol 2.1 – 2.2 min, and 90% methanol 2.2 – 2.5 min. Column 
was maintained at 40oC and samples were kept at 10oC in sample manager. MS 
detection was in negative ion mode with capillary voltage maintained at 3.00 kV. 
Cone voltages for nonadecadienoic acid (19:2 FFA) = 48v and heptadecanoic 
acid (17:1 FFA) = 64v. Lipids were quantified using a stable isotope dilution 
method of proton adducts of the molecular ions [M - H]- in selected ion recording 
(SIR) mode. Tissue processing and LCMS analyses for experiments occurred 
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independently of other experiments. Extracted ion chromatograms for SIR 
masses were used to quantify analytes: 19:2 FFA (m/z = 293.2) product of MGL 
enzyme assay and 17:1 FFA (m/z = 267.2) as internal standard. 
Gastric emptying 
To evaluate drug or endogenous endocannabinoid effects on gastric 
emptying, corn oil was spiked with 1.0 nmol 19:2 FFA and administered by oral 
gavage (500uL), then quantities of 19:2 FFA remaining in the stomach were 
evaluated at the time of blood collection 30 minutes after gavage. The stomach 
was removed and immediately placed into methanol containing 17:1 FFA as 
internal standard. Lipids were extracted and 19:2 FFA was detected and 
quantified as above. 
Gene expression analysis 
RNA isolation from intestinal epithelium 
Total RNA was extracted from intestinal epithelium using RNeasy kit (Qiagen, 
Valencia, CA, USA) method, and first-strand complementary DNA was generated 
using M-MLV reverse transcriptase (Invitrogen, Carlsbad, CA, USA). All surfaces 
for tissue collection and processing were sanitized using 70% ethanol and then 
treated with an RNAse inhibitor (RNAse out, G-Biosciences, St. Louis, MO, USA) 
to maintain integrity of isolated RNA. Reverse transcription of total RNA (1 µg 
epithelium) was performed as previously described (22).  
RNA isolation from sorted cells 
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Sorted cell suspensions were pelleted at 3000 G for 10 mins and 
resuspended in 0.5 mL of Qiazol (Qiagen, Valencia, CA) and subsequently 
processed using RNeasy kit to isolate total RNA. Reverse transcription was 
performed as described above using 50 ng total RNA. 
Quantitative polymerase chain reaction analysis 
RT-qPCR was carried out using PrimePCR Sybr Green Assays (Biorad, 
Hercules, CA, USA) with the following primers for mouse genes: CB1R (Cnr1), 
CB2R (Cnr2), cholecystokinin (Cck), fatty-acid amide hydrolase (Faah), n-acyl 
phosphatidyl ethanolamine-specific phospholipase D (Napepld), diacylglycerol 
lipase alpha (Dagla) and beta (Daglb), monoacylglycerol lipase (Mgll), alpha-
beta-hydrolyzing domain 6 (Abhd6) with Hprt and Actb as housekeeping genes 
for epithelium and sorted cells, respectively. Values are expressed as relative 
mRNA expression based on widely used methods [i.e., delta-delta cq; see (43)]. 
Reactions were run in triplicate for each animal.  
Statistical analysis 
Values are expressed as means ± SEM. Unpaired Student’s two-tailed t-
test was used to compare data for standard diet- and western diet-fed groups. 
Repeated measures two-way ANOVA was used for groups measured over time. 
Additionally, regular one-way and two-way ANOVA were used to determine 
differences in multiple groups with post-hoc Sidak’s multiple comparisons tests or 
Newman-Keul’s, as appropriate. Data were analyzed using GraphPad Prism6 
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software. Significance was determined as P < 0.05. Statistical outliers were 
determined using Grubb’s test in all datasets.  
 
Results 
CB1Rs are expressed in CCK-containing cells in the upper small-intestinal 
epithelium. 
We reported that eCB levels are increased in the upper small-intestinal 
epithelium from mice maintained on a Western Diet (WD; high-fat and sucrose 
diet) for 60 days when compared to lean controls maintained on a low-fat and 
low-sugar diet, and inhibiting peripheral CB1Rs blocked overeating associated 
with consumption of WD (i.e., increased meal size, rate of food intake, and total 
caloric intake) (22). To identify the molecular underpinnings of gut-brain eCB 
signaling important for feeding behavior and its dysregulation in DIO, we first 
evaluated whether CB1Rs are expressed in cells that produce and secrete the 
satiation peptide, CCK. CCK controls meal size and induces satiation by 
activating CCKA receptors on the afferent vagus nerve (31-35, 38, 39). CB1R 
immunoreactivity was found in CCK-eGFP-positive cells from the upper small-
intestinal epithelium (Figure 1) in a mouse line that expresses eGFP selectively 
in CCK-expressing cells [C57BL/6-Tg(Cck-EGFP)2Mirn/J] (44). Furthermore, 
immunoreactivity for CCK was co-localized with eGFP in the upper small-
intestinal epithelium, which confirms expression of CCK in eGFP-containing cells 
from this mouse line (Supplementary Figure 1). We next isolated eGFP-positive 
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and eGFP-negative cells from the upper small-intestinal epithelium by 
fluorescence-activated cell sorting (FACS). Messenger RNA (mRNA) for CB1Rs 
(Cnr1) was enriched in CCK-eGFP-positive cells when compared to CCK-eGFP-
negative cells (Figure 2A; eGFP-positive = 1.00 ± 0.24, eGFP-negative = 0.04 ± 
0.04; P = 0.016; data from three mice). Moreover, mRNA for CCK was present in 
CCK-eGFP-positive cells isolated by FACS but was not present in CCK-eGFP-
negative cells, which highlights the specificity of our FACS gating strategy for 
isolating CCK-eGFP cells and further confirms expression of CCK in these cells 
(Figure 2B). Our gating strategy was optimized for sorting of eGFP-positive and 
eGFP-negative events from cells isolated from the upper small-intestinal 
epithelium of CCK-eGFP mice (see Figure 2C). Cells from wild-type mice (see 
Figure 2D) show minimal fluorescence at less than 10% of levels found in CCK-
eGFP cells: eGFP-positive cells comprise 0.63% of total cells analyzed from 
CCK-eGFP mice, and wild-type show 0.06%, likely due to autofluorescence (see 
Supplementary Figure 2 for detailed FACS report). These results suggest that 
CCK-containing I-cells in the mouse upper small-intestinal epithelium are 
enriched in expression of CB1Rs.  
Peripheral CB1Rs control fat-induced CCK secretion. 
The arrival of fat and other macronutrients into the duodenum stimulates 
release of a variety of signaling molecules that include CCK, which is produced 
and secreted by enteroendocrine I-cells lining the upper small-intestinal 
epithelium (1, 28, 30, 45, 46). We next tested the hypothesis that CB1Rs control 
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nutrient-induced release of CCK from the upper small-intestinal epithelium. Oral 
gavage of corn oil (CO) in lean mice maintained on a standard rodent diet (SD; 
low-fat no-sucrose chow) increased plasma levels of bioactive CCK, CCK-8 
(octapeptide), when compared to control mice that received oral gavage of saline 
[Figure 3A; CO = 0.69 ± 0.11 ng per mL, saline control = 0.28 ± 0.02 ng per mL; 
P < 0.05 CO versus saline control, n=3-5). Peripheral administration of the 
general cannabinoid receptor agonist, WIN55,212-2 (WIN, 3 mg per kg), blocked 
CO-induced secretion of CCK-8 (Figure 3A; CO+WIN = 0.36 ± 0.04 ng per mL; P 
< 0.05 CO+WIN versus CO alone, n=5). Furthermore, the effect of WIN 
administration on CO-induced secretion of CCK-8 was reversed by co-treatment 
with the peripherally-restricted neutral CB1R-selective antagonist, AM6545 
(Figure 3A; CO+WIN+AM6545 = 0.75 ± 0.14 ng per mL; P < 0.05 CO+WIN 
versus CO+WIN+AM, n=5; AM6545 10 mg per kg). These results suggest that 
exogenous activation of CB1Rs inhibits nutrient-induced CCK release from the 
upper gut.  
We next tested the hypothesis that elevated endogenous activity (e.g., 
increased 2-AG levels) at upper small-intestinal CB1Rs in mice maintained on 
Western Diet (WD; high-fat and sucrose diet) for 60 days inhibits CO-induced 
increases in circulating levels of CCK-8. We first confirmed that levels of 2-AG – 
among other monoacylglycerols – were increased in the upper small-intestinal 
epithelium of WD mice when compared to lean mice fed SD for 60 days (see 
Table 1). Next, we tested the ability for oral gavage of CO to increase CCK-8 
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levels in plasma of WD mice. CO failed to affect levels of CCK-8 in WD mice 
when compared to mice fed a standard diet (SD) that is low in fat and absent of 
sucrose (Figure 3B; CO+WD = 0.33 ± 0.04 ng per mL, CO+SD = 0.8 ± 0.03 ng 
per mL; P < 0.01, n=5). Furthermore, AM6545 treatment in WD mice that 
received oral gavage of CO increased levels of CCK-8 to those comparable to 
SD mice under the same conditions (Figure 3B; CO+WD+AM = 0.7 ± 0.1 ng per 
mL; P < 0.01 CO+WD versus CO+WD+AM, n=6). Collectively, these results 
suggest that exogenous or endogenous activation of CB1Rs in the upper small-
intestinal epithelium inhibits nutrient-induced CCK secretion.  
All levels of CCK-8 in these experiments fell within the range of the 
standard curve for CCK-8 quantitation by a sensitive and selective CCK-8 ELISA, 
which shows no cross-reactivity for gastrin (see Supplementary Figure 3), 
another gut-derived peptide that shares some common molecular features with 
CCK-8 (47-50). Furthermore, the range of CCK-8 levels in our studies (from 0.27 
± 0.02 to 0.8 ± 0.03 ng per mL or 0.23 ± 0.02 to 0.7 ± 0.03 nM) aligns with 
reported Ki and EC50 values of sulfated CCK-8 in several binding and in vitro 
bioassays (e.g., amylase release from pancreatic acini and ileum contractions in 
guinea pig) (51).  
CB1R activation is reported to decrease gastric emptying, an effect also 
found in mice fed a high-fat diet for 14 weeks (52, 53). To identify if altered 
gastric emptying occurs under our conditions and may contribute in part to 
inhibited corn oil-induced CCK release, we developed a novel UPLC/MS/MS-
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based method to evaluate if CB1R activation with WIN 55,212-2 or exposure to 
WD for 60 days impacts gastric emptying following oral gavage of corn oil in SD 
and WD mice, respectively. Thirty min after administration of drugs, we 
administered by oral gavage corn oil (500µL) that contained 19:2 free-fatty acid 
(1nmol) as a tracer and measured by UPLC/MS/MS the remaining quantities of 
19:2 free-fatty acid in the stomach 30 min after gavage. WIN 55,212-2 (3 mg per 
kg) alone or in combination with AM6545 (10 mg per kg) had no effect on gastric 
emptying of corn oil in SD mice (see Supplementary Figure 4A). Similarly, WD 
mice displayed no changes in gastric emptying of corn oil when compared to SD 
mice (see Supplementary Figure 4B). These data suggest that exogenous 
activation (WIN in SD mice) or endogenous activation (elevated small-intestinal 
epithelial eCB levels in WD mice) of CB1Rs does not affect gastric emptying of 
corn oil under our conditions and does not likely impact CCK release by a 
mechanism that includes alterations in gastric emptying in mice.  
CB1Rs in pancreatic beta cells control insulin release and glucose 
homeostasis (54-59). Thus, we tested if drug treatment impacted glucose levels 
in response to corn oil gavage in SD mice, which in turn, could affect gastric 
emptying, motility, or enteroendocrine release from small-intestinal 
enteroendocrine cells. Glucose levels in blood were collected from tail vein and 
monitored via hand-held glucose monitor at (i) time of drug administration, (ii) 30 
min later just prior to corn oil gavage, and (iii) 30 min later at time of kill (See 
Supplementary Figure 5). Drug treatment had no significant impact on blood 
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glucose levels at any time point prior to or after gavage of corn oil (See 
Supplementary Figure 5). These data suggest that, under our conditions, 
activating CB1Rs does not impact blood glucose levels following oral gavage of 
corn oil in mice. 
Activity of enzymes responsible for metabolism of 2-AG and other 
monoacylglycerols is dysregulated in the upper small-intestinal epithelium in DIO. 
We next aimed to identify the mechanism(s) of increased 2-AG and 
related monoacylglycerol levels (see Table 1) in WD mice by analyzing activity of 
their biosynthetic (diacylglycerol lipase, DGL) and degradative enzymes 
(monoacylglycerol lipase, MGL) using our lab’s UPLC/MS/MS-based functional 
enzyme assay methods (see Supplementary Figure 6 for validation of enzyme 
assays). When compared to SD mice, WD mice displayed an increase in activity 
of DGL (Figure 4A; SD = 0.12 ± 0.02, WD = 0.22 ± 0.03 nmol per mg protein per 
minute; P = 0.016, reactions from 6 mice per diet group), and MGL (Figure 4B; 
SD = 36.32 ± 3.82, WD = 51.60 ± 4.95 nmol per mg protein per minute; P = 
0.035, reactions from 6 mice per diet group) in isolated tissue from the upper 
small-intestinal epithelium. Congruent with data in Table 1 and (22), these effects 
were met with increased levels of 2-AG in upper small-intestinal epithelium of 
separate mice (Figure 4C; SD = 45.71 ± 6.93, WD = 92.57 ± 16.41 nmol per g; P 
= 0.014, n = 9-10 per diet group). See Figure 4D for diagram of the 2-AG 
metabolic pathways. Together, these results suggest that monoacylglycerol 
metabolic pathways are dysregulated after chronic exposure to WD, which leads 
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to a net increase in monoacylglycerols, including 2-AG, in the upper small-
intestinal epithelium.  
Expression of select eCB system components in the upper small-intestinal 
epithelium is dysregulated in DIO and partially conserved in CCK-positive cells. 
  Relative expression of mRNA for intestinal CCK, CB1Rs, and CB2Rs 
(Cnr2) was unchanged in whole upper small-intestinal epithelial scrapings from 
mice fed WD versus SD mice (Figure 5A: CCK, SD = 1.00 ± 0.76, WD = 0.56 ± 
0.45, p = 0.64; Cnr1, SD = 1.00 ± 0.36, WD = 0.79 ± 0.31, P = 0.67; Cnr2, SD = 
1.00 ± 0.31, WD = 0.83 ± 0.188, P = 0.65; data from 4 mice per diet group). 
Expression of mRNA for the alpha isoform of DGL (Dagla) was also unaffected 
by diet (Figure 5A; SD = 1.00 ± 0.25, WD = 0.90 ± 0.29, P=0.80); however, 
expression of mRNA for the beta isoform of DGL (Daglb) was reduced in WD 
versus SD mice (Figure 5A; SD = 1.00 ± 0.15, WD = 0.35 ± 0.03, P = 0.005), 
while mRNA for MGL (Mgll) and the serine hydrolase alpha/beta hydrolase 
domain 6 (Abhd6) were increased in small-intestinal epithelium under the same 
conditions (Figure 5A: Mgll, SD = 1.00 ± 0.17, WD = 2.71 ± 0.46, P = 0.013; 
Abhd6, SD = 1.00 ± 0.16, WD = 1.54 ± 0.048, P = 0.02). No changes were found 
for the fatty acid ethanolamide biosynthetic enzyme, NAPE-PLD, or the fatty acid 
ethanolamide degradative enzyme, FAAH (Figure 5A: NAPE-PLD, SD = 1.00 ± 
0.18, WD = 0.89 ± 0.08, P = 0.6; FAAH, SD = 1.00 ± 0.17, WD = 1.00 ± 0.07, P = 
0.99). Furthermore, the upper small-intestinal epithelium is enriched in 
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expression of mRNA for Daglb when compared to Dagla (Figure 5A inset; Dagla 
= 1.00 ± 0.19, Daglb = 29.73 ± 4.3; P = 0.001; data from 4 mice fed SD).  
It is important to note, in contrast to our previous report that included 
analysis of eCB system expression in the upper small-intestinal epithelium of 
mice maintained on WD and SD [Lab Diet 5001 used in (22)], in this study we 
used a soy protein-free Teklad 2020x as a control SD in order to eliminate any 
potential effects of phytoestrogen-containing soy protein on eCB metabolism or 
behavior [see (60-63)]. We found two differences in results when comparing use 
of the two control diets versus WD. We reported no changes in expression of 
mRNA for the beta isoform of DGL and increases in expression of mRNA for 
FAAH in WD mice when compared to control SD mice (22); however, in this 
study, we found decreased expression of mRNA for the beta isoform of DGL and 
no changes in expression of mRNA for FAAH in WD mice when compared to SD 
mice. These differences highlight possible effects of diets that utilize soy protein 
on expression of eCB metabolic enzymes and eCB metabolic function.  A direct 
comparison of the impact of specific control diets on expression of eCB system 
components, however, remains to be evaluated. 
CCK-eGFP-positive cells isolated from mice fed SD or WD mice displayed 
no differences between diet condition in expression of mRNA for CCK and 
components of the eCB system that include Cnr1, Cnr2, Daglb, Abhd6, and 
FAAH (Figure 5B; P > 0.05 not significant, data from 3 mice per diet group). 
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Dagla, Mgll, and Napepld mRNA were below detectable levels, which suggests a 
lack of expression of these eCB system components in CCK-containing cells. 
Collectively, these results identify select eCB system gene transcripts in 
CCK-containing cells, and changes in expression of biosynthetic and degradative 
enzyme gene transcripts in whole epithelium of WD mice that do not fully 
correspond to changes in activity of their proteins, including DGL and MGL (see 
Figure 4). The latter suggests possible post-transcriptional and/or post-
translational changes in expression of these enzymes in the upper small-
intestinal epithelium in WD mice when compared to lean SD mice, although this 
hypothesis remains to be directly tested.  Furthermore, a lack of expression of 
the fatty acid ethanolamide (FAE) biosynthetic enzyme, NAPE-PLD, in CCK-
containing cells suggests that FAEs including anandamide – which is also found 
in small-intestinal epithelium of rodents (9-11, 21, 22, 64) – is generated in 
neighboring cells and therefore may act in a paracrine manner with I-cells that 
contain CB1Rs. In contrast, expression of mRNA for the beta isoform of the 
monoacylglycerol biosynthetic enzyme, DGL, is abundantly expressed in CCK-
containing cells, which suggests that 2-AG may signal at CB1Rs in an autocrine 
manner at these cells. Expression of the primary 2-AG degradative enzyme, 
MGL, is absent in CCK-containing I-cells, which suggests that 2-AG is degraded 
at adjacent cells and therefore may additionally signal CB1Rs on adjacent cells in 
a paracrine manner. A comprehensive analysis of eCB system architecture and 
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its cell-specific expression in the upper small-intestinal epithelium of mice 
remains for future studies.  
Western diet exposure for 60 days is associated with obesity and hyperphagia in 
male mice. 
Consistent with our previous studies (22), exposure to WD for 60 days, 
when compared to lean mice fed SD for 60 days, was associated with (i) a rapid 
and sustained increase in body mass when compared to control mice fed SD for 
60 days, (ii) increased 24 h meal size, (iii) rate of food intake, and (iv) total 24 h 
caloric intake (see Supplementary Figure 7 and Table 2 for details and data). No 
significant changes were found for other feeding behaviors including (i) first meal 
size, (ii) meal frequency, (iii) meal duration, and (iv) post-meal interval. As 
discussed above, in contrast to our previous study (22), in this study we used a 
soy-protein-free lab chow. Irrespective of control diet, however, WD intake was 
consistently associated with increased 2-AG levels (Table 1) and hyperphagia 
across relevant parameters in both studies [Table 2 and Figure 6 and (22)]. 
Together, these data suggest that exposure to a WD rapidly induces body weight 
gain that is met with increased meal size, rate of intake, and daily caloric intake, 
when compared to lean controls.  
Pharmacological inhibition of CCKA receptors blocks the anorexic effect of 
AM6545 in DIO.  
We next tested the hypothesis that peripheral CB1Rs control feeding 
behavior by a mechanism that includes control of CCK-mediated satiation 
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signaling. When compared to vehicle treatment in mice fed WD for 60 days, 
AM6545 treatment (10 mg per kg) in WD mice reduced meal size (Figure 6A; 
vehicle = 1.47  0.15 kcal, AM6545 = 1.13  0.67 kcal; P<0.05, n=12), rate of 
intake  (Figure 6B; vehicle = 0.76  0.12 kcal per minute, AM6545 = 0.46  0.05 
kcal per minute; P < 0.01), and total caloric intake (Figure 6C; vehicle = 9.11  
0.67 kcal per minute, AM6545 = 6.62  0.69 kcal per minute; P<0.01) during a 12 
h test, which is consistent with our previous findings (21). Furthermore, AM6545 
treatment had no significant effect in mice fed SD for 60 days on meal size 
(Figure 6A; vehicle = 0.74  0.05 kcal, AM6545 = 0.71  0.04 kcal; P > 0.05, 
n=12), rate of intake  (Figure 6B; vehicle = 0.30  0.03 kcal per minute, AM6545 
= 0.32  0.03 kcal per minute; P > 0.05), and total caloric intake (Figure 6C; 
vehicle = 5.51  0.42 kcal per minute, AM6545 = 5.45  0.28 kcal per minute; P > 
0.05) during a 12 h test. Importantly, co-administration of a low dose of the CCKA 
receptor antagonist, devazepide (Dev; 0.1 mg per kg), in WD mice blocked the 
effects of AM6545 on reducing meal size (Figure 6A; vehicle = 1.47  0.15 kcal, 
AM6545+devazepide = 1.49  0.16 kcal; P > 0.05), rate of intake  (Figure 6B; 
vehicle = 0.76  0.12 kcal per minute, AM6545+devazepide = 0.62  0.06 kcal 
per minute; P > 0.05), and total caloric intake (Figure 6C; vehicle = 9.11  0.67 
kcal per minute, AM6545+devazepide = 8.98  0.67 kcal per minute; P > 0.05). 
Administration of devazepide alone affected only on total 12-h caloric intake in 
SD mice (Figure 6C; vehicle = 5.51  0.42 kcal per minute, devazepide = 7.61  
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0.33 kcal per minute; P<0.05). Neither AM6545 or devazepide affected other 
meal parameters including meal frequency (Figure 6D), meal duration, (Figure 
6E), post-meal interval (Figure 6F), or first-meal size (Figure 6G) in SD or WD 
mice. These data suggest that the acute anorexic effects of AM6545 in DIO mice 
are dependent on a mechanism that includes activation of CCKA receptors and 
inhibition of gut-brain satiation signaling.  
 
Discussion  
The molecular underpinnings of gut-brain signaling and their dysregulation 
in DIO are poorly defined. Our studies suggest that eCB activity at CB1Rs in the 
upper small-intestinal epithelium is upregulated in mice chronically fed a WD, 
which in turn, promotes overeating by a mechanism that includes inhibiting 
nutrient-induced gut-brain satiation signaling (see Figure 7 for model). Six 
primary findings support this conclusion: (i) CB1Rs are enriched in CCK-
containing cells in the mouse upper small-intestinal epithelium; (ii) oral gavage of 
corn oil increased circulating levels of CCK-8 in lean mice, and pharmacological 
activation of CB1Rs blocked this effect, which was reversed by inhibition of 
peripheral CB1Rs with a peripherally-restricted CB1R neutral antagonist; (iii) 
levels of 2-AG and other monoacylglycerols were increased in the upper-small 
intestinal epithelium of WD mice when compared to lean mice, and this effect 
was associated with dysregulated monoacylglycerol metabolism; (iv) oral gavage 
of corn oil failed to affect circulating levels of CCK-8 in WD mice, and inhibition of 
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peripheral CB1Rs in WD mice restored the ability for corn oil to increase CCK 
levels; (v) pharmacological inhibition of peripheral CB1Rs in WD mice blocked 
overeating associated with increased meal size, rate of feeding, and total caloric 
intake; and (vi) the hypophagic effects of peripheral CB1R antagonism in WD 
mice were reversed by pretreatment with a low-dose CCKA receptor antagonist. 
Collectively, our studies identify a previously unknown role for the eCB system at 
the interface of nutrient-sensing and gut-brain satiation signaling that becomes 
dysregulated in DIO and promotes overeating by delaying satiation.  
Our studies suggest that the eCB system in the small-intestinal epithelium 
controls feeding behavior by a mechanism that includes inhibiting nutrient-
induced release of the gut-derived satiation peptide, CCK, which in turn 
increases meal size and caloric intake. CCK is secreted from enteroendocrine I-
cells in the upper small-intestinal epithelium after nutrients arrive in the lumen (1, 
28, 30, 37) and controls meal size and induces satiation by activating CCKA 
receptors on afferent vagal fibers (31-34, 36, 37) and possibly the brain (38, 39). 
Indeed, polymorphisms in CCKA receptor genes in humans is associated with 
increased meal size and food intake, and obesity (65-67). Furthermore, CCK in a 
stabilized form resistant to degradation in the GI tract is effective at reducing food 
intake and body weight in DIO rodents (68-70) and activating CCKA receptors 
enhances the anti-obesity properties of GLP-1 agonists, amylin, and leptin (71-
74).  
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Gene transcripts and immunoreactivity for CB1Rs were found in CCK-
containing I-cells in the upper small-intestinal epithelium of mice [see Figures 1 
and 2, and (40)]. Furthermore, the hypophagic effects of AM6545 were blocked 
by co-administration of the CCKA receptor antagonist, devazepide. These results 
suggest that when eCB activity is elevated at local CB1Rs in the upper small-
intestinal epithelium in DIO, increased CB1R activation may inhibit nutrient-
induced release of satiation peptides from small-intestinal enteroendocrine cells 
and lead to increased meal size and caloric intake. In support of this hypothesis, 
oral gavage of corn oil – which potently increases circulating levels of bioactive 
CCK-8 in lean mice that have low levels of small-intestinal eCB levels – failed to 
affect circulating levels of CCK-8 in mice chronically fed WD that have elevated 
eCB levels in the small-intestinal epithelium. Moreover, inhibiting elevated eCB 
signaling at peripheral CB1Rs with AM6545 in WD mice – at a dose that blocked 
overeating – restored the ability for corn oil to increase circulating levels of CCK-
8.  
The mechanisms of CB1R control of nutrient-induced release of CCK from 
enteroendocrine I-cells in the upper small-intestinal epithelium are unknown. 
Nonetheless, a primary mechanism by which CB1Rs block neurotransmitter 
release is by inhibiting calcium influx or mobilization (6, 75), and nutrient-induced 
CCK release is calcium-dependent (29, 76-79). Thus, CB1R activity may inhibit 
release of gut peptides by a mechanism that includes inhibiting calcium influx or 
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mobilization; however, a direct test of this hypothesis remains to be performed 
(see Figure 7 for proposed mechanism). 
It is controversial if obesity impacts CCK secretion [see for review (1)]. In 
line with our present findings in mice, several studies suggest that CCK secretion 
is reduced in obese humans: fasting CCK levels were lower than non-obese (80) 
and a trend towards lower CCK release after intra-duodenal infusions of oleic 
acid in overweight or obese subjects (81). Fat-induced CCK secretion and 
satiation induced by CCK administration were also reduced in rats fed a high-fat 
diet (82). Other studies, however, reported no differences in CCK levels between 
obese or lean humans following a meal (83), and increases in CCK after a high-
fat meal (84). Furthermore, several preclinical studies in rodents suggest that 
sensitivity of vagal afferent neurons to the satiating effects of CCK may be 
decreased in DIO (82, 85-87). This phenomenon may be due, in part, to changes 
in membrane properties of neurons in the nodose ganglion. The satiating actions 
of a physiological dose of CCK, however, was equally effective in suppressing 
food intake in obese and lean human subjects (88). Moreover, a variety of 
studies conducted over the past several decades show that CCK-induced 
satiation is mediated by the vagus nerve (31-37); however, select studies show 
that gut-derived CCK may additionally interact with CCKA receptors in the brain 
(38, 39). We used the brain-penetrant CCKA receptor antagonist, devazepide, in 
our studies; therefore, we cannot rule out the possibility that CCKA receptors in 
the brain participate in the appetite-suppressing effects of CCK release following 
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inhibition of peripheral CB1Rs. Thus, given discrepancies in the literature 
regarding the underlying mechanisms of gut-brain signaling and its dysregulation 
in DIO, it is critical to examine the impact of diet and obesity on gut-brain 
satiation signaling using reliable and reproducible model systems.  
It is plausible that CB1R control of nutrient-induced CCK release is one of 
several mechanisms by which peripheral CB1Rs impact gut-brain signaling 
pathways (23-26). For example, administration of ghrelin – which is produced in 
the stomach and upper small intestinal epithelium and increases feeding [see for 
review (1, 89)] – blocked downregulation of CB1Rs in the nodose ganglion after, 
both, re-feeding and CCK administration in fasted rats (24). Moreover, 
pharmacological inhibition of CB1Rs blocked fasting-induced ghrelin production in 
rats (90-92), which suggests that CB1Rs in the upper GI tract may control ghrelin 
signaling. Furthermore, Kunos and colleagues reported that a peripherally-
restricted CB1R inverse agonist improved a host of metabolic parameters as well 
as reducing food intake in DIO mice by a mechanism that may include reversing 
hyperleptinemia and leptin resistance associated with DIO (16) and restoring 
anorexic melanocortin signaling in the arcuate nucleus of the hypothalamus (17). 
Marsicano and colleagues reported that the hypophagic effects of CB1R inhibition 
with the CB1R inverse agonist, rimonabant, is blocked by pharmacological 
inhibition of peripheral beta-adrenergic neurotransmission (93), which suggests 
that CB1Rs may additionally control feeding behavior via interactions with the 
peripheral sympathetic nervous system. This study also showed that intact 
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afferent vagal signaling was required for the hypophagic effects of rimonabant, 
and CB1Rs in the brain were not required for its pharmacological actions. 
Nonetheless, circulating levels of the eCBs increase in human and rodent models 
of obesity (7, 19, 22, 94-99), which may directly interact with CB1Rs in the brain 
and control feeding behavior and energy homeostasis. A comprehensive analysis 
of this possibility remains to be performed. In addition to I-cells in the small-
intestinal epithelium [see Figures 1 and 2, and (40)], CB1Rs are also expressed 
in K-cells that produce and secrete glucose-dependent insulinotropic peptide 
[GIP (100, 101)]. Pharmacological activation of CB1Rs inhibits GIP release in 
rodents, which suggests that local CB1Rs may impact glucose homeostasis via a 
mechanism that includes controlling nutrient-induced incretin release. Lastly, 
enteroendocrine cells in the intestinal lining form functional synapses with 
afferent vagal fibers (37). Termed “neuropods” by Bohorquez and colleagues, 
these cells sense nutrients and release glutamate and CCK in a coordinated 
manner that interact with corresponding receptors on local afferent vagal fibers, 
which in turn, communicate with the brain. Our data suggest that CB1Rs may be 
at the interface of this signaling. It is unknown, however, if CB1Rs control 
glutamate signaling at these synapses in the small intestine as they do in the 
brain (102). Collectively, these studies – in combination with the present report – 
describe key roles for peripheral CB1Rs in feeding behavior and energy 
homeostasis. 
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In summary, our results provide evidence of a previously unknown 
mechanism of CB1R-mediated inhibition of gut-brain satiation signaling in DIO 
that promotes overeating. Pharmacological manipulation of these pathways in 
the periphery may provide a therapeutic advantage for the treatment of obesity 
and related metabolic disorders when compared to anti-obesity drugs that 
interact with the brain and display psychiatric side-effects (8, 103). Despite the 
peripherally-restricted properties of these CB1R antagonists, however, their 
impact on cognition and brain function by altering gut microbe activity is unknown 
and remains to be reported.  
Author Disclosure Statement:  The authors declare no conflict of interest. 
 
125 
 
 
References 
 
1. Steinert RE, Feinle-Bisset C, Asarian L, Horowitz M, Beglinger C, Geary 
N. Ghrelin, CCK, GLP-1, and PYY(3-36): Secretory Controls and Physiological 
Roles in Eating and Glycemia in Health, Obesity, and After RYGB. Physiol Rev. 
2017;97(1):411-63. doi: 10.1152/physrev.00031.2014. PubMed PMID: 28003328. 
2. DiPatrizio NV. Endocannabinoids in the Gut. Cannabis and Cannabinoid 
Research. 2016;1(1):67-77. 
3. DiPatrizio NV, Piomelli D. The thrifty lipids: endocannabinoids and the 
neural control of energy conservation. Trends Neurosci. 2012;35(7):403-11. 
Epub 2012/05/25. doi: 10.1016/j.tins.2012.04.006. S0166-2236(12)00066-5 [pii]. 
PubMed PMID: 22622030. 
4. DiPatrizio NV, Piomelli D. Intestinal lipid-derived signals that sense dietary 
fat. The Journal of clinical investigation. 2015;125(3):891-8. doi: 
10.1172/JCI76302. PubMed PMID: 25642767; PMCID: PMC4362267. 
5. Piomelli D. The molecular logic of endocannabinoid signalling. Nature 
reviews. 2003;4(11):873-84. PubMed PMID: 14595399. 
6. Pertwee RG. Endocannabinoids and Their Pharmacological Actions. 
Handb Exp Pharmacol. 2015;231:1-37. doi: 10.1007/978-3-319-20825-1_1. 
PubMed PMID: 26408156. 
7. Simon V, Cota D. MECHANISMS IN ENDOCRINOLOGY: 
Endocannabinoids and metabolism: past, present and future. Eur J Endocrinol. 
2017;176(6):R309-R24. doi: 10.1530/EJE-16-1044. PubMed PMID: 28246151. 
8. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy 
and safety of the weight-loss drug rimonabant: a meta-analysis of randomised 
trials. Lancet. 2007;370(9600):1706-13. doi: 10.1016/S0140-6736(07)61721-8. 
PubMed PMID: 18022033. 
9. DiPatrizio NV, Astarita G, Schwartz G, Li X, Piomelli D. Endocannabinoid 
signal in the gut controls dietary fat intake. Proceedings of the National Academy 
of Sciences of the United States of America. 2011;108(31):12904-8. Epub 
2011/07/07. doi: 1104675108 [pii] 10.1073/pnas.1104675108. PubMed PMID: 
21730161; PMCID: 3150876. 
126 
 
 
10. DiPatrizio NV, Joslin A, Jung KM, Piomelli D. Endocannabinoid signaling 
in the gut mediates preference for dietary unsaturated fats. Faseb J. 
2013;27(6):2513-20. Epub 2013/03/07. doi: 10.1096/fj.13-227587. fj.13-227587 
[pii]. PubMed PMID: 23463697; PMCID: 3659363. 
11. DiPatrizio NV, Igarashi M, Narayanaswami V, Murray C, Gancayco J, 
Russell A, Jung KM, Piomelli D. Fasting stimulates 2-AG biosynthesis in the 
small intestine: role of cholinergic pathways. Am J Physiol Regul Integr Comp 
Physiol. 2015;309(8):R805-13. doi: 10.1152/ajpregu.00239.2015. PubMed PMID: 
26290104. 
12. LoVerme J, Duranti A, Tontini A, Spadoni G, Mor M, Rivara S, Stella N, Xu 
C, Tarzia G, Piomelli D. Synthesis and characterization of a peripherally 
restricted CB1 cannabinoid antagonist, URB447, that reduces feeding and body-
weight gain in mice. Bioorg Med Chem Lett. 2009;19(3):639-43. Epub 
2009/01/09. doi: S0960-894X(08)01582-5 [pii] 10.1016/j.bmcl.2008.12.059. 
PubMed PMID: 19128970. 
13. Randall PA, Vemuri VK, Segovia KN, Torres EF, Hosmer S, Nunes EJ, 
Santerre JL, Makriyannis A, Salamone JD. The novel cannabinoid CB1 
antagonist AM6545 suppresses food intake and food-reinforced behavior. 
Pharmacology, biochemistry, and behavior. 2010;97(1):179-84. Epub 
2010/08/18. doi: S0091-3057(10)00233-9 [pii] 10.1016/j.pbb.2010.07.021. 
PubMed PMID: 20713079. 
14. Cluny NL, Vemuri VK, Chambers AP, Limebeer CL, Bedard H, Wood JT, 
Lutz B, Zimmer A, Parker LA, Makriyannis A, Sharkey KA. A novel peripherally 
restricted cannabinoid receptor antagonist, AM6545, reduces food intake and 
body weight, but does not cause malaise, in rodents. British journal of 
pharmacology. 2011;161(3):629-42. Epub 2010/10/01. doi: BPH908 [pii] 
10.1111/j.1476-5381.2010.00908.x. PubMed PMID: 20880401; PMCID: 
2990160. 
15. Maccarrone M, Bab I, Biro T, Cabral GA, Dey SK, Di Marzo V, Konje JC, 
Kunos G, Mechoulam R, Pacher P, Sharkey KA, Zimmer A. Endocannabinoid 
signaling at the periphery: 50 years after THC. Trends Pharmacol Sci. 
2015;36(5):277-96. doi: 10.1016/j.tips.2015.02.008. PubMed PMID: 25796370; 
PMCID: PMC4420685. 
16. Tam J, Cinar R, Liu J, Godlewski G, Wesley D, Jourdan T, Szanda G, 
Mukhopadhyay B, Chedester L, Liow JS, Innis RB, Cheng K, Rice KC, 
Deschamps JR, Chorvat RJ, McElroy JF, Kunos G. Peripheral cannabinoid-1 
127 
 
 
receptor inverse agonism reduces obesity by reversing leptin resistance. Cell 
Metab. 2012;16(2):167-79. Epub 2012/07/31. doi: 10.1016/j.cmet.2012.07.002 
S1550-4131(12)00277-X [pii]. PubMed PMID: 22841573. 
17. Tam J, Szanda G, Drori A, Liu Z, Cinar R, Kashiwaya Y, Reitman ML, 
Kunos G. Peripheral cannabinoid-1 receptor blockade restores hypothalamic 
leptin signaling. Molecular metabolism. 2017;6(10):1113-25. doi: 
https://doi.org/10.1016/j.molmet.2017.06.010. 
18. Cani PD, Knauf C. How gut microbes talk to organs: The role of endocrine 
and nervous routes. Molecular metabolism. 2016;5(9):743-52. Epub 2016/09/13. 
doi: 10.1016/j.molmet.2016.05.011. PubMed PMID: 27617197; PMCID: 
PMC5004142. 
19. Hillard CJ. Circulating Endocannabinoids: From Whence Do They Come 
and Where are They Going? Neuropsychopharmacology. 2017. doi: 
10.1038/npp.2017.130. PubMed PMID: 28653665. 
20. Gomez R, Navarro M, Ferrer B, Trigo JM, Bilbao A, Del Arco I, Cippitelli A, 
Nava F, Piomelli D, Rodriguez de Fonseca F. A peripheral mechanism for CB1 
cannabinoid receptor-dependent modulation of feeding. J Neurosci. 
2002;22(21):9612-7. PubMed PMID: 12417686. 
21. Izzo AA, Piscitelli F, Capasso R, Aviello G, Romano B, Borrelli F, 
Petrosino S, Di Marzo V. Peripheral endocannabinoid dysregulation in obesity: 
relation to intestinal motility and energy processing induced by food deprivation 
and re-feeding. British journal of pharmacology. 2009;158(2):451-61. Epub 
2009/04/18. doi: BPH183 [pii] 10.1111/j.1476-5381.2009.00183.x. PubMed 
PMID: 19371345; PMCID: 2757684. 
22. Argueta DA, DiPatrizio NV. Peripheral endocannabinoid signaling controls 
hyperphagia in western diet-induced obesity. Physiology & behavior. 
2017;171:32-9. doi: 10.1016/j.physbeh.2016.12.044. PubMed PMID: 28065722. 
23. Burdyga G, Lal S, Varro A, Dimaline R, Thompson DG, Dockray GJ. 
Expression of cannabinoid CB1 receptors by vagal afferent neurons is inhibited 
by cholecystokinin. J Neurosci. 2004;24(11):2708-15. PubMed PMID: 15028763. 
24. Burdyga G, Varro A, Dimaline R, Thompson DG, Dockray GJ. Ghrelin 
receptors in rat and human nodose ganglia: putative role in regulating CB-1 and 
MCH receptor abundance. American journal of physiology. 2006;290(6):G1289-
97. doi: 10.1152/ajpgi.00543.2005. PubMed PMID: 16423919. 
128 
 
 
25. Burdyga G, Varro A, Dimaline R, Thompson DG, Dockray GJ. Expression 
of cannabinoid CB1 receptors by vagal afferent neurons: kinetics and role in 
influencing neurochemical phenotype. American journal of physiology. 
2010;299(1):G63-9. doi: 10.1152/ajpgi.00059.2010. PubMed PMID: 20430875; 
PMCID: 2904113. 
26. Cluny NL, Baraboi ED, Mackie K, Burdyga G, Richard D, Dockray GJ, 
Sharkey KA. High fat diet and body weight have different effects on cannabinoid 
CB(1) receptor expression in rat nodose ganglia. Auton Neurosci. 2013;179(1-
2):122-30. Epub 2013/10/23. doi: 10.1016/j.autneu.2013.09.015. PubMed PMID: 
24145047; PMCID: 3866822. 
27. Vianna CR, Donato J, Jr., Rossi J, Scott M, Economides K, Gautron L, 
Pierpont S, Elias CF, Elmquist JK. Cannabinoid receptor 1 in the vagus nerve is 
dispensable for body weight homeostasis but required for normal gastrointestinal 
motility. J Neurosci. 2012;32(30):10331-7. Epub 2012/07/28. doi: 
10.1523/JNEUROSCI.4507-11.2012. PubMed PMID: 22836266. 
28. McLaughlin J, Grazia Luca M, Jones MN, D'Amato M, Dockray GJ, 
Thompson DG. Fatty acid chain length determines cholecystokinin secretion and 
effect on human gastric motility. Gastroenterology. 1999;116(1):46-53. PubMed 
PMID: 9869601. 
29. McLaughlin JT, Lomax RB, Hall L, Dockray GJ, Thompson DG, Warhurst 
G. Fatty acids stimulate cholecystokinin secretion via an acyl chain length-
specific, Ca2+-dependent mechanism in the enteroendocrine cell line STC-1. 
The Journal of physiology. 1998;513 ( Pt 1):11-8. PubMed PMID: 9782155; 
PMCID: PMC2231256. 
30. Raybould HE, Glatzle J, Freeman SL, Whited K, Darcel N, Liou A, Bohan 
D. Detection of macronutrients in the intestinal wall. Auton Neurosci. 2006;125(1-
2):28-33. Epub 2006/03/01. doi: S1566-0702(06)00014-2 [pii] 
10.1016/j.autneu.2006.01.016. PubMed PMID: 16504594. 
31. Smith GP, Jerome C, Cushin BJ, Eterno R, Simansky KJ. Abdominal 
vagotomy blocks the satiety effect of cholecystokinin in the rat. Science. 
1981;213(4511):1036-7. Epub 1981/08/28. PubMed PMID: 7268408. 
32. Smith GP, Jerome C, Norgren R. Afferent axons in abdominal vagus 
mediate satiety effect of cholecystokinin in rats. Am J Physiol. 1985;249(5 Pt 
2):R638-41. Epub 1985/11/01. PubMed PMID: 4061684. 
129 
 
 
33. Schwartz GJ, Moran TH. CCK elicits and modulates vagal afferent activity 
arising from gastric and duodenal sites. Annals of the New York Academy of 
Sciences. 1994;713:121-8. PubMed PMID: 8185153. 
34. Raybould HE. Mechanisms of CCK signaling from gut to brain. Current 
opinion in pharmacology. 2007;7(6):570-4. doi: 10.1016/j.coph.2007.09.006. 
PubMed PMID: 17954038; PMCID: PMC2692370. 
35. Dockray GJ. Enteroendocrine cell signalling via the vagus nerve. Current 
opinion in pharmacology. 2013. doi: 10.1016/j.coph.2013.09.007. PubMed PMID: 
24064396. 
36. Schwartz GJ. Roles for gut vagal sensory signals in determining energy 
availability and energy expenditure. Brain research. 2018;1693(Pt B):151-3. 
Epub 2018/06/16. doi: 10.1016/j.brainres.2018.04.004. PubMed PMID: 
29903617; PMCID: PMC6004821. 
37. Kaelberer MM, Buchanan KL, Klein ME, Barth BB, Montoya MM, Shen X, 
Bohorquez DV. A gut-brain neural circuit for nutrient sensory transduction. 
Science. 2018;361(6408). Epub 2018/09/22. doi: 10.1126/science.aat5236. 
PubMed PMID: 30237325. 
38. Reidelberger RD, Hernandez J, Fritzsch B, Hulce M. Abdominal vagal 
mediation of the satiety effects of CCK in rats. Am J Physiol Regul Integr Comp 
Physiol. 2004;286(6):R1005-12. Epub 2004/01/01. doi: 
10.1152/ajpregu.00646.2003 00646.2003 [pii]. PubMed PMID: 14701717. 
39. Ripken D, van der Wielen N, van der Meulen J, Schuurman T, Witkamp 
RF, Hendriks HF, Koopmans SJ. Cholecystokinin regulates satiation 
independently of the abdominal vagal nerve in a pig model of total 
subdiaphragmatic vagotomy. Physiology & behavior. 2015;139:167-76. doi: 
10.1016/j.physbeh.2014.11.031. PubMed PMID: 25449395. 
40. Sykaras AG, Demenis C, Case RM, McLaughlin JT, Smith CP. Duodenal 
Enteroendocrine I-Cells Contain mRNA Transcripts Encoding Key 
Endocannabinoid and Fatty Acid Receptors. PLoS ONE. 2012;7(8):e42373. doi: 
10.1371/journal.pone.0042373. 
41. Gregg LC, Jung KM, Spradley JM, Nyilas R, Suplita RL, 2nd, Zimmer A, 
Watanabe M, Mackie K, Katona I, Piomelli D, Hohmann AG. Activation of type 5 
metabotropic glutamate receptors and diacylglycerol lipase-alpha initiates 2-
arachidonoylglycerol formation and endocannabinoid-mediated analgesia. J 
130 
 
 
Neurosci. 2012;32(28):9457-68. Epub 2012/07/13. doi: 
10.1523/JNEUROSCI.0013-12.2012. PubMed PMID: 22787031; PMCID: 
3652685. 
42. Jung KM, Sepers M, Henstridge CM, Lassalle O, Neuhofer D, Martin H, 
Ginger M, Frick A, DiPatrizio NV, Mackie K, Katona I, Piomelli D, Manzoni OJ. 
Uncoupling of the endocannabinoid signalling complex in a mouse model of 
fragile X syndrome. Nat Commun. 2012;3:1080. Epub 2012/09/27. doi: 
10.1038/ncomms2045 ncomms2045 [pii]. PubMed PMID: 23011134. 
43. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using 
real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 
2001;25(4):402-8. Epub 2002/02/16. doi: 10.1006/meth.2001.1262. PubMed 
PMID: 11846609. 
44. Schmidt MJ, Horvath S, Ebert P, Norris JL, Seeley EH, Brown J, Gellert L, 
Everheart M, Garbett KA, Grice TW, Caprioli RM, Mirnics K. Modulation of 
behavioral networks by selective interneuronal inactivation. Molecular psychiatry. 
2014;19(5):580-7. Epub 2013/12/11. doi: 10.1038/mp.2013.167. PubMed PMID: 
24322205; PMCID: PMC4179403. 
45. Cvijanovic N, Isaacs NJ, Rayner CK, Feinle-Bisset C, Young RL, Little TJ. 
Duodenal fatty acid sensor and transporter expression following acute fat 
exposure in healthy lean humans. Clin Nutr. 2017;36(2):564-9. doi: 
10.1016/j.clnu.2016.02.005. PubMed PMID: 26926575. 
46. Raybould HE. Nutrient tasting and signaling mechanisms in the gut. I. 
Sensing of lipid by the intestinal mucosa. Am J Physiol. 1999;277(4 Pt 1):G751-
5. PubMed PMID: 10516140. 
47. Wolfe MM, Paquet RJ, Reel GM. Specificity of commercially available 
antibodies used for gastrin measurement. J Lab Clin Med. 1985;105(4):417-21. 
Epub 1985/04/01. PubMed PMID: 3981055. 
48. Walsh JH, Lamers CB, Valenzuela JE. Cholecystokinin-octapeptidelike 
immunoreactivity in human plasma. Gastroenterology. 1982;82(3):438-44. Epub 
1982/03/01. PubMed PMID: 6172314. 
49. Eysselein VE, Reeve JR, Jr., Shively JE, Miller C, Walsh JH. Isolation of a 
large cholecystokinin precursor from canine brain. Proceedings of the National 
Academy of Sciences of the United States of America. 1984;81(21):6565-8. Epub 
1984/11/01. PubMed PMID: 6093106; PMCID: PMC391970. 
131 
 
 
50. Shulkes A, Baldwin GS. Biology of gut cholecystokinin and gastrin 
receptors. Clin Exp Pharmacol Physiol. 1997;24(3-4):209-16. Epub 1997/03/01. 
PubMed PMID: 9131287. 
51. Charpentier B, Pelaprat D, Durieux C, Dor A, Reibaud M, Blanchard JC, 
Roques BP. Cyclic cholecystokinin analogues with high selectivity for central 
receptors. Proceedings of the National Academy of Sciences of the United States 
of America. 1988;85(6):1968-72. Epub 1988/03/01. PubMed PMID: 3162318; 
PMCID: PMC279903. 
52. Di Marzo V, Capasso R, Matias I, Aviello G, Petrosino S, Borrelli F, 
Romano B, Orlando P, Capasso F, Izzo AA. The role of endocannabinoids in the 
regulation of gastric emptying: alterations in mice fed a high-fat diet. British 
journal of pharmacology. 2008;153(6):1272-80. Epub 2008/01/29. doi: 0707682 
[pii] 10.1038/sj.bjp.0707682. PubMed PMID: 18223666; PMCID: 2275439. 
53. Pertwee RG. Cannabinoids and the gastrointestinal tract. Gut. 
2001;48(6):859-67. Epub 2001/05/19. PubMed PMID: 11358910; PMCID: 
PMC1728337. 
54. Gonzalez-Mariscal I, Montoro RA, Doyle ME, Liu QR, Rouse M, O'Connell 
JF, Santa-Cruz Calvo S, Krzysik-Walker SM, Ghosh S, Carlson OD, Lehrmann 
E, Zhang Y, Becker KG, Chia CW, Ghosh P, Egan JM. Absence of cannabinoid 1 
receptor in beta cells protects against high-fat/high-sugar diet-induced beta cell 
dysfunction and inflammation in murine islets. Diabetologia. 2018;61(6):1470-83. 
Epub 2018/03/03. doi: 10.1007/s00125-018-4576-4. PubMed PMID: 29497784. 
55. Bermudez-Silva FJ, Suarez J, Baixeras E, Cobo N, Bautista D, Cuesta-
Munoz AL, Fuentes E, Juan-Pico P, Castro MJ, Milman G, Mechoulam R, Nadal 
A, Rodriguez de Fonseca F. Presence of functional cannabinoid receptors in 
human endocrine pancreas. Diabetologia. 2008;51(3):476-87. Epub 2007/12/20. 
doi: 10.1007/s00125-007-0890-y. PubMed PMID: 18092149. 
56. Li C, Bowe JE, Jones PM, Persaud SJ. Expression and function of 
cannabinoid receptors in mouse islets. Islets. 2010;2(5):293-302. Epub 
2010/11/26. PubMed PMID: 21099327. 
57. De Petrocellis L, Marini P, Matias I, Moriello AS, Starowicz K, Cristino L, 
Nigam S, Di Marzo V. Mechanisms for the coupling of cannabinoid receptors to 
intracellular calcium mobilization in rat insulinoma beta-cells. Exp Cell Res. 
2007;313(14):2993-3004. Epub 2007/06/26. doi: 10.1016/j.yexcr.2007.05.012. 
PubMed PMID: 17585904. 
132 
 
 
58. Nakata M, Yada T. Cannabinoids inhibit insulin secretion and cytosolic 
Ca2+ oscillation in islet beta-cells via CB1 receptors. Regul Pept. 2008;145(1-
3):49-53. Epub 2007/09/22. doi: 10.1016/j.regpep.2007.08.009. PubMed PMID: 
17884194. 
59. Juan-Pico P, Fuentes E, Bermudez-Silva FJ, Javier Diaz-Molina F, Ripoll 
C, Rodriguez de Fonseca F, Nadal A. Cannabinoid receptors regulate Ca(2+) 
signals and insulin secretion in pancreatic beta-cell. Cell Calcium. 
2006;39(2):155-62. Epub 2005/12/03. doi: 10.1016/j.ceca.2005.10.005. PubMed 
PMID: 16321437. 
60. Thors L, Belghiti M, Fowler CJ. Inhibition of fatty acid amide hydrolase by 
kaempferol and related naturally occurring flavonoids. British journal of 
pharmacology. 2008;155(2):244-52. Epub 2008/06/17. doi: 
10.1038/bjp.2008.237. PubMed PMID: 18552875; PMCID: PMC2538700. 
61. Peroni RN, Abramoff T, Neuman I, Podesta EJ, Adler-Graschinsky E. 
Phytoestrogens enhance the vascular actions of the endocannabinoid 
anandamide in mesenteric beds of female rats. Int J Hypertens. 
2012;2012:647856. Epub 2012/02/10. doi: 10.1155/2012/647856. PubMed 
PMID: 22319644; PMCID: PMC3272812. 
62. McFarland MJ, Porter AC, Rakhshan FR, Rawat DS, Gibbs RA, Barker 
EL. A role for caveolae/lipid rafts in the uptake and recycling of the endogenous 
cannabinoid anandamide. J Biol Chem. 2004;279(40):41991-7. Epub 
2004/08/05. doi: 10.1074/jbc.M407250200. PubMed PMID: 15292270. 
63. Thors L, Eriksson J, Fowler CJ. Inhibition of the cellular uptake of 
anandamide by genistein and its analogue daidzein in cells with different levels of 
fatty acid amide hydrolase-driven uptake. British journal of pharmacology. 
2007;152(5):744-50. Epub 2007/08/07. doi: 10.1038/sj.bjp.0707401. PubMed 
PMID: 17676056; PMCID: PMC2190009. 
64. Perez PA, DiPatrizio NV. Impact of maternal western diet-induced obesity 
on offspring mortality and peripheral endocannabinoid system in mice. PLoS 
One. 2018;13(10):e0205021. doi: 10.1371/journal.pone.0205021. PubMed PMID: 
30273406. 
65. de Krom M, van der Schouw YT, Hendriks J, Ophoff RA, van Gils CH, 
Stolk RP, Grobbee DE, Adan R. Common genetic variations in CCK, leptin, and 
leptin receptor genes are associated with specific human eating patterns. 
133 
 
 
Diabetes. 2007;56(1):276-80. Epub 2006/12/29. doi: 10.2337/db06-0473. 
PubMed PMID: 17192493. 
66. Marchal-Victorion S, Vionnet N, Escrieut C, Dematos F, Dina C, Dufresne 
M, Vaysse N, Pradayrol L, Froguel P, Fourmy D. Genetic, pharmacological and 
functional analysis of cholecystokinin-1 and cholecystokinin-2 receptor 
polymorphism in type 2 diabetes and obese patients. Pharmacogenetics. 
2002;12(1):23-30. Epub 2002/01/05. PubMed PMID: 11773861. 
67. Miller LJ, Holicky EL, Ulrich CD, Wieben ED. Abnormal processing of the 
human cholecystokinin receptor gene in association with gallstones and obesity. 
Gastroenterology. 1995;109(4):1375-80. Epub 1995/10/01. PubMed PMID: 
7557108. 
68. Irwin N, Frizelle P, Montgomery IA, Moffett RC, O'Harte FPM, Flatt PR. 
Beneficial effects of the novel cholecystokinin agonist (pGlu-Gln)-CCK-8 in 
mouse models of obesity/diabetes. Diabetologia. 2012;55(10):2747-58. Epub 
2012/07/21. doi: 10.1007/s00125-012-2654-6. PubMed PMID: 22814764. 
69. Irwin N, Montgomery IA, O'Harte FP, Frizelle P, Flatt PR. Comparison of 
the independent and combined metabolic effects of subchronic modulation of 
CCK and GIP receptor action in obesity-related diabetes. International journal of 
obesity (2005). 2013;37(8):1058-63. Epub 2012/11/21. doi: 10.1038/ijo.2012.179. 
PubMed PMID: 23164696. 
70. Pierson ME, Comstock JM, Simmons RD, Kaiser F, Julien R, Zongrone J, 
Rosamond JD. Synthesis and biological evaluation of potent, selective, 
hexapeptide CCK-A agonist anorectic agents. J Med Chem. 1997;40(26):4302-7. 
Epub 1998/01/22. doi: 10.1021/jm970477u. PubMed PMID: 9435899. 
71. Irwin N, Pathak V, Flatt PR. A Novel CCK-8/GLP-1 Hybrid Peptide 
Exhibiting Prominent Insulinotropic, Glucose-Lowering, and Satiety Actions With 
Significant Therapeutic Potential in High-Fat-Fed Mice. Diabetes. 
2015;64(8):2996-3009. Epub 2015/04/18. doi: 10.2337/db15-0220. PubMed 
PMID: 25883113. 
72. Irwin N, Montgomery IA, Flatt PR. Comparison of the metabolic effects of 
sustained CCK1 receptor activation alone and in combination with upregulated 
leptin signalling in high-fat-fed mice. Diabetologia. 2013;56(6):1425-35. Epub 
2013/03/07. doi: 10.1007/s00125-013-2878-0. PubMed PMID: 23462797. 
134 
 
 
73. Trevaskis JL, Sun C, Athanacio J, D'Souza L, Samant M, Tatarkiewicz K, 
Griffin PS, Wittmer C, Wang Y, Teng CH, Forood B, Parkes DG, Roth JD. 
Synergistic metabolic benefits of an exenatide analogue and cholecystokinin in 
diet-induced obese and leptin-deficient rodents. Diabetes, obesity & metabolism. 
2015;17(1):61-73. Epub 2014/09/11. doi: 10.1111/dom.12390. PubMed PMID: 
25204356. 
74. Trevaskis JL, Turek VF, Griffin PS, Wittmer C, Parkes DG, Roth JD. Multi-
hormonal weight loss combinations in diet-induced obese rats: therapeutic 
potential of cholecystokinin? Physiology & behavior. 2010;100(2):187-95. Epub 
2010/03/09. doi: 10.1016/j.physbeh.2010.02.023. PubMed PMID: 20206194. 
75. Howlett AC, Blume LC, Dalton GD. CB(1) cannabinoid receptors and their 
associated proteins. Curr Med Chem. 2010;17(14):1382-93. Epub 2010/02/20. 
PubMed PMID: 20166926; PMCID: PMC3179980. 
76. Hira T, Elliott AC, Thompson DG, Case RM, McLaughlin JT. Multiple fatty 
acid sensing mechanisms operate in enteroendocrine cells: novel evidence for 
direct mobilization of stored calcium by cytosolic fatty acid. J Biol Chem. 
2004;279(25):26082-9. Epub 2004/04/07. doi: 10.1074/jbc.M400098200. 
PubMed PMID: 15066999. 
77. Liou AP, Sei Y, Zhao X, Feng J, Lu X, Thomas C, Pechhold S, Raybould 
HE, Wank SA. The extracellular calcium-sensing receptor is required for 
cholecystokinin secretion in response to l-phenylalanine in acutely isolated 
intestinal I cells. American Journal of Physiology - Gastrointestinal and Liver 
Physiology. 2011;300(4):G538-G46. doi: 10.1152/ajpgi.00342.2010. PubMed 
PMID: PMC3074990. 
78. Nakajima S, Hira T, Hara H. Calcium-sensing receptor mediates dietary 
peptide-induced CCK secretion in enteroendocrine STC-1 cells. Mol Nutr Food 
Res. 2012;56(5):753-60. Epub 2012/06/01. doi: 10.1002/mnfr.201100666. 
PubMed PMID: 22648622. 
79. Gevrey J-C, Cordier-Bussat M, Némoz-Gaillard E, Chayvialle J-A, Abello 
J. Co-requirement of Cyclic AMP- and Calcium-dependent Protein Kinases for 
Transcriptional Activation of Cholecystokinin Gene by Protein Hydrolysates. 
Journal of Biological Chemistry. 2002;277(25):22407-13. doi: 
10.1074/jbc.M201624200. 
80. Baranowska B, Radzikowska M, Wasilewska-Dziubinska E, Roguski K, 
Borowiec M. Disturbed release of gastrointestinal peptides in anorexia nervosa 
135 
 
 
and in obesity. Diabetes, obesity & metabolism. 2000;2(2):99-103. Epub 
2001/02/28. PubMed PMID: 11220530. 
81. Stewart JE, Seimon RV, Otto B, Keast RS, Clifton PM, Feinle-Bisset C. 
Marked differences in gustatory and gastrointestinal sensitivity to oleic acid 
between lean and obese men. Am J Clin Nutr. 2011;93(4):703-11. Epub 
2011/02/12. doi: 10.3945/ajcn.110.007583. PubMed PMID: 21310831. 
82. Duca FA, Zhong L, Covasa M. Reduced CCK signaling in obese-prone 
rats fed a high fat diet. Hormones and behavior. 2013;64(5):812-7. doi: 
10.1016/j.yhbeh.2013.09.004. PubMed PMID: 24100196. 
83. Brennan IM, Luscombe-Marsh ND, Seimon RV, Otto B, Horowitz M, 
Wishart JM, Feinle-Bisset C. Effects of fat, protein, and carbohydrate and protein 
load on appetite, plasma cholecystokinin, peptide YY, and ghrelin, and energy 
intake in lean and obese men. American journal of physiology. 
2012;303(1):G129-40. doi: 10.1152/ajpgi.00478.2011. PubMed PMID: 22556143. 
84. French SJ, Murray B, Rumsey RD, Sepple CP, Read NW. Preliminary 
studies on the gastrointestinal responses to fatty meals in obese people. Int J 
Obes Relat Metab Disord. 1993;17(5):295-300. Epub 1993/05/01. PubMed 
PMID: 8389339. 
85. Covasa M, Grahn J, Ritter RC. High fat maintenance diet attenuates 
hindbrain neuronal response to CCK. Regul Pept. 2000;86(1-3):83-8. Epub 
2000/02/15. PubMed PMID: 10672906. 
86. Daly DM, Park SJ, Valinsky WC, Beyak MJ. Impaired intestinal afferent 
nerve satiety signalling and vagal afferent excitability in diet induced obesity in 
the mouse. The Journal of physiology. 2011;589(Pt 11):2857-70. Epub 
2011/04/14. doi: 10.1113/jphysiol.2010.204594. PubMed PMID: 21486762; 
PMCID: PMC3112560. 
87. de Lartigue G. Role of the vagus nerve in the development and treatment 
of diet-induced obesity. The Journal of physiology. 2016. doi: 10.1113/JP271538. 
PubMed PMID: 26959077. 
88. Lieverse RJ, Jansen JB, Masclee AA, Lamers CB. Satiety effects of a 
physiological dose of cholecystokinin in humans. Gut. 1995;36(2):176-9. Epub 
1995/02/01. PubMed PMID: 7883212; PMCID: PMC1382399. 
136 
 
 
89. Kaelberer MM, Bohorquez DV. The now and then of gut-brain signaling. 
Brain research. 2018;1693(Pt B):192-6. Epub 2018/03/28. doi: 
10.1016/j.brainres.2018.03.027. PubMed PMID: 29580839; PMCID: 
PMC6003878. 
90. Al-Massadi O, Gabellieri E, Trujillo ML, Senaris R, Pagotto U, Pasquali R, 
Casanueva FF, Seoane LM. Peripheral endocannabinoid system-mediated 
actions of rimonabant on growth hormone secretion are ghrelin-dependent. J 
Neuroendocrinol. 2011;22(11):1127-36. Epub 2010/09/03. doi: JNE2065 [pii] 
10.1111/j.1365-2826.2010.02065.x. PubMed PMID: 20807320. 
91. Senin LL, Al-Massadi O, Folguiera C, Pardo M, Barja-Fernandez S, Roca-
Rivada A, Amil M, Criujeiras AB, Garcia-Caballero T, Gabellieri E, Leis R, 
Dieguez C, Pagotto U, Casanueva FF, Seoane LM. The gasric CB1 receptor 
modulates ghrelin production through the mTOR pathway to regulate food intake. 
PLoS ONE. 2013;8(11):e80339. 
92. Cani PD, Montoya ML, Neyrinck AM, Delzenne NM, Lambert DM. 
Potential modulation of plasma ghrelin and glucagon-like peptide-1 by 
anorexigenic cannabinoid compounds, SR141716A (rimonabant) and 
oleoylethanolamide. Br J Nutr. 2004;92(5):757-61. Epub 2004/11/10. doi: 
S0007114504002363 [pii]. PubMed PMID: 15533263. 
93. Bellocchio L, Soria-Gomez E, Quarta C, Metna-Laurent M, Cardinal P, 
Binder E, Cannich A, Delamarre A, Haring M, Martin-Fontecha M, Vega D, Leste-
Lasserre T, Bartsch D, Monory K, Lutz B, Chaouloff F, Pagotto U, Guzman M, 
Cota D, Marsicano G. Activation of the sympathetic nervous system mediates 
hypophagic and anxiety-like effects of CB1 receptor blockade. Proceedings of 
the National Academy of Sciences of the United States of America. 
2013;110(12):4786-91. Epub 2013/03/15. doi: 10.1073/pnas.1218573110 
1218573110 [pii]. PubMed PMID: 23487769; PMCID: 3607008. 
94. Little TJ, Cvijanovic N, DiPatrizio NV, Argueta DA, Rayner CK, Feinle-
Bisset C, Young RL. Plasma endocannabinoid levels in lean, overweight and 
obese humans: relationships with intestinal permeability markers, inflammation 
and incretin secretion. Am J Physiol Endocrinol Metab. 2018. Epub 2018/02/14. 
doi: 10.1152/ajpendo.00355.2017. PubMed PMID: 29438631. 
95. Bluher M, Engeli S, Kloting N, Berndt J, Fasshauer M, Batkai S, Pacher P, 
Schon MR, Jordan J, Stumvoll M. Dysregulation of the peripheral and adipose 
tissue endocannabinoid system in human abdominal obesity. Diabetes. 
2006;55(11):3053-60. PubMed PMID: 17065342. 
137 
 
 
96. Cote M, Matias I, Lemieux I, Petrosino S, Almeras N, Despres JP, Di 
Marzo V. Circulating endocannabinoid levels, abdominal adiposity and related 
cardiometabolic risk factors in obese men. International journal of obesity (2005). 
2007;31(4):692-9. Epub 2007/01/17. doi: 0803539 [pii] 10.1038/sj.ijo.0803539. 
PubMed PMID: 17224929. 
97. Di Marzo V, Cote M, Matias I, Lemieux I, Arsenault BJ, Cartier A, Piscitelli 
F, Petrosino S, Almeras N, Despres JP. Changes in plasma endocannabinoid 
levels in viscerally obese men following a 1 year lifestyle modification programme 
and waist circumference reduction: associations with changes in metabolic risk 
factors. Diabetologia. 2009;52(2):213-7. Epub 2008/10/31. doi: 10.1007/s00125-
008-1178-6. PubMed PMID: 18972095. 
98. Matias I, Gatta-Cherifi B, Tabarin A, Clark S, Leste-Lasserre T, Marsicano 
G, Piazza PV, Cota D. Endocannabinoids measurement in human saliva as 
potential biomarker of obesity. PLoS One. 2012;7(7):e42399. doi: 
10.1371/journal.pone.0042399. PubMed PMID: 22860123; PMCID: 
PMC3409167. 
99. Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Janke J, Batkai S, 
Pacher P, Harvey-White J, Luft FC, Sharma AM, Jordan J. Activation of the 
peripheral endocannabinoid system in human obesity. Diabetes. 
2005;54(10):2838-43. PubMed PMID: 16186383. 
100. Moss CE, Marsh WJ, Parker HE, Ogunnowo-Bada E, Riches CH, Habib 
AM, Evans ML, Gribble FM, Reimann F. Somatostatin receptor 5 and 
cannabinoid receptor 1 activation inhibit secretion of glucose-dependent 
insulinotropic polypeptide from intestinal K cells in rodents. Diabetologia. 
2012;55(11):3094-103. Epub 2012/08/09. doi: 10.1007/s00125-012-2663-5. 
PubMed PMID: 22872212; PMCID: PMC3464380. 
101. Reimann F, Gribble FM. Mechanisms underlying glucose-dependent 
insulinotropic polypeptide and glucagon-like peptide-1 secretion. J Diabetes 
Investig. 2016;7 Suppl 1:13-9. doi: 10.1111/jdi.12478. PubMed PMID: 27186350; 
PMCID: PMC4854499. 
102. Jung KM, Astarita G, Zhu C, Wallace M, Mackie K, Piomelli D. A key role 
for diacylglycerol lipase-alpha in metabotropic glutamate receptor-dependent 
endocannabinoid mobilization. Molecular pharmacology. 2007;72(3):612-21. 
Epub 2007/06/23. doi: mol.107.037796 [pii] 10.1124/mol.107.037796. PubMed 
PMID: 17584991. 
138 
 
 
103. Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, Loomba 
R, Camilleri M, Singh S. Association of Pharmacological Treatments for Obesity 
With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. 
JAMA. 2016;315(22):2424-34. doi: 10.1001/jama.2016.7602. PubMed PMID: 
27299618. 
104. Tanaka T, Katsuma S, Adachi T, Koshimizu TA, Hirasawa A, Tsujimoto G. 
Free fatty acids induce cholecystokinin secretion through GPR120. Naunyn 
Schmiedebergs Arch Pharmacol. 2008;377(4-6):523-7. doi: 10.1007/s00210-007-
0200-8. PubMed PMID: 17972064. 
105. Liou AP, Lu X, Sei Y, Zhao X, Pechhold S, Carrero RJ, Raybould HE, 
Wank S. The G-protein-coupled receptor GPR40 directly mediates long-chain 
fatty acid-induced secretion of cholecystokinin. Gastroenterology. 
2011;140(3):903-12. doi: 10.1053/j.gastro.2010.10.012. PubMed PMID: 
20955703; PMCID: PMC4717904. 
106. Wang Y, Chandra R, Samsa LA, Gooch B, Fee BE, Cook JM, Vigna SR, 
Grant AO, Liddle RA. Amino acids stimulate cholecystokinin release through the 
Ca2+-sensing receptor. American journal of physiology. 2011;300(4):G528-37. 
Epub 2010/12/25. doi: 10.1152/ajpgi.00387.2010. PubMed PMID: 21183662; 
PMCID: PMC3074989. 
107. Rehfeld JF. Accurate measurement of cholecystokinin in plasma. Clin 
Chem. 1998;44(5):991-1001. Epub 1998/05/20. PubMed PMID: 9590372. 
 
 
 
 
 
 
 
 
 
139 
 
 
Tables  
 
 
Table 1. Impact of diet on monoacylglycerols in mouse small-intestinal 
epithelium.  
MAG, Monoacylglycerol represented as fatty acid chain. SD, Standard Diet n=10. 
WD, Western Diet n=9. Mean values are shown as ± S.E.M. Bold values are 
significantly different determined by Two-tailed Unpaired T-Test.  
 
 
 
 
 
 
 
 
 
 
 
 
MAG 20:4 (2-AG) 
(nmol g-1) 
18:1 
(nmol g-1) 
18:2 
(nmol g-1) 
16:0 
(nmol g-1) 
22:6 
(nmol g-1) 
Total 
(nmol g-1) 
SD 80.23 ± 8.542 49.57 ± 9.804 217.7 ± 52.09 33.99 ± 4.125 9.413 ± 1.996 390.9 ± 72.24 
WD 132.5 ± 22.20 109.0 ± 22.03 415.3 ± 83.26 150.1 ± 21.53 22.63 ± 3.703 829.4 ± 144.2 
P-value 0.0353 0.0206 0.0554 <0.0001 0.0049 0.0122 
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Table 2. Consumption of WD is associated with hyperphagia.  
 
PMI, Post Meal Interval. Mean values are shown as ± S.E.M. n=10. Bold values 
are significantly different determined by Two-tailed Unpaired T-Test. 
 
 
 
 
 
 
 
 
 
 
 
 
 Δ Body Mass 
(g) 
Meal Size 
(kcal) 
Intake Rate 
(kcal min-1) 
24h Intake 
(kcal) 
First Meal  
(kcal) 
Frequency 
(meals day-1) 
Duration 
(Min) 
PMI 
(Min) 
SD 8.90 ±0.31 0.69 ±0.04 0.33 ±0.02 8.10 ±0.61 0.72 ±0.11 11.67 ±0.45 8.61 ±1.16 114.7 ±8.4 
WD 18.14 ±0.46 1.29 ±0.10 
 
0.71 ±0.08 13.28 ±0.81 1.99 ±0.66   9.83 ±1.42 6.85 ±0.98   129.3 ±14.3 
P-value <0.0001 <0.0001 <0.0001 <0.0001 0.07 0.23 0.26 0.31 
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Figures 
 
 
 
Figure 1. CB1Rs co-localize with CCK-containing cells in the upper small-
intestinal epithelium. Immunohistochemical detection of eGFP (CCK-eGFP: B, F, 
J) and CB1Rs (CB1R-ab: C, G, K) reveals co-localization (merge: A, E, I) in villi of 
intestinal epithelium. Arrows indicate separate enteroendocrine cells that contain 
immunoreactivity for CB1Rs that co-localize with CCK-eGFP cells. 
Representative images from three CCK-eGFP mice. (Scale bar 15 µm) 
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Supplementary Figure 1. CCK receptors co-localize with eGFP in upper small-
intestinal epithelium. Immunohistochemical detection of CCK (CCK-ab) in eGFP-
containing cells (CCK-eGFP) confirms co-localization, which highlights the 
validity of this CCK-eGFP reporter mouse. Arrows indicate three separate 
enteroendocine cells that contain immunoreactivity for CCK that co-localizes with 
CCK-eGFP-positive cells. Representative images from three CCK-eGFP mice. 
(Scale bar 15 µm) 
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Figure 2. CB1R mRNA expression is enriched in CCK-containing cells in the 
upper small-intestinal epithelium. Fluorescence-activated cell sorting (FACS) of 
eGFP-CCK-positive (+) and eGFP-CCK-negative (-) cells from the upper small-
intestinal epithlium reveals enhanced Cnr1 expression in eGFP-CCK-positive 
cells (A). Expression of mRNA for CCK is found in eGFP-CCK-positive cells but 
not in eGFP-CCK-negative cells, (B). Gating strategy shown for sorting of eGFP-
positive and eGFP-negative events, with eGFP-positive cells highlighted in green 
and demarked by thin line (C) and compared to upper small-intestinal epithelial 
cells from a wild-type (WT) mouse (D). Data expressed as mean ± S.E.M. 
Analyzed using Student’s T-test, two-tailed (c); n=3 per group; *P <0.05. 
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Supplementary Figure 2. Details of gating strategy for fluorescence-assisted cell 
sorting (FACS) of CCK-eGFP-positive cells from upper small-intestinal epithelium 
of CCK-eGFP reporter mice, and wild-type control. CCK-eGFP-positive cells (A; 
associated graphic Fig 2D) represent 0.63% of total cells (value denoted by *). 
Wild-type cells show minimal fluorescence at 0.06% otal cells (B, value denoted 
by *; associated graphic Fig 2E), which represents less than 10% of CCK-eGFP-
positive cells from CCK-eGFP reporter mice and likely reflects autofluorescence. 
 
 
 
 
145 
 
 
 
Figure 3. Exogenous or endogenous activation of peripheral CB1Rs inhibits fat-
induced CCK release. Compared to control [0.5 mL saline (Sal) by oral gavage 
and vehicle (Veh) by IP injection], corn oil (CO; 0.5 mL by oral gavage) increased 
levels of CCK-8 in plasma of lean mice fed  a low-fat no-sugar standard diet 
(SD), an effect blocked by the CB1R agonist, WIN 55,212-2 (WIN, IP 3 mg per kg 
30 min before CO)(A). The effects of WIN were inhibited by co-administration 
with the peripherally-restricted CB1R antagonist, AM6545 (AM; 10 mg per kg 30 
min before CO). When compared to control SD mice (CO+SD), CO failed to elicit 
changes in levels of CCK-8 in plasma in mice fed western diet (WD) for 60 days, 
and inhibition of peripheral CB1Rs with AM6545 normalized levels of CCK-8 to 
those found in SD CO controls (B). Data expressed as means ± S.E.M. Analyzed 
by one-way ANOVA with post hoc Newman-Keuls multiple comparison test. n=3-
5 per condition, * p<0.05, ** p<0.01.  
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Supplementary Figure 3. Standard curve for ELISA analysis of CCK-8 in plasma 
and analysis of gastrin cross-reactivity. All values of CCK-8 fall within the range 
of the standard curve (10 to 1000 pmol per mL) for CCK-8 quantitation by a 
sensitive and selective CCK-8 ELISA (A), which shows no cross-reactivity for 
gastrin(B). Gastrin and CCK-8 (1 ng per mL each) were analyzed side-by-side. 
Data from plasma from two mice ± S.E.M. Analyzed with linear regression. ND = 
not detected. 
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Supplementary Figure 4. Analysis of gastric emptying. Gastric emptying was 
evaluated by quantitating via UPLC/MS/MS levels of 19:2 free fatty acid (19:2 
FFA) recovered from stomach 30 min following oral gavage of corn oil (CO) in 
mice maintained on a standard low-fat no-sucrose chow (SD).  Thirty min prior to 
gavage, mice were administered WIN 55,212-2 (WIN), AM6545 (AM), or vehicle 
(CO). Drug treatment had no significant effect on gastric emptying of CO (A). 
Similarly, mice fed a western diet (WD) for 60 days displayed no changes in 
gastric emptying of CO, when compared to SD mice (B). Data expressed as 
mean ± S.E.M. Analyzed using one-way ANOVA (A) or student’s t-test (B; two-
tailed). n = 4 (A) or 3 (B) per condition, p>0.05 
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Supplementary Figure 5. Effects of drug treatment on glucose levels in mice 
maintained on a standard low-fat no-sucrose diet. Blood glucose levels were 
measured at time -30 just prior to administration of the drugs WIN 55,212-2 
(WIN), AM6545 (AM), or vehicle (Veh). Blood glucose was again measured 30 
min later at time 0 just prior to oral gavage of corn oil (CO, 500 uL), then again at 
time of kill at time 30. Drug treatment had no significant effect on blood glucose 
levels at any time point, and CO did not impact blood glucose levels 30 minutes 
later at time 30 (A). Drug treatment also had no impact on area under the curve 
(AUC, all timepoints included) for blood glucose levels (B). Data expressed as 
mean ± S.E.M. Analyzed using repeated measures (time) two-way ANOVA with 
Sidak’s post hoc multiple comparison’s test (A) and one-way ANOVA (B). n = 4 
per condition, p>0.05.
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Figure 4. 2-AG biosynthesis and degradation are upregulated in small intestine 
during obesity. Hydrolytic activity of DGL (A) and MGL (B) are increased in mice 
maintained on western diet (WD) when compared to controls fed a standard diet 
(SD). Levels of the endocannabinoid, 2-AG, are increased in jejunum mucosa of 
WD mice, when compared to SD mice (C). 2-AG is formed by the hydrolysis of its 
1,stearoyl,2-arachidonoyl-sn-glycerol precursor by DGL and is subsequently 
degraded by MGL into arachidonic acid and glycerol (D). Data expressed as 
mean ± S.E.M. Analyzed using Student’s two-tailed T-test. n=6 per condition, *P 
<0.05. 
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Supplementary Figure 6. Validation of DGL and MGL functional enzyme assays. 
Inhibitors of DGL (A) and MGL (B) (THL and JZL184, respectively) dose-
dependently inhibited hydrolytic activity of these enzymes in isolated protein form 
the upper small-intestinal epithelium. Analyzed using nonlinear regression of log-
inhibitor vs. response. n=3 per group and R2 = goodness of fit > 0.8. 
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Figure 5. Expression of select components of the eCB system is dysregulated in 
the upper small intestine of DIO mice and partially conserved in CCK-eGFP+ 
cells. Expression of mRNA for cholecystokinin (Cck), cannabinoid receptor 
subtype 1 (Cnr1) and 2 (Cnr2), and other components of the eCB system in 
upper small-intestinal mucosal scrapings are not impacted by western diet (WD) 
exposure when compared to controls fed a standard diet (SD)(A). Expression of 
diacylglycerol lipase beta (Daglb) is decreased, and expression of the 
degradative enzymes monoacylglycerol lipase (Mgll) and alpha-beta hydrolyzing 
domain 6 (Abhd6) are increased in WD mice. Expression of mRNA for CCK or 
components of the eCB system were not significantly affected by diet in eGFP (+) 
sorted cells (B). Expression of mRNA for diacylglycerol lipase alpha (Dagla), 
Mgll, and N-acyl phosphatidylethanolamine specific phospholipase D (Napepld) 
was not detected (ND)(B). Data expressed as mean ± S.E.M. Analyzed using 
Student’s two-tailed T-test. n = 3 per group in triplicate and *P <0.05, **P <0.01 
(A); n = 3 per group in triplicate, P >0.05 (B). 
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Figure 6. Peripheral eCB signaling drives hyperphagia in mice maintained on a 
WD via a CCK-dependent mechanism. Caloric intake (A), meal size (B), and rate 
of intake (C) of a western diet (closed bars) are significantly reduced during a 12 
h test following inhibition of peripheral CB1Rs with AM6545 (AM, 10mg per kg), 
an effect absent in low-fat chow fed mice (open bars) and that is blocked by co-
administration with the CCKA receptor antagonist, devazepide (Dev; 0.1mg per 
kg). Diet and drug had no effect on meal frequency (D), meal duration (E), post 
meal interval (F), or first meal size (G). All data represented as means ± SEM. 
Analyzed using regular 2-Way ANOVA with post hoc Newman-Keuls multiple 
comparison’s test. n=11-12 per condition, *p<0.05, **p<0.01. 
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Supplementary Figure 7. Mice fed WD displayed large increases in body weight. 
Mice maintained on a western diet for 60 days showed a significant increase in 
body weight (A) and change in body weight (B) when compared to littermates 
maintained on a chow diet. Data expressed as mean ± S.E.M. Analyzed using 
repeated measures (time) two-way ANOVA with Sidak’s post hoc multiple 
comparison’s test. n = 9-10, ***P<0.001. 
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Figure 7. Model of CB1R control of nutrient-induced CCK release.  
Our studies suggest that cannabinoid CB1Rs in the upper small-intestinal 
epithelium control nutrient-induced satiation signaling, and their signaling is 
increased in diet-induced obesity, which drives overeating by delaying satiation. 
The upper small-intestinal epithelium contains enteroendocrine I-cells, which are 
a subpopulation of enterocytes that secrete cholecystokinin (CCK) when 
nutrients – including dietary fats – enter the lumen (83, 104-107). Dietary fats 
(e.g., corn oil), in the form of triacylglycerols, are hydrolyzed in the lumen into 
mostly monoacylglycerols and free-fatty acids (FFAs) that are sensed by free-
fatty acid receptors (FFARs) located on enteroendocrine cells in the small-
intestinal epithelium. Activation of FFARs stimulates secretion of CCK by a 
mechanism that requires calcium (Ca2+) influx and/or intracellular (i.e., 
endoplasmic reticulum, ER) mobilization (29, 76, 104). CCK activates CCKA 
receptors located on adjacent afferent sensory vagal fibers, which in turn, 
communicate with the brain and control meal size and satiation (31-33, 37). 
Consumption of a Western diet (WD) is associated with increased levels of the 
endocannabinoids (eCBs) and their activity at CB1Rs in the upper small-intestinal 
epithelium, which we propose inhibits CCK release and satiation signaling. The 
molecular mechanism(s) mediating CB1R control of CCK release is unknown but 
may include inhibition of Ca2+-mediated CCK release. A future test of this 
hypothesis is warranted.  
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Abstract 
Helminths have coevolved with their hosts, resulting in the development of 
specialized host immune mechanisms and parasite-specific regulatory products. 
Identification of new pathways that regulate helminth infection could provide a 
better understanding of host-helminth interaction and may identify new 
therapeutic targets for helminth infection. Here we identify the endocannabinoid 
system as a new mechanism that influences host immunity to helminths. 
Endocannabinoids are lipid-derived signaling molecules that control important 
physiologic processes, such as feeding behavior and metabolism. Following 
murine infection with Nippostrongylus brasiliensis, an intestinal nematode with a 
life cycle similar to that of hookworms, we observed increased levels of 
endocannabinoids (2-arachidonoylglycerol [2-AG] or anandamide [AEA]) and the 
endocannabinoid-like molecule oleoylethanolamine (OEA) in infected lung and 
intestine. To investigate endocannabinoid function in helminth infection, we 
employed pharmacological inhibitors of cannabinoid subtype receptors 1 and 2 
(CB1R and CB2R). Compared to findings for vehicle-treated mice, inhibition of 
CB1R but not CB2R resulted in increased N. brasiliensis worm burden and egg 
output, associated with significantly decreased expression of the T helper type 2 
cytokine interleukin 5 (IL-5) in intestinal tissue and splenocyte cultures. Strikingly, 
bioinformatic analysis of genomic and transcriptome sequencing (RNA-seq) data 
sets identified putative genes encoding endocannabinoid biosynthetic and 
degradative enzymes in many parasitic nematodes. To test the novel hypothesis 
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that helminth parasites produce their own endocannabinoids, we measured 
endocannabinoid levels in N. brasiliensis by mass spectrometry and quantitative 
PCR and found that N. brasiliensis parasites produced endocannabinoids, 
especially at the infectious larval stage. To our knowledge, this is the first report 
of helminth- and host-derived endocannabinoids that promote host immune 
responses and reduce parasite burden. 
 
Introduction 
Parasitic helminths infect an estimated two billion individuals worldwide 
(1). Although helminth infection is not typically fatal, it is associated with a 
multitude of pathologic conditions, including malnutrition and growth retardation. 
A majority of soil-transmitted helminths reside in the gastrointestinal tract, where 
they can negatively impact the host’s nutritional status by stealing nutrients or 
preventing nutrient absorption by damaging or causing inflammation of the 
intestinal tissue (2). Additionally, recent studies have identified new mechanisms 
by which helminths impact host feeding and metabolism (3). Gastrointestinal 
helminth infection was reported to decrease food intake (4), and was beneficial in 
mice fed a high-fat diet, in which it improved glucose metabolism and reduced 
adiposity (5, 6). This effect was partly mediated through T helper type 2 (Th2) 
cytokine-activated M2 macrophages in the adipose tissue, which have a known 
beneficial effect in metabolic homeostasis (7). In the intestine, helminth infection 
induced a Th2 cytokine-dependent expansion of tuft cells, which express taste 
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receptors, and cholecystokinin (CCK)-positive enteroendocrine cells, which 
secrete hormones that regulate feeding behavior (8). Overall, these findings 
support a multifactorial relationship between helminth and host immune response 
that affects host feeding behavior and metabolism. Identification of new helminth 
or host-derived factors that regulate this process, and how they affect host health 
and helminth killing, could provide a better understanding of the pathologic or 
beneficial effects of helminth infection that could be exploited therapeutically. 
Among the many host-derived molecules that affect feeding and 
metabolism, endocannabinoids are an important class of lipid molecules that 
regulate these physiologic processes (9, 10). Endocannabinoids are the body’s 
natural cannabis-like molecules that signal through cannabinoid receptors, which 
are highly expressed on neurons (11). Unsurprisingly, a highly recognized 
function of endocannabinoids is promoting neural-mediated behaviors such as 
food intake and reward (9). Endocannabinoids, however, are generated 
throughout the body, and cannabinoid receptors are present on extraneuronal 
cells, including intestinal epithelial cells and immune cells (12-14). Signaling by 
the endocannabinoids, 2-arachidonoylglycerol (2-AG) or anandamide (AEA), at 
cannabinoid receptors on intestinal cells impacts feeding behavior (15, 16), while 
signaling on immune cells can promote anti-inflammatory pathways (17). Despite 
functional effects on intestinal physiology and immune responses, no studies 
reported to date have investigated the role of endocannabinoids in intestinal 
parasite infection.  
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In this study, we investigated the expression and function of 
endocannabinoids in murine infection with Nippostrongylus brasiliensis, a rodent 
nematode parasite that has a life cycle similar to that of human hookworms (18). 
We show that N. brasiliensis infection significantly induces the biosynthesis of 
endocannabinoids and endocannabinoid-like molecules in the infected lung and 
intestine. We also performed functional assays to measure endocannabinoid 
biosynthetic and degradative enzyme activity in infected jejunal tissue, and we 
observed significantly increased endocannabinoid synthetic but not degradative 
enzyme activity. Endocannabinoid levels were negatively correlated with early 
infection-induced weight loss, associated with reduced food intake, and N. 
brasiliensis egg output, suggesting that endocannabinoids are associated with 
improved host immunity. To test this hypothesis, we employed validated 
peripheral pharmacological inhibitors of the cannabinoid subtype 1 receptor 
(CB1R) and CB2R, AM6545 and AM630, respectively, which act peripherally and 
do not cross the blood-brain barrier (16, 19). Pharmacological inhibition of CB1R, 
but not CB2R, significantly increased N. brasiliensis worm burdens and fecal egg 
output. Increased parasite burden was associated with reductions in Th2 
cytokines (interleukin 5 [IL-5] and IL-4) but not in the Th1 cytokine gamma 
interferon (IFN-γ), suggesting that N. brasiliensis-induced endocannabinoid 
signaling through CB1R was important for optimal host Th2 immune responses. 
Strikingly, bioinformatic analyses of the genomes and transcriptome sequencing 
(RNA-seq) data sets from N. brasiliensis and other parasitic nematodes, 
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including the hookworms Ancylostoma ceylanicum and Necator americanus, 
revealed putative genes encoding endocannabinoid synthetic and degradative 
enzymes. We validated the bioinformatic predictions for N. brasiliensis by 
quantitative real-time PCR and mass spectrometry (MS) and showed that N. 
brasiliensis produces endocannabinoids at all life cycle stages. Taken together, 
these studies show for the first time the production of endocannabinoids by 
parasitic helminths and suggest that helminth infection-induced 
endocannabinoids functionally influence the host immune response and parasite 
burden. These findings support a new area of investigation into the function of 
the endocannabinoid system in infectious diseases. 
 
Materials and methods 
Parasite 
The Nippostrongylus brasiliensis life cycle was maintained in Sprague-
Dawley rats, as previously described (20, 21). Hatched infectious L3 larvae were 
recovered from 1- to 2-week-old fecal egg cultures by a Baermann apparatus. L4 
larvae were recovered from lung tissue of day 2-infected rats by manual picking 
from coarsely minced lung tissue in media after 2h incubation at 37C. Adult N. 
brasiliensis parasites were recovered from day 6 to 8 N. brasiliensis infected 
mice by dissection and slitting of the whole small intestine, followed by 2 hour 
incubation in warm PBS and manual picking of the worms from the intestinal 
tissue or supernatant. Eggs in the feces of infected mice and rats were counted 
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using a McMaster counting chamber. For endocannabinoid quantification, 
parasites were washed 3x in excess PBS, counted, and weighed. 
Mice and tissue recovery 
C57BL/6 mice were purchased from the Jackson Laboratory or bred in-
house. All mice in the experiment were age-matched (6- to 8-week-old) males 
and females housed in a specific-pathogen-free facility. Mice were anesthetized 
with isoflurane and injected subcutaneously with 500 N. brasiliensis L3 larvae. 
Behavior was assessed using single-housing units (TSE Systems, Chesterfield, 
MO). Mice were placed into units 3 days prior to recording for acclimation, and 
daily feeding was monitored using Phenomaster software (TSE Systems). Where 
indicated, mice were treated intraperitoneally with a vehicle control (7.5% DMSO, 
7.5% Tween 80, and 85% saline), CB1R antagonist AM6545 (10 mg/kg of body 
weight), or CB2R antagonist AM630 (10 mg/kg). Blood recovery was done by 
cardiac puncture into tubes containing 7.2 mg of EDTA. Following excision of the 
small intestine, mucosa was stripped and recovered for endocannabinoid 
quantification. One-centimeter jejunal tissues were weighed and homogenized in 
0.5 mL of PBS with Mini-Beadbeater-96 (BioSpec Products) at 4oC, and 
supernatant was collected after centrifugation (4000 x g for 15 min at 4oC) for 
cytokine quantification. All protocols for animal use and euthanasia were 
approved by the University of California, Riverside Institutional Animal Care and 
Use Committee (https://or.ucr.edu/ori/committees/iacuc.aspx; protocols A-
20150028E and A-20170036) and were in accordance with the National Institutes 
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of Health Guidelines. Animal studies are in accordance with the provisions 
established by the Animal Welfare Act and the Public Health Services (PHS) 
policy on the humane care and use of laboratory animals.  
Lipid extraction and FAEs and MAGs analysis  
Lipid extraction and analysis were performed as previously described (16, 
22). Frozen tissue or worms were homogenized in 1.0 mL of methanol solution 
containing the internal standards, [2H5] 2-AG and [2H4]-AEA (Cayman Chemical, 
Ann Arbor, MI, USA). Lipids were extracted with chloroform (2 mL) and washed 
with water (1 mL). Lipids were similarly extracted from serum samples, with the 
exception of a 0.9 % saline wash replacing water (0.1 mL serum at the expense 
of saline). Organic phases were collected and separated by open-bed silica gel 
column chromatography as previously described (15). Eluate was gently dried 
under N2 stream (99.998% pure) and resuspended in 0.1 mL of 
methanol:chloroform (9:1), with 1μL injection for ultra-performance liquid 
chromatography/tandem mass spectrometry (UPLC/MS/MS) analysis. 
Data was acquired using an Acquity I Class UPLC with in-line connection 
to a Xevo TQ-S Micro Triple Quadrapole Mass Spectrometer (Waters 
Corporation, Milford, MA, USA) with electrospray ionization (ESI) sample 
delivery. Lipids were separated using an Acquity UPLC BEH C18 column (2.1 x 
50 mm i.d., 1.7 µm, Waters) and inline Acquity guard column (UPLC BEH C18 
VanGuard PreColumn; 2.1 x 5 mm i.d.; 1.7 µm, Waters), and eluted by a gradient 
of water and methanol (containing 0.25% acetic acid, 5 mM ammonium acetate) 
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at a flow rate of 0.4 mL/min and gradient: 80% methanol 0.5 min, 80% to 100% 
methanol 0.5 to 2.5 mins, 100% methanol 2.5 to 3.0 mins, 100% to 80% 
methanol 3.0 to 3.1 mins, and 80% methanol 3.1 to 4.5 mins. Column was 
maintained at 40oC and samples were kept at 10oC in sample manager. MS 
detection was in positive ion mode with capillary voltage maintained at 1.10 kV 
and Argon (99.998%) was used as collision gas. Cone voltages and collision 
energies for respective analytes: 2-AG = 30v, 12v; 2-DG = 34v, 14v; 19:2 MAG = 
18v, 10v; AEA = 30v, 14v; OEA = 28v, 16v; DHEA = 30v, 16v; [2H5]-2-AG = 25v, 
44v; [2H4]-AEA = 26v, 16v; [2H4]-OEA = 48v. 14v. Lipids were quantified using a 
stable isotope dilution method detecting proton or sodium adducts of the 
molecular ions [M + H/Na]+ in multiple reaction monitoring (MRM) mode. For 
many MAGs acyl migration from sn-2 to sn-1 glycerol positions is known to 
occur; for these analytes, the sum of these isoforms is presented. Tissue 
processing and LCMS analyses for experiments occurred independently of other 
experiments. Extracted ion chromatograms for MRM transitions were used to 
quantify analytes: 2-AG (m/z = 379.3 > 287.3), 2-DG (m/z = 403.3 > 311.2), AEA 
(m/z = 348.3 > 62.0), OEA (m/z = 326.4 > 62.1), DHEA, (m/z = 372.3 > 62.0), 
19:2 MAG (m/z = 386.4 > 277.2), with [2H5]-2-AG (m/z = 384.3 > 93.4), [2H4]-AEA 
(m/z = 352.4 > 66.1), and [2H4]-OEA (m/z = 330.4 > 66.0) as internal standards. 
Controls included one “blank” sample that was processed and analyzed in the 
same manner as all samples, except no tissue was included. This control 
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revealed no detectable endocannabinoids and related lipids included in our 
analysis. 
Functional enzyme assays of DGL and MGL activity 
Free-fatty acid measurements 
Data for free fatty acids (FFA) (19:2 FFA, product of MGL assay) were 
measured using the UPLC/MS/MS instrument as described above. Mobile phase 
compositions for 19:2 FFA were the same as described above, but the flow 
gradient began at flow rate 0.4 mL/min: 90% Methanol 0.1 min, 90% to 100% 
methanol 0.1 to 2.0 mins, 100% methanol 2.0 to 2.1 mins, 100% to 90% 
methanol 2.1 to 2.2 mins, and 90% methanol 2.2 to 2.5 mins. 19:2 MAG, product 
of DGL assay, was analyzed exactly as described above as for other MAGs. MS 
detection of fatty acids was in negative ion mode with capillary voltage 
maintained at 1.10 kV. Cone voltages for respective analytes: 19:2 FFA = 48v; 
17:1 FFA = 64v. Lipids were quantified using a dilution series detecting 
deprotonated molecular ions (23)- in selected ion recording (SIR) mode. 
Extracted ion chromatograms for SIR masses were used to quantify the analytes: 
19:2 FFA (m/z = 293.3) and the internal standard 17:1 FFA (m/z = 267.2). 
Tissue Preparation 
Intestinal epithelium was collected as described above and approximately 
100 mg of frozen tissue was homogenized in 2 mL of ice-cold 50mM Tris-HCl, 
320mM sucrose (pH 7.5) buffer. Homogenates were centrifuged at 800g for 10 
minutes while kept at 4oC and supernatant collected. Protein supernatants were 
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sonicated twice for 10 s and then freeze-thawed in liquid nitrogen twice. Samples 
were spun again, as described above, and supernatant was quantified with BCA 
assay and diluted with Tris-HCl/sucrose buffer. 
DGL activity assay 
25 µg tissue homogenates, in 0.1 mL Tris-HCl/sucrose (pH7.5), were 
incubated with 0.3 µM JZL184 [MGL inhibitor; Cayman Chemical, Ann Arbor, 
Michigan (24)] and accompanying treatments for 10 min at room temperature. 
Homogenates were incubated with 0.1 mL solution of Tris-HCL with 0.2% Triton 
X-100 (pH 7.0) containing 20 nmol dinonadecadienoin (Nu-Chek Prep, 
Waterville, MN; final volume 0.2 mL/reaction) at 37oC for 30 min. Reaction was 
stopped by adding 1 mL of MeOH containing 25 pmol [2H5]-2-AG. Lipids were 
extracted as described above an analyzed via UPLC/MS/MS. 
MGL activity assay 
10 µg tissue homogenates, in 0.1 mL Tris-HCl/sucrose (pH 7.5) were 
incubated with 0.4 mL solution of Tris-HCL with 0.1% BSA (pH 8.0) containing 50 
nmol nonadecadienoin (Nu-Chek Prep; final volume 0.5 mL/reaction) at 37oC for 
10 min. Reaction was stopped by adding 1 mL of MeOH containing 10 nmol 
heptadecanoic acid (Nu-Chek Prep). Lipids were extracted as described above 
and analyzed via UPLC/MS/MS. 
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Cytokine quantification 
ELISA 
 IL-5 quantification of intestinal homogenate and spleen supernatants was 
performed by standard sandwich enzyme-linked immunosorbent assay (ELISA) 
according to previously described protocols (20). 
Cytokine bead array 
 IL-4, IFN-γ, and IL-10 quantification was performed on intestinal 
homogenate and supernatants from 72-h-stimulated splenocytes (5 ×106/well; 
0.5 µg/ml of anti-CD3 and anti-CD28) using the Th1/Th2 CBA assay (BD 
Biosciences) according to the manufacturer’s instructions. 
RNA quantification 
Mouse tissue recovered for RNA extraction was first incubated overnight 
in RNAlater (Qiagen) at 4˚C then extracted by TRIzol (Life Technologies). iScript 
Reverse Transcriptase (Biorad) was used for cDNA synthesis. Relative 
quantification of cDNA was measured by real-time PCR using the Biorad CFX 
Connect. 18S primers were purchased from Qiagen, and Cnr1 and Cnr2 primers 
were purchased from Biorad.  
L3 infective juveniles (3 replicates of 500 to ~1,000) were collected from 
cultured rat fecal plates. L4 worms (3 replicates of 100 to 500) were collected 
from dissected lungs of infected rats 2 days post infection. Adult worms (3 
replicates of 100 to 200) were collected from dissected intestines of infected rats. 
Worms were washed in double-distilled water (ddH2O), flash-frozen, and then 
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homogenized in RiboZol (VWR) using pellet pestles and a pestle motor (Fisher 
Scientific and VWR). RNA was extracted according to RiboZol manufacturer 
instructions. Reverse transcription was done using Proto- Script II reverse 
transcriptase (New England BioLabs [NEB]), followed by real-time PCR as 
described above. Primer sequences were as follows: N. brasiliensis actin gene, 
ACGACGTGGCAGCTCTCGTTGTGG (forward) and 
GGTGCTTCGGTCAGCAGCACGGGA (reverse); N. brasiliensis faah gene, 
TCGGAGCAGGTGTTGTGAAGA (forward) and AGCCGGTACCACGGATCTGA 
(reverse); and N. brasiliensis nape gene, GGCGTACAGTCCACGATGGTT 
(forward) and GGTGCTTCGGCTCGAGGTAG (reverse). 
Gene orthology analysis and protein alignment 
To identify enzymes and regulatory proteins involved in lipolysis and 
endocannabinoid signaling we leveraged previously identified orthologs in C. 
elegans (25, 26). WormBase ParaSite (version WBPS9) was consulted to identify 
putative orthologs of these genes in several parasitic nematodes. To validate the 
putative parasitic nematode orthologs, we performed an orthology analysis using 
available predicted protein datasets from WormBase release WSPS9 — 
Ancylostoma ceylanicum, Ancylostoma duodenale, Ascaris lumbricoides, Ascaris 
suum, C. elegans, Necator americanus, N. brasiliensis, Steinernema 
carpocapsae, Strongyloides ratti, Strongyloides stercoralis, and Toxocara canis. 
Version 1.4 of the OrthoMCL pipeline was used to cluster proteins into families of 
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orthologous genes, with default settings and the BLAST parameters 
recommended in the OrthoMCL documentation (27). 
The NAPE-PLD gene was further explored by aligning the sequence of 
mouse NAPE-PLD and the putative homolog from N. brasiliensis. Protein 
sequences were aligned using MUSCLE (28) and visualized using Mesquite 
(version 3.2). The accession numbers of the proteins used are NP_848843 for 
the mouse NAPEPLD from GenBank and NBR_0001270801-mRNA-1 for the N. 
brasiliensisNAPEPLD from WormBase ParaSite. The B_2 lactamase domain in 
the alignment was identified using Smart protein database (29).  
Gene expression analysis 
To determine if genes for the endocannabinoid system are expressed in 
other parasitic nematodes, we downloaded the RNA-seq data for T. canis (30) 
(SRR1707010, SRR1707031-6), S. ratti (31) (ERR299168-79, ERR225783-4), S. 
stercoralis (32) (ERR146945-6, ERR146948-9), A. suum (33) (SRR851186-95), 
N. americanus (34) (SRR609895, SRR609951), N. brasiliensis (35); 
PRJEB16076, and A. ceylanicum (36) (SRR1124912-4, SRR1124985-6) from 
NCBI. The published RNA-seq data for N. brasiliensis was downloaded from 
European Nucleotide Archive (http://www.ebi.ac.uk/) (58). The reads were 
mapped to each species’ indexed transcriptome (downloaded from WormBase 
ParaSite, WSPS9) with bowtie 1.0.0 in paired-end mode with the following 
settings: bowtie –X 800 -m 200 -S --seedlen 25 –trim3 [50 or 100] -n 2 --offrate 1 
(37). Gene expression was quantified with RSEM version 1.2.31 (38).  
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Statistical Analysis  
GraphPad Prism software was used for statistical analyses. Where 
appropriate, Student’s t test (for normal distribution data), one-way analysis of 
variance (ANOVA) (for analysis of more than two groups), two-way ANOVA (for 
analysis of more than one experiment), linear regression, and nonparametric 
Spearman correlation (for correlation analysis) were performed. Statistical 
significance is indicated in Table 1 and in figures as follows: *, P < 0.05; **, P < 
0.01; and ***, P < 0.0001. To evaluate CB1R inhibitor effect on N. brasiliensis 
burdens across experimental repeats, we employed linear mixed models. The 
inhibitor was tested as the main effect, which was adjusted by baseline weight 
and the weight on day 3; the experimental cooperation was the random effect. 
On the basis of the distribution types for egg and worm, the corresponding 
distribution families were Gamma and Poisson, respectively. 
 
Results 
Nippostrongylus brasiliensis infection induces lung and intestinal 
endocannabinoids production 
Endocannabinoids are lipid signaling mediators that affect a variety of 
behaviors (e.g. feeding and memory) and metabolic processes (e.g. glucose 
homeostasis) (see Fig. S1 in the supplemental material) (9). Additionally, 
endocannabinoids can regulate the immune response and dampen inflammation 
(39). Despite reported immunoregulatory function, however, whether 
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endocannabinoids are generated in parasite infection and the functional 
consequence for the host or pathogen are unknown. N. brasiliensis infects the 
small intestine of mice and has been shown to affect food intake and 
metabolism(3-5). Given that endocannabinoids and endocannabinoid receptors 
are expressed in the intestine, we hypothesized that N. brasiliensis infection may 
affect endocannabinoid signaling. Similar to the hookworm life cycle, N. 
brasiliensis infects both the lung and the intestine as part of its life cycle and 
feeds on host blood(40). We therefore measured tissue and circulating 
endocannabinoid levels in naive and N. brasiliensis-infected mice at days 2 and 7 
postinfection, when the parasites had infected the lung and jejunum, respectively. 
We observed a modest but significant increase in 2-AG and AEA in N. 
brasiliensis-infected lung tissue and a trend toward increased levels of 
endocannabinoid-like molecule oleoylethanolamine (OEA) (Fig. 1A). Strikingly, 2-
AG levels in jejunal tissue were almost 10-fold higher than in the lung, and we 
observed a >2-fold increase following N. brasiliensis infection (Fig. 1B). AEA and 
OEA, both of which regulate feeding and are anti-inflammatory(15, 41, 42), were 
also significantly elevated in the jejunum in response to N. brasiliensis infection 
(Fig. 1B). In contrast, circulating endocannabinoid levels in the plasma were 
unchanged following N. brasiliensis infection (Fig. 1C), suggesting that N. 
brasiliensis-induced endocannabinoids were restricted to the tissue infection site. 
Given that the 2-AG levels were highest in the infected jejunum, we next 
evaluated the activity of the biosynthetic and degradative enzymes responsible 
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for 2-AG metabolism in jejunal epithelium of infected versus naive mice. 
Specifically, we measured the enzymatic activities of diacylglycerol lipase (DGL, 
biosynthetic) and monoacylglycerol lipase (MGL, degradative) by functional 
enzyme assays (15). We found significant increases in the activity of DGL in 
jejunal tissue of infected mice compared to noninfected mice (Fig. 1D, left), which 
suggests that levels of 2-AG in jejunum are elevated in infected mice by a 
mechanism that includes increases in jejunal DGL-mediated 2-AG biosynthesis. 
In contrast, we did not observe any changes in enzymatic activity of MGL (Fig. 
1D, right). Endocannabinoids signal through the G protein-coupled cannabinoid 
receptors subtype 1 and 2; therefore, we measured the cannabinoid receptor 
coding genes Cnr1 and Cnr2 mRNA by quantitative PCR of the jejunal tissue. N. 
brasiliensis infection induced increases in both Cnr1 and Cnr2 (Fig. 1E). 
Collectively, these data demonstrate that N. brasiliensis infection increases 
endocannabinoid levels locally in the infected lung and intestinal tissue and 
promotes intestinal endocannabinoid receptor expression, suggesting that the 
endocannabinoid system is induced in helminth infection. 
Intestinal endocannabinoids are negatively correlated with Nippostrongylus 
brasiliensis infection-induced weight loss and parasite egg burdens  
We examined if N. brasiliensis-induced endocannabinoids were 
associated with health outcomes for the host or parasite by correlative analyses 
between endocannabinoid levels and infection-induced weight loss or parasite 
egg burdens. N. brasiliensis infectious larval stage 3 (L3) helminths migrate to 
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the lung, where they develop into L4, followed by infection of the small intestine, 
where they develop into adults and produce eggs (Fig. 2A and B). At the 
infectious dose of 500 L3 helminths, N. brasiliensis infection of the lung, which 
occurs between day 1 and 3 postinfection, causes lung hemorrhaging and 
inflammation likely due to the physical damage of the worm burrowing through 
the lung tissue. During this acute infection of the lung, we observe significant 
weight loss that was remarkably resolved once the N. brasiliensis parasites were 
established in the intestine, at day 6 (Fig. 2A). Consistent with this weight loss, 
analysis of feeding patterns in naive and infected mice revealed reduced food 
intake (P < 0.05) and motor activity (P < 0.05) at day 1 postinfection, when the N. 
brasiliensis parasites had reached the lung, that was also resolved by day 6 
postinfection (Fig. 2C). We also observed a significant positive correlation 
between N. brasiliensis-induced acute weight loss at day 3 and N. brasiliensis 
egg burdens at day 7 post infection (Fig. 2D, left). This correlation suggests that 
acute infection-induced weight loss at day 3 may be a good predictor of 
subsequent parasite establishment in the intestine. The effect of N. brasiliensis 
infection on mouse weight changes may be due to lung tissue inflammation or 
changes in mouse feeding behavior.  
Given that endocannabinoids can regulate both these processes, we 
investigated correlations between endocannabinoids and N. brasiliensis parasite 
burdens. We observed that 2-AG intestinal levels from day 7 infected mice were 
negatively correlated with early infection-induced weight loss (day 3) and day 7 
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parasite egg burden (Fig. 2D, right). To comprehensively define the relationship 
between endocannabinoids versus host and parasite fitness, we performed 
Spearman correlation analyses across all experiments (Table 1). We observed a 
negative correlation between day 7 infected jejunum 2-AG and OEA and (i) early 
(day 3) infection-induced weight changes and (ii) day 7 parasite egg burden. In 
contrast, we observed a positive correlation between plasma 2-AG and OEA, 
weight loss, and parasite egg burden. These data indicate that high 
endocannabinoid levels locally in the intestine are associated with reduced early 
infection-induced weight loss and decreased parasite egg burden. 
Disruption of CB1 receptor but not CB2 receptor signaling increases 
Nippostrongylus brasiliensis egg burden and impairs intestinal IL-5 responses 
The endocannabinoids, 2-AG and AEA, both of which were upregulated 
following N. brasiliensis infection (Fig. 1), signal through CB1R and CB2R (12). 
We investigated the function of endocannabinoid signaling in N. brasiliensis 
infection by treatment with the peripherally restricted neutral CB1R antagonist 
AM6545 (43, 44), CB2R antagonist AM630 (19), and dimethyl sulfoxide (DMSO) 
as a vehicle control. To rule out potential confounding effects on parasite 
establishment in the intestine, mice were treated daily with antagonists or vehicle 
starting at day 4 postinfection, when all N. brasiliensis parasites had reached the 
intestine. At this time point, CB1R or CB2R inhibition had no effect on mouse 
weight (Fig. 3A). Interestingly, CB1R but not CB2R inhibition led to increased 
fecal N. brasiliensis egg output and intestinal N. brasiliensis worm counts (Fig. 
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3B), suggesting that CB1R signaling is necessary for optimal N. brasiliensis 
expulsion. We validated these CB1R inhibitor-mediated differences in N. 
brasiliensis burdens across three experimental repeats, using generalized linear 
models, and found that CB1R inhibitor treatment led to a 2.21-fold-higher egg 
burden (P < 0.01) and 1.46-fold-higher worm burden (P < 0.01) (Table 2). CB1R 
inhibition resulted in significantly decreased intestinal levels of the Th2 cytokine 
IL-5 but not IL-4, IFN-γ or IL-10 (Fig. 3C). Further, in vitro CD3/CD28-activated 
splenocytes from CB1R inhibitor-treated mice secreted significantly less IL-5, IL-
4, and IL-10 than vehicle-treated mice but exhibited no defect in IFN-γ secretion 
(Fig. 3D). This cytokine effect was specific to CB1R signaling, as inhibition of 
CB2R signaling had no significant effect. Given that host immunity to N. 
brasiliensis is dependent on Th2 cytokines, the CB1R inhibitor-induced decrease 
in IL-5 and IL-4 may explain the increase in parasite egg burden. Additionally, the 
significant reduction in IL-10 secretion is consistent with an anti-inflammatory 
function for CBR signaling (41). These data support the functional link between 
the endocannabinoid system and immunity to N. brasiliensis and suggest that 
CB1R signaling has a beneficial impact for the host following N. brasiliensis 
infection by promoting Th2 cytokine expression and reducing parasite burdens. 
Endocannabinoid system is present in Nippostrongylus brasiliensis and other 
parasitic helminths 
 The endocannabinoid system is conserved in vertebrates and some 
invertebrates (45), and endocannabinoid biosynthetic enzymes are expressed in 
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Caenorhabditis elegans(46). However, whether the endocannabinoid system 
exists in parasitic helminths is unknown. We conducted bioinformatic analyses of 
available parasitic nematode genomes for genes involved in the 
endocannabinoid synthetic and signaling pathway (Table 4). Within the N. 
brasiliensis genome, genes encoding synthetic enzymes for the 
monoacylglycerols, 2-AG and DHAG (dagl), and the fatty acid ethanolamides, 
AEA, OEA, and docosahexaenoylethanolamide (DHEA) (nape) were identified. 
We also found orthologs of the fatty acid ethanolamide degradative enzyme, fatty 
acid amide hydrolase (faah-1), the proposed monoacylglycerol degradative 
enzymes, alpha beta hydroxylases (abhd-12 and abhd-5). Although nematodes 
did not have obvious orthologs of monoacylglycerol lipase (magl), the major 
degradative enzyme for 2-AG found in mammals, we identified a putative 
nematode gene encoding the minor 2-AG degradative enzyme, abhd-6 (47). 
Moreover, the synthetic and degradative endocannabinoid genes were 
conserved in other nematodes, including human hookworms Ancylostoma 
duodenale and Necator americanus, and human roundworm Ascaris 
lumbricoides. 
Analysis of available RNA-seq data set revealed the expression of putative 
genes for the endocannabinoid pathway in parasitic nematodes of humans (A. 
ceylanicum, Ascaris suum, N. americanus, Toxocara canis, and Strongyloides 
stercoralis), rodents (N. brasiliensis and Strongyloides ratti), and even insects 
(Steinernema carpocapsae) (Fig. 4; see also Fig. S2 in the supplemental 
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material). Further, these genes were expressed in a tissue- or stage-specific 
manner in some of these parasites. For example, the hookworm A. ceylanicum, 
which infects humans and other mammals, showed expression of abhd-5 in all 
stages sampled but showed highest expression of abhd-5 in the infective L3 
stage. In the human hookworm N. americanus, both nape-1 and abhd-12 were 
more highly expressed in L3 larvae than in adult nematodes. Although it was 
previously thought that no obvious orthologs of CB1 and CB2 receptors were 
present in nematodes, a recent study identified the neuropeptide receptor NPR-
19 as a cannabinoid-like receptor in C. elegans (26, 48-51). We were able to find 
putative orthologs of the cannabinoid like receptor NPR-19 in other nematodes, 
including A. ceylanicum, N. americanus, and Wuchereria bancrofti (Table 3). 
However, we were not able to find an obvious ortholog of NPR-19 in N. 
brasiliensis, though this may be due to the incomplete state of the available N. 
brasiliensis genome (N50 = 33.5 kb; i.e., nearly 30% of the predicted protein-
coding genes are on contigs smaller than 10 kb), rather than the absence of an 
NPR-19 ortholog(52, 53).  
Nippostrongylus brasiliensis produces endocannabinoids 
Given the presence of genes encoding endocannabinoid synthetic 
enzymes in the N. brasiliensis genome, we investigated if N. brasiliensis could 
produce endocannabinoids at any stage of its life cycle. We isolated infectious N. 
brasiliensis L3 from hatched fecal cultures, N. brasiliensis L4 from day 2 infected 
lungs, and N. brasiliensis adults from day 7 infected jejunum, performed thorough 
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washes in phosphate-buffered saline (PBS), and measured endocannabinoid 
levels. Although there were no endocannabinoids in the control washes, we 
measured detectable levels of endocannabinoids and endocannabinoid-like 
molecules in worm extracts from all life cycle stages (Fig. 5A). These exhibited 
identical chromatogram patterns to reference endocannabinoids, AEA (Fig. 5B) 
and 2-AG (Fig. 5C), and endocannabinoid-like molecules (see Fig. S3A to C in 
the supplemental material). On a per-weight basis, adult N. brasiliensis produced 
the most 2-AG and DHAG, whereas L4s produced OEA. Strikingly, infectious L3 
produced over 100-fold more AEA than the other life cycle stages or the host 
(Fig. 1B). L4 and adult N. brasiliensis worms feed on host tissue and blood; 
therefore, it may be possible that some endocannabinoids detected may be host-
derived. However, the infectious L3 were isolated from culture and 
concentrations of AEA reached 1000 pmol per gram of worm, which is 100-200 
times levels found in upper intestinal mucosal scrapings (5 to 10 pmol per g of 
tissue) and 300-1000 times found in circulation (1 to 3 pmol per mL) (Fig. 1, and 
(16)). Thus, the endocannabinoids measured in L3 worms are likely generated by 
the parasite. Consistent with the presence of a functional endocannabinoid 
system in N. brasiliensis, sequence alignment of the predicted N. brasiliensis 
gene encoding NAPE-PLD, the dominant enzyme catalyzing the biosynthesis of 
fatty acids ethanolamides, including AEA, OEA, and DHEA, revealed 43% 
identity, and sequence conservation in the functional lactamase domain (Fig. 
5D). To validate that the predicted N. brasiliensis genes encoding 
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endocannabinoid biosynthetic and degradative enzymes were expressed, we 
performed quantitative PCR for predicted nape and faah and the actin gene as a 
housekeeping gene control (Fig. 5E). nape and faah mRNAs were present in all 
N. brasiliensis life cycle stages, with the highest expression in the infectious L3 
stage. Overall, these data show for the first time that endocannabinoids are 
produced by N. brasiliensis and suggest that the endocannabinoid system is also 
present in parasitic nematodes that infect humans. 
 
Discussion 
In this study, we investigated the endocannabinoid signaling system 
following infection with N. brasiliensis. While recognized for its critical function in 
the central and enteric nervous system, the endocannabinoid system is also 
activated by and can influence inflammatory immune responses (22, 39, 54). For 
example, 2-AG and AEA are anti-inflammatory, which has provided the basis for 
the potential therapeutic use of synthetic cannabinoids, or cannabis, in 
autoimmune or inflammatory diseases (55). Oral treatment of mice with AEA 
promoted a tolerogenic immune response and regulatory macrophages in the 
intestine that were protective in a non-obese diabetic model (56). Despite an 
immune function in the intestine, the functional significance of endocannabinoids 
in intestinal parasite infection has not been examined. Our finding that helminth 
infection triggers significant endocannabinoid expression that is correlated with 
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both host health outcomes and parasite fecundity suggests that 
endocannabinoids may be important players in host-helminth dynamics. 
Inhibition of CB1R led to decreased expression of the Th2 cytokine IL-5 in 
the intestine and IL-4, IL-5, and IL-10 in the spleen but no difference in the Th1 
cytokine IFN-γ. This was associated with increased parasite egg and worm 
burdens, suggesting that CB1R signaling may be important for the optimal host 
immune response to keep helminth burdens in check. Endocannabinoids also 
signal through CB2R (39); however, CB2R antagonist treatment did not 
significantly change cytokine responses or helminth burdens. CB1R and CB2R 
inhibition was conducted during a short time frame, days 4 to 6 post-infection, 
and we cannot confirm complete abrogation of CB1R or CB2R signaling in the 
intestine with this treatment regime. Future studies with earlier treatment regimes 
or CB1R/CB2R-deficient mice may delineate functional differences between these 
signaling pathways in helminth infection. Cannabinoid CB1Rs are expressed in 
cholecystokinin (CCK)-positive enteroendocrine cells in the duodenum of mice 
(57) and ghrelin-expressing cells of the stomach of rats (58), and N. brasiliensis 
infection in rats is associated with elevations in circulating levels of CCK (4, 59). 
Thus, it is possible that helminth infection may induce changes in feeding 
behavior, as seen in Fig. 2, by a mechanism that includes endocannabinoid-
mediated changes in the production and/or release of peptides important for 
feeding behavior, including CCK. We observed significant correlations between 
endocannabinoid levels, infection-induced weight loss, and parasite burdens. 
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However, further functional studies are necessary to determine causal 
relationships between these multiple parameters and the contribution, if any, of 
infection-induced endocannabinoids to feeding behavior. 
In addition to host endocannabinoid expression, we show for the first time 
that N. brasiliensis produces endocannabinoids and that genes encoding 
endocannabinoid biosynthetic and degradative enzymes are present in the 
genomes of multiple parasitic nematodes, including some of the most common 
helminth parasites of humans. One proposed strategy by which parasites 
modulate host immunity is by releasing molecules that are already native within 
the host, or at least native-like molecules (60). For example, A. suum and T. 
canis have been shown to synthesize opioid or opioid-like substrates, and 
morphine is a known immunomodulator (61, 62). It is well recognized that the 
endocannabinoid system is conserved in a diverse variety of vertebrates, 
including pythons (63) and goldfish (64); however, whether it evolved earlier and 
is functional in more primitive eukaryotic organisms is less well understood (48). 
We observed that N. brasiliensis has a predicted gene encoding the NAPE-PLD 
and FAAH enzymes that catalyze endocannabinoid synthesis and breakdown. 
Quantitative PCR analysis confirmed N. brasiliensis expression of both of these 
predicted genes. Moreover, mass spectrometry analysis revealed that infectious 
L3 N. brasiliensis produced extremely high levels of AEA, reaching 100 to 1000 
times that found in tissue or blood of mice. A recent study showed that truffles, 
the fruiting body of fungi produce AEA potentially as an attractant and feeding 
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stimulant for animals to ensure its dissemination (65). Given that AEA is anti-
inflammatory, high level synthesis at the infectious stage may also function to 
dampen the host immune response. It is possible that in addition to 
endocannabinoids, N. brasiliensis may produce and release other signaling 
molecules endogenous to the host, such as opioids, and that there is overlap in 
the biological effects of these molecules on host immunity or behavior. Given the 
difference in mass between N. brasiliensis and the host, the endocannabinoids 
detected in the infected mice are likely host derived. However, it is possible that 
N. brasiliensis derived endocannabinoids may functionally impact the host at the 
cellular level. Future studies are necessary to test these hypotheses. 
Inhibition of CB1R signaling significantly increased N. brasiliensis egg 
burden; however, whether the functional effect was through influencing the host 
or alteration of the endocannabinoid system in N. brasiliensis is unclear. In the 
host, the increased N. brasiliensis burdens when CB1R signaling is inhibited 
could be due to the altered immune response or to reduced intestinal motility. 
Indeed, immune cells express both CB1 and CB2 receptors (66) (i.e., 
macrophages, dendritic cells, and T cells) and intestinal epithelial cells express 
CB1R (14). Whether the CB1R inhibitor-mediated increase in N. brasiliensis 
burden was through direct effects on immune cells, effects on the intestinal 
epithelial cells, or a combination of such effects is unclear and would require 
further studies. In addition to regulating immune responses, the endocannabinoid 
system throughout the gastrointestinal tract plays a variety of physiological roles, 
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including the control of motility, immune function, mucosal barrier function, and 
feeding behavior (67-69). Although outside the scope of the present study, future 
studies should include an evaluation of the impact that endocannabinoid-induced 
changes in intestinal motility have on egg burden. Furthermore, it is possible that 
endocannabinoid metabolism and/or release may be secondarily affected by 
perturbations in physiological responses governed by endocannabinoids 
themselves. It is also possible that CB1R inhibition could directly affect N. 
brasiliensis. Although the N. brasiliensis genome does not have canonical 
cannabinoid receptor genes, genes encoding endocannabinoid degradative 
enzymes are present in the N. brasiliensis genome, suggesting that N. 
brasiliensis may also respond to the endocannabinoids it produces through an 
as-yet-unidentified receptor. Consistent with this, C. elegans produces and 
responds to cannabinoids through NPR-19 (26, 50, 51). Inhibiting CB1R signaling 
was ultimately beneficial to N. brasiliensis, leading to improved parasite fertility. 
Why N. brasiliensis would produce endocannabinoids that adversely affect its 
fertility is unclear at present. Our data, however, support a functional impact of 
the host and parasite endocannabinoid system and suggest that further studies 
delineating the beneficial or detrimental function of endocannabinoids in the host 
versus the helminth are warranted. For example, the timing of cannabinoid 
receptor signaling inhibition may be critical. In our studies, we inhibited CB1R 
signaling after adult parasite establishment in the intestine; however, N. 
brasiliensis produces the most AEA during the initial infection, possibly as an 
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anti-inflammatory mechanism to downregulate the host immune response. N. 
brasiliensis-derived AEA may also prevent excessive host inflammation that 
could lead to host mortality, which would be an equally adverse outcome for the 
helminth. Notwithstanding this, our discovery of parasite-derived 
endocannabinoids implicates the endocannabinoid system as a primitive 
pathway that contributes to host-pathogen interaction and suggests that 
investigation of the existence of the endocannabinoid system in other pathogens 
is warranted.  
 The complexity of host-helminth interaction and the numerous factors that 
influence the health outcomes for the parasite and the host are increasingly 
recognized. In addition to an optimized Th2 response for parasite expulsion, 
parasitic helminths trigger a multitude of non-immune pathways that affect 
physiologic processes, such as feeding and metabolism, but can also influence 
the immune response (70-72). Our findings suggest that the endocannabinoid 
system is a previously unrecognized contributor to this dynamic process and may 
therefore have a significant impact on the host’s health outcome beyond parasite 
expulsion. 
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Tables 
 
Table 1: Correlation analysis between endocannabinoids, infection-induced 
weight loss and parasite egg burden (n=26-28, ns=not significant, n/a=not 
applicable).  
 Jejunum eCB Plasma eCB Parasite 
Weight 
Loss  2AG OEA AEA DHAG DHEA 2AG OEA AEA DHAG 
DHEA Egg Worm   
Spearman r -0.55 -0.53 -0.44 -0.61 0.15 -0.50 0.04 0.66 -0.68 0.38 -0.50 -0.29 
p value *** *** * *** ns *** ns *** *** ns * ns 
Egg 
Burden  2AG OEA AEA DHAG DHEA 2AG OEA AEA DHAG 
DHEA Egg Worm   
Spearman r -0.57 -0.52 -0.56 0.17 -0.34 -0.59 0.37 0.28 0.25 -0.49 n/a 0.48 
p value ** ** ** ns ns ** ns ns ns * n/a * 
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Table 2: Association test of Nippostrongylus brasiliensis egg burden with 
endocannabinoids and prohibitive effect of CB1R inhibition (n=6/group) S.E. 
standard error. 
  eCB CBR Effect size S.E p value 95% CI 
Jejunum 2AG vehicle -226.51 106.84 0.05 -447.54 ~ -5.49 
   CBR1 102.25 488.40 0.84 -1002.58 ~ 1207.08 
DHAG vehicle -1041.55 498.69 0.07 -2169.66 ~ 86.56 
   CBR1 1027.62 722.56 0.19 -606.92 ~ 2662.16 
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Table 3: Association test by the principal component (PC) analysis best selection 
between endocannabinoid and N. brasiliensis egg burden and effect of CB1R 
inhibition (n=6/group), CI, confidence interval. 
  Estimation 95% CI p value 
(Intercept) 58220.75 -13183.61 ~ 129625.11 0.11 
Weight change 
percentages 
-3188.06 -4664.40 ~ -1711.71 <0.001 
PC3 -3857.27 -7184.62 ~ -529.91 0.02 
PC4 -6137.77 -11118.12 ~ -1157.43 0.02 
CBR1 -1245.51 -10688.23 ~ 8197.22 0.80 
196 
 
 
 
Table 4: Putative genes in endocannabinoid signaling and degradation identified 
in the genome of Nb, human hookworms and other parasitic nematodes.  
  Nbra Aduo Acey Name Scar Alum Srat Sste Tcan 
nape-1 √ √ √ √ √ √ X X √ 
faah-1 √ √ √ √ √ √ √ √ √ 
dagl-2 √ √ √ √ √ √ √ √ √ 
magl X X X X X X X X X 
abhd-6 √ √ √ √ √ √ √ √ √ 
abhd-
12 
√ √ √ √ √ √ √ √ √ 
abhd-5 √ √ √ √ √ √ √ √ √ 
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Figures 
 
 
Figure 1. N. brasiliensis infection induces endocannabinoid production and 
cannabinoid receptor expression. C57BL/6 mice were left naïve or infected for 2 
or 7 days with 500 N. brasiliensis L3 worms. 2-AG, AEA, and OEA levels in the 
lung at day 2 (A), jejunum at day 7 (B), and plasma at day 2 and day 7 (C).  
(D) 2-AG biosynthetic (DGL, left) and degradative (MGL, right) enzyme activities 
were measured in jejunal tissue from naive or day 7 infected mice.  
(E) N. brasiliensis infection-induced Cnr1 and Cnr2 mRNA in the jejunal tissue at 
day 7 was quantified as fold induction over naive after normalization with the 18S 
rRNA housekeeping gene. Data are presented as means ± SEM (n = 4 to 
6/group) and are representative of results from four experiments. 
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Figure 2. Intestinal endocannabinoid levels are negatively correlated with 
infection-induced weight loss and fecal egg burdens. (A) Time course of N. 
brasiliensis infection-induced weight loss. (B) Compiled data of N. brasiliensis 
parasite burdens in lung and small intestine. (C) Food, water intake, and motor 
activities of naive (N) and N. brasiliensis-infected (INF) mice were evaluated in a 
feeding chamber. (D) Correlation analysis between parasite egg burden and 
weight loss (left) and jejunal 2-AG (right) was performed. Data are presented as 
means ± SEM and are representative of results from two to four experiments  
(n = 4 to 6/group). 
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Figure 3. Pharmacologic inhibition of cannabinoid receptor 1 but not cannabinoid 
receptor 2 increases helminth burdens associated with decreased IL-5 
expression. C57BL/6 mice were left naive (black) or infected with N. brasiliensis. 
At days 4 to 7 postinfection, mice were treated intraperitoneally with AM6545 
(CB1R inhibitor [Inh]; red), AM630 (CB2R inhibitor; gray), or DMSO (VEH; blue). 
(A) Infection induced weight loss was monitored and compared to that in naive 
mice. (B) Fecal egg burdens (left) and intestinal worm counts (right) were 
quantified in N. brasiliensis-infected mice. (C and D) IL-5, IL-4, IFN-γ, and IL-10 
were quantified in day 8 infected (C) intestinal tissue homogenate and (D) 
supernatant from 72-h anti-CD3/anti-CD28-stimulated splenocytes. Data are 
presented as means ± SEM (n = 4 to 6/group) and representative of results from 
three separate experiments. 
 
201 
 
 
 
 
Figure 4. Expression of genes encoding endocannabinoid biosynthetic and 
degradative enzymes in parasitic nematodes. Nematode expression data for 
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endocannabinoid biosynthetic enzyme gene nape-1 (A) and degradative enzyme 
gene faah-1 (B), the monoacylglycerol biosynthetic enzyme gene dagl-2 (C), and 
genes for the potential degradative enzymes alpha beta hydrolases (abhd-5 [D]) 
and (abhd-12 [E]), and the minor 2-AG degradative enzyme (abhd-6 [F]) are 
shown in transcripts per million (TPM). The life stages for S. ratti expression are: 
free-living female (FLF), parasitic female (PF), free-living male (FLM), and 
infective L3 (L). The tissues for expression data for T. canis expression are 
female gut (1), female reproductive tract (2), female anterior body (3), male gut 
(4), male reproductive tract (5), male anterior body (6), and L3 (7). The life stages 
for N. americanus expression are adult (A) and infectious L3 (L). The life stages 
for S. carpocapsae expression are nonactivated infective juveniles (IJs) (NA IJ), 
12-h in vitro activated IJs (VIT 12 h), 9-h in vivo activated IJs (VIV 9h), 12-h in 
vivo activated IJs (VIV 12h), and 15 h in vivo activated IJs (VIV 15h). The life 
stages for S. stercoralis expression are nonactivated IJ (NA IJ) and activated IJ 
(A IJ). The life stages for A. ceylanicum expression are 17 days postinfection (1), 
12 days postinfection (2), 5 days postinfection (3), 24-h incubation in hookworm 
culture media (4), and infective L3 (5). The life stages for N. brasiliensis 
expression are adult (1), L4 from mouse lung (2), infectious L3 (3), and eggs (4). 
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Figure 5. N. brasiliensis produces endocannabinoids and cannabinoid-like 
molecules. N. brasiliensis parasites from life cycle stages were isolated, washed, 
and assessed for levels of endocannabinoids and endocannabinoid-like 
molecules by UPLC/MS/MS. (A) Levels of analytes at various life stages: 
anandamide (AEA), 2-arachidonoyl-sn-glycerol (2-AG), oleoylethanolamide 
(OEA), docosahexaenoylethanolamide (DHEA), and docosahexaenoylglycerol 
(DHAG). (B and C) Representative chromatograms of AEA (B) and 2-AG (C). (D) 
A 68-amino-acid (aa) region of an alignment of mouse and N. brasiliensis NAPE-
PLD (43% shared identity). The alignment region shown is the first 68 aa in a 
202-aa lactamase (B_2) domain identified in mouse NAPE-PLD. (E) Quantitative 
reverse transcription-PCR of Nippostrongylus life cycle stages for predicted nape 
and faah. 
205 
 
 
 
 
 
 
Supplementary Figure 1. Endocannabinoid metabolism and signaling pathways. 
Endocannabinoids are lipid-derived signaling molecules that belong to two lipid 
classes: fatty acid ethanolamides (FAEs) and monoacylglycerols (MAGs). FAEs 
include the endocannabinoid, anandamide (AEA), and the endocannabinoid-
related molecules, oleoylethanolamide (OEA) and 
docosahexaenoylethanolamide (DHEA), as well as others. FAEs are generated 
by the activity of N-acyl phosphatidylethanolamie-specific phospholipase D 
(NAPE-PLD) and are degraded by fatty acid amide hydrolase (FAAH). The MAG 
endocannabinoid, 2-AG, on the other hand, is synthesized primarily by the 
activities of diacylglycerol lipase  or  (DGL/) and is degraded primarily by 
monoacylglycerol lipase (MGL) or to a lesser extent by several alpha beta 
hydrolase domain enzymes (ABHD). Both, AEA and 2-AG, bind and activate 
cannabinoid type-1 (CB1) and type-2 receptors (CB2), and activation of CB1 
receptor is known to generally increase feeding and is associated with decreased 
inflammation. OEA is known to act through peroxisome proliferator-activated 
receptor  (PPAR) to decrease feeding and possibly inflammation. The 
physiological relevance and cognate receptors of DHEA and the MAG, 
docosahexaenoyl glycerol (DHAG), are unclear.  
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Supplementary Figure 2. RNA-seq expression of Ascaris suum. The life stages 
for A. suum expression were not clearly identified in the RNA-seq data available 
in the public database and are therefore not defined in the figure. 
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Supplementary Figure 3. Chromatograms for endocannabinoid-like molecules in 
Nb. Representative chromatograms of (A) OEA, (B) DHEA, and (C) DHAG. 
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Conclusion 
 
 This body of work provides novel mass spectrometric analyses for 
components of the endocannabinoid (eCB) system, while describing the pitfalls 
of the current technique. Using the described methods, a role for eCBs signaling 
via peripheral cannabinoid type 1 receptor (CB1R) in the control of hyperphagia is 
discussed in the context of obesity. This work was enhanced by further scrutiny 
of the intestinal eCB system, which revealed that corn-oil induced secretion of 
intestine-derived cholecystokinin is blunted by CB1R activation; activation 
occurred via pharmacological agonists or enhanced eCB levels following diet 
induced obesity. Additionally, the role for eCB control of feeding was assessed in 
a separate disease model; helminth infection was used to evaluate intestinal and 
lung eCB levels in a model of hookworm infection. Infection revealed an 
enhancement of eCB levels that were met with reduced feeding, but this is 
suggestive of feeding independent mechanisms of eCB control of immune 
response. Together, this body of work provides novel insight to the varied roles 
that intestinal and peripheral eCBs have during obesity and hookworm infection 
in the modulation of feeding behaviors and immune response. 
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Identification of a Widespread Palmitoylethanolamide Contamination in Standard 
Laboratory Glassware 
 Current GC/MS (1) and LC/MS (2) analytical techniques for detection and 
subsequent quantification of eCBs and eCB-like fatty acid ethanolamines (FAEs) 
and monoacylglycerols (MAGs) of biological origin, including human serum (3), 
exist, but may sometimes lack proper controls to determine false positive results. 
During development of novel, sensitive quantitative LC/MS method to quantify 
blood lipid content, literature review revealed discrepancies in the observed 
eCBs and eCB-like concentrations in human blood plasma and serum (Table 
1.1). The EC50 for the eCBs N-arachidonoyl ethanolamine (AEA) and 2-
arachidonoyl-sn-glycerol (2-AG) vary between assays, tissue types and source; 
however, reported levels (see Table 1.1) for both eCBs in plasma/serum are 
below the reported concentrations required for functional activation of the CB 
receptors [comprehensively reviewed in specific assays performed by a multiple 
investigators (4)]. Relative levels of the FAEs palmitoylethanolamide (PEA) and 
oleoylethanolamide (OEA) have been reported on the same order of magnitude 
by some groups (5-9), however others have observed PEA at two-fold higher 
concentrations than OEA (3, 10-14). Following absolute quantitation of PEA and 
OEA, two separate groups reported plasma levels that were far greater than the 
amount required to activate their native receptor (15, 16). The homeostatic 
amounts of eCBs in healthy plasma/serum may reflect an equilibrium of secreted 
eCBs from peripheral tissues and their subsequent enzymatic breakdown in 
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circulation. In rodent tissues (e.g., brain, upper small intestine), PEA and OEA 
levels are present in the same order of magnitude (17, 18); therefore, the 
expectation was that levels would be similar across studies evaluating samples 
of human origin. In our method validation, OEA levels were in agreement with 
reported value. By contrast, PEA was one order of magnitude higher than 
expected. This finding prompted us to carefully evaluate all possible sources of 
contamination including solvents, reagents, and glassware used for lipid 
extraction and quantitative analysis.  
In the present study, we identify glass Pasteur pipets (5¾”) that are used 
during sample preparation for mass spectrometric analysis as the source of PEA 
contamination. PEA was identified as the contaminant by its exact mass and 
liquid chromatography retention time using three similarly functioning, but 
different chromatographic systems. Additionally, the contaminant’s fragmentation 
pattern during tandem mass spectrometric detection were identical to those of 
standard PEA, purchased commercially. Further, we provide evidence that the 
polyurethane foam used by manufacturers to wrap and transport the pipets 
contained PEA; this suggests a source by which PEA “leaks” onto the glass 
pipets. Moreover, accurate exact mass measurements with ppm deviation lower 
than 5 unambiguously confirmed the identity of the contaminant as PEA. 
Quantification of pipet contamination revealed a substantial amount of PEA in 
each individual piece of glassware. Unfortunately, all 5¾” glass Pasteur pipets 
tested – purchased from various manufacturers – were contaminated (see 
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Figure. 1.S6). PEA was undetectable in 9” pipets from only one vendor (see 
Figure. 1.3A), allowing the use of these consumables in the overall procedure. 
Lipidomics research is rapidly expanding; however, reproducible standard 
procedures across multiple laboratories have not been established. Therefore, 
discrepancies in lipidomics data are common between independent laboratories 
(19). These discrepancies are generally thought to be caused by variation in 
instrumentation, preparation procedures, and technical expertise. The present 
study provides results confirmed by two independent laboratories using different 
liquid chromatography (LC) systems and triple quadrapole (QQQ) mass 
spectrometers (Agilent 1200 LC system coupled to an Agilent G6410A QQQ 
Mass Spectrometer in the Piomelli laboratory, and Waters Acquity I Class UPLC 
system coupled to a Xevo TQ-S QQQ Mass Spectrometer in the DiPatrizio 
laboratory). Furthermore, accurate mass data were acquired on a third Shimadzu 
IT-TOF High Resolution Mass Spectrometer for definitive confirmation that the 
contaminant was indeed PEA. Putatively, various contaminations derive 
experimental artifacts. Lipids are often present in laboratory equipment including 
glassware and solvents due to being common contaminants in detergents, 
mineral oils, greases, and plasticizers involved in manufacturing. FAEs are not 
sheltered from this pitfall of lipidomics. We provide evidence that glass Pasteur 
pipets, commonly used in lipid extraction protocols to transfer organic solvents, 
may and often contain PEA as a contaminant. This contamination gives rise to 
artifacts in the measurement of PEA in biological samples, especially when the 
212 
 
 
procedure for sample preparation includes fractionation of the lipid extract, which 
concentrates the contaminant. The present study is an alert to lipidomics 
researchers about possible PEA analytical artifacts. Therefore, it is essential that 
proper controls are in place to avoid misinterpretation of false positive results; 
future application of these findings include proper inclusion of “blank” samples to 
monitor analytes of non-biological origin. Additionally, use of the analytic 
techniques presented here will provide for accurate and reproducible 
measurement of eCB and eCB-like molecules and other bioactive lipid 
compounds.  
Future directions for mass spectrometric analysis of the endocannabinoid 
system will involve development of novel assays for targeted detection of the 
biosynthetic and degradative enzymes. Utilizing non-endogenous lipid substrates 
for the enzymes responsible for endocannabinoid production and degradation will 
allow us a glimpse into the cellular function and demand for endocannabinoids. 
Additionally, this work will provide a platform for drug development and 
identification of compounds to selectively reduce or enhance endocannabinoid 
levels in situ.  
 
Peripheral Endocannabinoid Signaling Controls Hyperphagia in Western Diet-
Induced Obesity 
 The analytical tools described above were used in several contexts, 
including the dysregulation of eCB lipid production that occurs during diet 
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induced obesity (DIO)(20). In 2013, the American Medical Association declared 
obesity a disease; presently it affects nearly one-third of adults in the United 
States and carries a significant burden while reducing life expectancy (21). A 
growing body of evidence suggests that overconsumption of high-energy foods – 
rich in fats and sugars – is a primary contributing factor of climbing obesity rates 
(22, 23). The eCB system has been identified as a controller of feeding 
behaviors, especially those related to hedonic eating via central mechanisms (24, 
25). However, the role for eCBs in the control of feeding during obesity have not 
been delineated. 
 Central attenuation of eCB signaling has positive impacts on metabolism 
(26-28), but interventions targeting CBRs in the brain have been stopped due to 
deleterious side effects (29, 30). Recent evidence, however, indicates that 
obesity causes a dysregulation of feeding and peripheral endocannabinoid tone 
(31-33). Similarly, taste of dietary fats, termed oleogustus, and 24 h fast 
mobilized intestinal 2-AG in rats through a cholinergic mechanism of vagal 
efferent neurons (34-36). These observations are suggestive of a yet-unknown 
mechanism of peripheral endocannabinoid control of feeding. 
We evaluated the impact of a western style diet (i.e. high in fat and 
sucrose; WD) on body weight, feeding behavior, and endocannabinoid levels – 
measured using ultra-performance liquid chromatography tandem mass 
spectrometry (UPLC-MS/MS) – in small intestinal epithelium (jejunum mucosa) 
and blood plasma. We observed that mice maintained on WD for 60 days 
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become hyperphagic due to increases in both meal size and rate of consumption. 
We also showed pharmacologically that feeding responses are driven – in part – 
by increases in small intestinal and circulating eCB tone following WD exposure. 
Specifically, treatment with the peripherally-restricted CB1R neutral antagonist, 
AM6545, normalized hyperphagia in diet induced obese mice only. Investigations 
of the specific downstream pathways by which peripheral eCBs signal are 
essential to further our understanding of peripheral communications to the brain 
that control feeding; these studies may include possible neural (e.g., vagal) and 
endocrine (i.e., circulation) mechanisms. Additionally, various other dietary lipids 
(e.g., high in mono- or di-unsaturated fats versus saturated and polyunsaturated 
fats) and carbohydrates (e.g., fructose, sucrose) will need to be evaluated to 
determine their effect on eCB signaling in the gut and brain; further parsing of 
dietary components can give insight to their impact on hyperphagic behaviors 
that often lead to obesity.  
Our findings suggest peripheral CB1Rs may be an effective target of 
therapeutic value for attenuation of eating disorders that may or may not be 
associated with western diet-induced obesity.  The proposed, novel approach 
has advantage over previously used CB1Rs antagonists/inverse agonists (e.g., 
rimonabant), which may permeate the blood-brain barrier and influence central 
mechanisms. Rimonabant, for example, displayed positive clinical results for the 
treatment of obesity and metabolic syndrome. However, central mechanisms 
associated with rimonabant use resulted in reports of severe psychiatric side 
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effects, including depression and suicidal ideation (54); thereby eliminating 
rimonabant from clinical trials and sale in the United States and Europe. 
Alternatively, our work and the work of others (12, 24-34) suggests that 
peripheral CB1Rs may be targeted with antagonists (e.g., AM6545) incapable of 
reaching the brain. These new compounds may provide effective treatment for 
metabolic syndrome and eating disorders, without the deleterious psychiatric 
side-effects that are consequent of brain-penetrant CB1R inhibitors. 
Future directions for this study include a discreet analysis of the specific 
dietary components (i.e. specific sugars and fatty acids) that contribute to the 
obese phenotype and impaired endocannabinoid levels. The role for specific 
dietary fatty acids in endocannabinoid production is largely unknown, so this 
work could provide a foundation for translational or behavioral interventions to 
combat obesity. Additionally, upstream mechanisms that contribute to intestinal 
endocannabinoid production during a fast – which include cholinergic vagal 
efferents – will be investigated for their potential role in obesity. 
 
Cannabinoid CB1 Receptors Inhibit Gut-Brain Satiation Signaling in Diet-Induced 
Obesity 
 Feeding behavior and energy balance are controlled by a dynamic 
crosstalk of gut-brain signaling pathways that remain poorly defined but are 
suggested to become dysregulated during obesity (37).  Recent studies human 
and rodent studies suggest the endocannabinoid (eCB) system plays a key role 
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in regulating these processes (38-40). One of the primary mechanism of gut-
brain control of feeding is by intestinal release of gut neuropeptides from 
enteroendocrine cells in response to sensing dietary nutrients in the small 
intestinal lumen (37, 41-44). These gut-derived neuropeptides include 
cholecystokinin (CCK), which is released from enteroendocrine I-cells in the 
proximal small intestine and regulates meal size and induces satiation by 
activating CCKA receptors on vagal afferent fibers (45-50) and possibly the brain 
(51, 52). Recent evidence indicates a functional interaction between CB1Rs 
present on CCK-producing cells in central regions responsible for fear and 
learning (53, 54); other findings show that I-cells express mRNA encoding CB1R 
(55), although a functional link in intestinal CB1R and CCK signaling has not 
been identified. 
Our present study suggests that eCB signaling in small-intestinal 
epithelium controls feeding behavior by a mechanism that involves inhibition of 
nutrient-induced CCK release, which subsequently increases meal size and 
caloric intake. We confirm mRNA transcripts encoding CB1R in isolated CCK-
producing cells, sorted using enhanced green fluorescent protein (eGFP), and 
provide the first immunohistochemical evidence of co-localization of the receptor 
to CCK cells (see Figures. 3.1 and 3.2). Furthermore, the anorexigenic effects of 
AM6545 were blocked by co-administration of the CCKA receptor antagonist, 
devazepide. These results suggest that when eCB activity is elevated at local 
CB1Rs in the upper small-intestinal epithelium in DIO – measured as described 
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above – increased CB1R activation may inhibit nutrient-induced release of 
bioactive CCK-8 from small-intestinal enteroendocrine I-cells and lead to 
increased meal size and caloric intake. In further support of this hypothesis, oral 
gavage of corn oil – which potently stimulates bioactive CCK-8 release into 
circulation in lean mice that have low levels of small-intestinal eCB levels – failed 
to increase circulating amounts of CCK-8 in DIO mice that have elevated eCB 
levels in the small-intestinal epithelium. Moreover, inhibiting elevated eCB 
signaling at peripheral CB1Rs with AM6545 in DIO mice – at a dose that blocked 
hyperphagia – restored the ability for corn oil to increase circulating levels of 
CCK-8. 
In summary, our data provide evidence of a previously unknown 
mechanism of CB1R-mediated inhibition of gut-brain satiation signaling in DIO 
that controls hyperphagia. Pharmacological manipulation of these pathways in 
the periphery may provide a therapeutic advantage for the treatment of obesity 
and related metabolic disorders when compared to anti-obesity drugs that 
interact with the brain and display psychiatric side-effects (56, 57).  
Future work involves deeper investigation of the molecular mechanisms 
that control CCK release in response to manipulation of the eCB system. It has 
been well-described that CB1Rs reduce probability of neurotransmitter release by 
inhibiting calcium influx or mobilization in neurons (4, 58), and nutrient-induced 
CCK secretion is calcium-dependent (43, 59-62). Thus, it may be likely that CB1R 
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activity inhibits release of gut peptides by a mechanism that involves inhibition of 
calcium influx or mobilization; however, a direct test of this hypothesis remains. 
 
Host and Helminth-Derived Endocannabinoids Are Generated During Infection 
with Functional Effects on Host Immunity 
 In addition to obesity, many other disease-states have a major impact on 
body weight, feeding, and metabolism. Of particular interest, intestinal hookworm 
infections present with a major reduction in body weight and decreased nutrient 
absorption (63). Helminth parasites infect approximately two billion individuals 
worldwide (64). Although not typically fatal, helminth infection is associated with 
many pathologic conditions, including malnutrition and growth retardation. 
Recently described mechanisms may indicate how helminths impact feeding and 
metabolism in their host (65). Gastrointestinal helminth infection decreases food 
intake (66), and has been beneficial in mice maintained on a high-fat diet, 
improving glucose metabolism and reducing adiposity (67, 68). Immune 
responses in the intestine following helminth infection caused an expansion of 
cholecystokinin (CCK)-positive enteroendocrine I-cells, which regulate feeding 
behavior (69). Despite mounting evidence for intestinal endocannabinoid control 
of feeding and immune responses(70), no studies reported to date have 
investigated the role of eCBs in intestinal helminth infection. 
 In the present study, we investigated components of the eCB system 
following infection with Nippostrongylus brasiliensis – a murine model of human 
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hookworm infection – as well the impact that modulating eCB signaling has on 
disease phenotype and inflammatory outcomes. While recognized for its critical 
functions in the central and enteric nervous systems, the endocannabinoid 
system is also affect by and can modulate inflammatory immune responses (70-
72). For example, 2-AG and AEA mobilization are anti-inflammatory, which has 
provided the premise for the potential therapeutic value of synthetic 
cannabinoids, or cannabis, in autoimmune or inflammatory diseases (73). Oral 
AEA administration in mice promoted a tolerogenic immune response and 
enhanced regulatory macrophages in the intestine, which proved to be protective 
in a non-obese diabetic model (74). Despite playing a role in intestinal immunity, 
the functional significance of endocannabinoids during intestinal parasite 
infection has not been evaluated. Our finding that helminth infection triggers 
significant endocannabinoid expression that is correlated with both host health 
outcomes and parasite fecundity suggests that endocannabinoids may be 
important players in host-helminth dynamics. 
 Pharmacological CB1R inhibition led to decreased IL-5 expression in the 
intestine and IL-4, IL-5, and IL-10 in the spleen, but no difference was observed 
for IFN-γ. CB1R inhibition was associated with increased parasite egg and worm 
burdens, suggesting that functional CB1R signaling is important for optimal host 
immune response during helminth infection. eCBs also signal through CB2R (71); 
however, we observed that treatment with a CB2R-selective antagonist did not 
significantly affect cytokine or helminth responses. Pharmacological CB1R and 
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CB2R inhibition occurred only during days 4 to 6 post-infection (during intestinal 
infection), and thus we cannot confirm complete abrogation of intestinal CB1R or 
CB2R signaling with this treatment schedule. Future studies may incorporate 
treatment schedules at earlier time points during infection or utilize genetic 
CB1R/CB2R-knockout mice to delineate functional differences between these 
signaling pathways during helminth infection. Additionally, CCK-containing cells 
in the proximal small intestine express mRNA encoding CB1Rs in mice (55), and 
rat N. brasiliensis infection is associated with increased circulating CCK (66, 75). 
Thus, it is possible that helminth infection modulates feeding behavior by a 
mechanism that involves eCB-mediated changes in the production and/or 
secretion of gut-derived peptides that control feeding behavior, including CCK. 
We observed significant correlations between eCB levels, infection-induced 
weight loss, and parasite burdens. However, further functional studies are 
necessary to determine causal relationships between these multiple parameters 
and the contribution of infection-induced eCBs to feeding behavior. 
 In addition to changes in host eCB expression, we provide the first 
evidence that N. brasiliensis produces eCBs and possesses genes encoding 
eCB biosynthetic and degradative enzymes. One proposed strategy by which 
parasites evade host immunity is release of anti-inflammatory molecules that are 
endogenous to the host, or similar to endogenous molecules (76). For example, 
A. suum and T. canis possess the ability to synthesize morphine or morphine-like 
substrates, and morphine is a known immunomodulator (77, 78). Putatively, the 
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eCB system is conserved in vertebrates across multiple families, including 
pythons (79) and goldfish (80); however, whether the system evolved earlier and 
is present/functional in more primitive eukaryotic organisms is less well 
understood (81). We observed that N. brasiliensis has a gene predicted to 
encode N-acyl phosphatidyl ethanolamine-specific phospholipase D and fatty 
acid amide hydrolase, enzymes that catalyze FAE synthesis and breakdown. 
Quantitative PCR analysis confirmed N. brasiliensis expression of both of these 
predicted genes. Moreover, mass spectrometry analysis revealed that infectious 
L3-life cycle N. brasiliensis produced extremely high levels of AEA, reaching 100 
to 1000 times the amounts found in mouse tissue or blood. Recently it has been 
observed that truffles, the fruiting body of fungi, may produce AEA as a potential 
attractant and feeding stimulant for animals as a method to ensure its 
dissemination (82). Given that AEA is anti-inflammatory, high level synthesis at 
the infectious stage may also function to dampen the host immune response. It is 
possible that in addition to eCBs, N. brasiliensis may produce and release other 
signaling molecules endogenous to the host, such as opioids, and that there is 
overlap in the biological effects of these molecules on host immunity or behavior. 
Given the difference in mass and distribution between N. brasiliensis and the 
host, the eCBs detected in the infected mice are likely host derived. However, it 
is possible that N. brasiliensis derived eCBs may functionally impact the host at 
the cellular level. Future studies are necessary to test these hypotheses. These 
findings suggest that the eCB system is a newly observed contributor to the 
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dynamic process of helminth infection, and eCB signaling may have a significant 
impact on a host’s health outcome beyond parasite clearance.  
 Future work involves a detailed assessment of the mechanism by which 
N. brasiliensis is creating endocannabinoids. Utilization of the current analytical 
tools for the assessment of endocannabinoid synthesis and degradation (i.e. 
functional MGL and DGL assays) will be paired with pharmacology to target 
candidate enzymes. Further scrutiny of the endocannabinoids being produced in 
helminths will help to delineate their potential role in evading or enhancing host 
immunity. 
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